<table><thead><th>Patient</th></thead><tr><td>Age</td></tr><tr><td>History of illness</td></tr><tr><td>Attitudes and perceptions</td></tr><tr><td>Sexual orientation</td></tr><tr><td>Habits (e.g., use of alcohol, tobacco, and other drugs)</td></tr><tr><td>Family</td></tr><tr><td>Patient's status (e.g., married, separated, living with a partner, divorced)</td></tr><tr><td>Caregiving (e.g., young children, children with disabilities, aging parents)</td></tr><tr><td>Siblings (e.g., number, ages, closeness of relationship)</td></tr><tr><td>History (e.g., disease)</td></tr><tr><td>Environment</td></tr><tr><td>Social environment (e.g., community, social connectedness)</td></tr><tr><td>Economic status (e.g., poverty, insuredness)</td></tr><tr><td>Religion (e.g., religiosity, spirituality)</td></tr><tr><td>Culture and ethnic background (e.g., first language, community)</td></tr><tr><td>Career (e.g., work environment, satisfaction, responsibilities, stress)</td></tr></table>
======================================
<table><thead><th>The Physician Is:</th><th>The Physician Is Not:</th></thead><tr><td>A good listener</td><td>Confrontational</td></tr><tr><td>Empathetic</td><td>Combative</td></tr><tr><td>Compassionate</td><td>Argumentative</td></tr><tr><td>Honest</td><td>Condescending</td></tr><tr><td>Genuine</td><td>Overbearing</td></tr><tr><td>Respectful</td><td>Dogmatic</td></tr><tr><td>Fair</td><td>Judgmental</td></tr></table>
======================================
<table><thead><th>Preparing the Environment</th><th>Negotiating a Priority Problem</th></thead><tr><td>Create privacy</td><td>Ask patient for priorities</td></tr><tr><td>Eliminate noise and distractions</td><td>State own priorities</td></tr><tr><td>Provide comfortable seating at equal eye level</td><td>Establish mutual interests</td></tr><tr><td>Provide access</td><td>Reach agreement on order of addressing issues</td></tr><tr><td>Preparing Oneself</td><td>Developing a Narrative Thread</td></tr><tr><td>Eliminate distractions and interruptions</td><td>Develop personal ways of asking patient to tell her story</td></tr><tr><td>Focus</td><td>Ask when last felt healthy</td></tr><tr><td>Self-hypnosis.</td><td>Ask about entire course of illness</td></tr><tr><td>Meditation</td><td>Ask about recent episode or typical episode</td></tr><tr><td>Constructive imaging</td><td>Establishing the Life Context of the Patient</td></tr><tr><td>Let intrusive thoughts pass through</td><td>Use first opportunity to inquire about personal and social details</td></tr><tr><td>Observation</td><td>Flesh out developmental history</td></tr><tr><td>Create a personal list of categories of observation</td><td>Learn about patient's support system</td></tr><tr><td>Practice in a variety of settings</td><td>Learn about home, work, neighborhood, safety</td></tr><tr><td>Notice physical signs</td><td>Establishing a Safety Net</td></tr><tr><td>Presentation</td><td>Memorize complete review of systems</td></tr><tr><td>Affect</td><td>Review issues as appropriate to specific problem</td></tr><tr><td>What is said and not said</td><td>Presenting Findings and Options</td></tr><tr><td>Greeting</td><td>Be succinct</td></tr><tr><td>Create a personal stereotypical beginning</td><td>Ascertain patient’s level of understanding, cognitive style</td></tr><tr><td>Introduce oneself</td><td>Ask patient to review and state understanding</td></tr><tr><td>Check the patient’s name and how it is said</td><td>Summarize and check</td></tr><tr><td>Create a positive social setting</td><td>Tape record and give tape to patient</td></tr><tr><td>Introduction</td><td>Ask patient's perspectives</td></tr><tr><td>Explain one’s role and purpose</td><td>Negotiating Plans</td></tr><tr><td>Check patient's expectation</td><td>Activate patient</td></tr><tr><td>Negotiate about differences in perspective</td><td>Agree on what is feasible</td></tr><tr><td>Be sure expectations are congruent with patient's</td><td>Respect patient's choices whenever possible</td></tr><tr><td>Detecting and Overcoming Barriers to Communication</td><td>Closing</td></tr><tr><td>Develop personal list of barriers to look for</td><td>Ask patient to review plans and arrangements</td></tr><tr><td>nclude appropriate language</td><td>Clarify what to do in the interim</td></tr><tr><td>Physical impediments such as deafness, delirium</td><td>Schedule next encounter</td></tr><tr><td>nclude cultural barriers</td><td>Say goodbye</td></tr></table>
======================================
<table><thead><th>Rank</th><th>Physicians’ Support Services</th><th>Always or Often (%)</th><th>Rarely or Never (%,</th></thead><tr><td>1</td><td>Answering the patient's questions about the disease and its treatment, side effects, and possible outcomes</td><td>99</td><td>1</td></tr><tr><td>2</td><td>Making sure that the patient clearly understands the explanation of the medical treatment procedures</td><td>99</td><td>1</td></tr><tr><td>3</td><td>Encouraging the patient to develop an attitude of hope and optimism concerning treatment outcome</td><td>95</td><td>5</td></tr><tr><td>4</td><td>Adjusting treatment plans to enhance compliance when the patient exhibits noncompliance</td><td>88</td><td>12</td></tr><tr><td>5</td><td>Directly counseling family members</td><td>87</td><td>13</td></tr><tr><td>6</td><td>Continuing to serve as primary physician when the patient receives supplementary treatment at another facility</td><td>85</td><td>15</td></tr><tr><td>7</td><td>Providing referral to social support groups</td><td>83</td><td>17</td></tr><tr><td>8</td><td>Providing the patient with educational materials</td><td>81</td><td>19</td></tr><tr><td>9</td><td>Helping the patient develop methods to improve the quality of his or her life</td><td>74</td><td>26</td></tr><tr><td>10</td><td>Assisting the patient in determining which of his or her coping mechanisms are most productive and helping to activate them</td><td>62</td><td>38</td></tr></table>
======================================
<table><thead><th></th><th></th><th></th><th></th><th></th><th></th><th></th><th></th></thead><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr></table>
======================================
<table></table>
======================================
<table><tr><td></td><td>covenantal relationships between physician and patient are intertwined and compli- cated by health care payers and colleagues, which create considerable pressure. The conflict with financial considerations directly influences how patients’ lives are affected, often without their consent. Rennie (20) described that pressure eloquently: “Instead of receiving more respect (for more responsibility), physicians feel they are being increasingly questioned, challenged, and sued. Looking after a patient seems less and less a compact between two people and more a match in which increasing numbers of specta- tors claim the right to interfere and referee.” An honest response to this environment is for the physician to attempt to protect his or her efforts by assuming that the physician—patient relationship is contractual, and only contractual, in nature. This allocation of responsibil- ity and authority for the contract precludes the need for the covenant between the physi- cian and patient. For example, a preexisting contract, insurance, relationship with a particular hospital system, or managed-care plan may discourage referral to a more knowl- edgeable specialist, removing the physician’s responsibility. Thus, the contract seems to establish the extent of the physician—patient relationship. All health care providers must decide whether they will practice within a covenantal or contractual relationship and whether the relationship they develop remains true to this decision. In either setting, a reasonable perception of that relationship is “one that allows clients as much freedom as possible to determine how their lives are affected as is reasonably warranted on the basis</td></tr></table>
======================================
<table><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr></table>
======================================
<table><thead><th>Year</th><th>%</th><th>Year</th><th>%</th></thead><tr><td>1990</td><td>17</td><td>1998</td><td>3.7</td></tr><tr><td>1991</td><td>18</td><td>1999</td><td>7.8</td></tr><tr><td>1992</td><td>12</td><td>2000</td><td>9.4</td></tr><tr><td>1993</td><td>10</td><td>2001</td><td>10.2</td></tr><tr><td>1994</td><td>6.5</td><td>2002</td><td>14.3</td></tr><tr><td>1995</td><td>-1</td><td>2003</td><td>13.9</td></tr><tr><td>1996</td><td>2</td><td>2004</td><td>11.2</td></tr><tr><td>1997</td><td>4</td><td></td><td></td></tr></table>
======================================
<table></table>
======================================
<table><tr><td>Quality of life</td><td>Five-year survival rate</td></tr><tr><td>Take baby home</td><td>Pregnancy</td></tr><tr><td>Pain relief</td><td>Fewer adhesions</td></tr><tr><td>No transfusion</td><td>Less blood loss</td></tr></table>
======================================
<table></table>
======================================
<table><thead><th>Status Determined by Screening</th><th>Positive</th><th>Negative</th><th>Total</th></thead><tr><td>Positive</td><td>a (true positives)</td><td>b (false-positives)</td><td>a + b (all screened positives)</td></tr><tr><td>Negative</td><td>c (false-negatives)</td><td>d (true negatives)</td><td>c +d (all screened negatives)</td></tr><tr><td>Total</td><td>a + c (all diseased)</td><td>b + d (all nondiseased)</td><td>N (all subjects)</td></tr><tr><td>Measure</td><td>Definition</td><td>Formula</td><td></td></tr><tr><td rowspan="2">a. Sensitivity</td><td>True positives</td><td>a</td><td></td></tr><tr><td></td><td>“All diseased</td><td>ate</td><td></td></tr><tr><td rowspan="2">an Specificity</td><td></td><td>True negatives</td><td>d</td><td></td></tr><tr><td>All nondiseased</td><td>bad</td><td></td></tr><tr><td>Predictive value</td><td>True positives</td><td>a</td><td></td></tr><tr><td>of a positive screen</td><td>All screened positives</td><td>atb</td><td></td></tr></table>
======================================
<table><thead><th></th><th>All Ages</th><th>1-19 Yr</th><th>20-39 Yr</th><th>40-59 Yr</th><th>60-79 Yr</th><th>80+Yr</th></thead><tr><td></td><td>All causes:</td><td>All causes:</td><td>All causes:</td><td>All causes:</td><td>All causes:</td><td>All causes:</td></tr><tr><td>1</td><td>983,940 Heart diseases: 356,014</td><td>6,993 Accidents: 3,778</td><td>22,204 Accidents: 6,859</td><td>104,055 Cancer: 49,570</td><td>336,929 Cancer: 29,699</td><td>523,794 Heart diseases: 231,969</td></tr><tr><td>2</td><td>Cancer: 268,503</td><td>Cancer: 957</td><td>Cancer: 5,403</td><td>Heart diseases: 21,677</td><td>Heart diseases: 99,160</td><td>Cancer: 82,840</td></tr><tr><td>3</td><td>Cerebrovascular diseases: 100,050</td><td>Homicide: 636</td><td>Heart diseases: 2,640</td><td>Accidents: 8,076</td><td>Chronic obstructive pulmonary diseases: 29,905</td><td>Cerebrovascular diseases: 67,702</td></tr><tr><td>4</td><td>— Chronic obstructive pulmonary diseases: 64,103</td><td>Congenital anomalies: 552</td><td>Suicide: 1,913</td><td>Cerebrovascular diseases 5,536</td><td>Cerebrovascular diseases 25,934</td><td>Alzheimer’s diseases 35,225</td></tr><tr><td>5</td><td>Alzheimer’s disease: 41,877</td><td>Heart diseases: 332</td><td>Homicide: 1,723</td><td>Diabetes mellitus: 4,675</td><td>Diabetes mellitus: 17,038</td><td>Chronic obstructive pulmonary diseases: 29,619</td></tr><tr><td>6</td><td>Diabetes mellitus: 38,948</td><td>Suicide: 298</td><td>HIV: 1,391</td><td>Chronic obstructive pulmonary diseases: 4,089</td><td>Pneumonia and influenza: 7,508</td><td>Pneumonia and influenza: 27,094</td></tr><tr><td>7</td><td>Accidents: 37,485</td><td>Pneumonia and influenza: 134</td><td>Cerebrovascular diseases: 740</td><td>_ Liver diseases: 3,617</td><td>Nephritis: 7,375</td><td>Diabetes mellitus: 16,566</td></tr><tr><td>8</td><td>Pneumonia and influenza 36,763</td><td>Chronic obstructive pulmonary diseases: 108</td><td>Diabetes: mellitus: 629</td><td>Suicide: 2,879</td><td>Accidents: 6,987</td><td>Nephritis: 11,784</td></tr><tr><td>9</td><td>Nephritis: 21,279</td><td>Septicemia: 108</td><td>Liver disease: 475</td><td>HIV: 1,998</td><td>Septicemia: 6,781</td><td>Accidents: 11,381</td></tr><tr><td>10</td><td>Septicemia: 18,918</td><td>Benign neoplasms: 90</td><td>Congenital anomalies: 431</td><td>Septicemia: 1,938</td><td>Alzheimer’s disease: 6,542</td><td>Septicemia: 9,614</td></tr></table>
======================================
<table><thead><th></th><th>All Ages</th><th>20-34</th><th>35-44</th><th>45-54</th><th>55-64</th><th>65-74</th><th>75-84</th><th>Bot</th></thead><tr><td>Breast (females)</td><td>208,089</td><td>2,497</td><td>14,358</td><td>31,838</td><td>37,040</td><td>45,572</td><td>47,444</td><td>29,132</td></tr><tr><td>Cervix</td><td>21,335</td><td>1,281</td><td>3,652</td><td>4,736</td><td>3,712</td><td>3,414</td><td>2,944</td><td>1,600</td></tr><tr><td>Corpus and uterus, NOS</td><td>32,445</td><td>162</td><td>649</td><td>2,336</td><td>5,191</td><td>9,052</td><td>9,863</td><td>5,191</td></tr><tr><td>Ovary</td><td>68,998</td><td>552</td><td>2,415</td><td>7,659</td><td>12,075</td><td>18,422</td><td>19,664</td><td>8,211</td></tr></table>
======================================
<table><thead><th></th><th>Origin</th><th>Insertion</th><th>Action</th><th>Innervation</th></thead><tr><td colspan="5">Lateral Pelvic Wall</td></tr><tr><td>Piriformis</td><td>Anterior aspect of $2— S4 and sacrotuberous ligament</td><td>Greater trochanter of the femur</td><td>Lateral rotation, abduction of thigh in flexion; holds head of femur in acetabulum</td><td>S1-S2; forms a muscular bed for the sacral plexus</td></tr><tr><td>Obturator internus</td><td>Superior and inferior pubic rami</td><td>Greater trochanter of the femur</td><td>Lateral rotation of thigh in flexion; assists in holding head of femur in acetabulum</td><td>(L5, $1) Obturator internus nerve</td></tr><tr><td>lliopsoas</td><td>Psoas from the lateral margin of the lumbar vertebrae; iliacus from the iliac fossa</td><td>Lesser trochanter of the femur</td><td>Flexes thigh and stabilizes trunk on thigh; flexes vertebral column or bends it unilaterally</td><td>(L1-L3) Psoas-ventral rami of lumbar nerve (L2-L3) lliacus-femoral nerve contains the</td></tr></table>
======================================
<table><thead><th></th><th></th><th></th><th></th><th>within its muscle body</th></thead><tr><td colspan="5">Pelvic Floor Pelvic Diaphragm</td></tr><tr><td>Levator Ani Pubococcygeus Pubovaginalis Puborectalis</td><td>From the tendinous arch, extending from the body of the pubis to the ischial spine</td><td>Central tendon of the perineum; wall of the anal canal; anococcygeal ligament; coccyx; vaginal wall</td><td>Assists the anterior abdominal wall muscles in containing the abdominal and pelvic contents; supports the posterior wall of the vagina; facilitates defecation; aids in fecal continence; during parturition, supports the fetal head during cervical dilation</td><td>$3-S4; the inferior rectal nerve</td></tr><tr><td>Coccygeus</td><td>Ischial spine and sacrospinous ligament</td><td>Lateral margin of the fifth sacral vertebra and coccyx</td><td>Supports the coccyx and pulls it anteriorly</td><td>= $4—5</td></tr><tr><td colspan="5">Urogenital Diaphragm</td></tr><tr><td>Deep transverse perineal</td><td>Medial aspect of the ischiopubic rami</td><td>Lower part of the vaginal wall; anterior fibers blend with those of the sphincter urethrae</td><td>Steadies the central —_ perineal tendon</td><td>$2-S4; perineal nerve</td></tr><tr><td>Sphincter urethrae</td><td>Medial aspect of the ischiopubic rami</td><td>Urethra and vagina</td><td>Compresses the urethra</td><td>$2-S4; perineal nerve</td></tr></table>
======================================
<table><tr><td></td><td>aseuresg snoua,</td><td>Yo] JOLIOJUI AY} OJU! sUreIpP apts 1YyBIY uayo jUaWes!| peoig</td><td>UIA [Rudd Yo] ay} Oyu! sureip</td><td></td><td>UldA ay) oyu sandwa UIDA D1Ja}UASALU JOLOJU] ‘ainxalj d1uajds ‘uojoo ‘wg d1Ajad</td><td>SIuUa|ds</td><td>uojoo prowsis Ajddns</td><td>uunygas Om} O|U! saplAIp—(jeployuoway)</td><td>pue ar]</td><td>; ‘sauayse 0} |eIpatu Anysijs Jola}sod</td><td>JOayUe AY} S4a]Ud se Alaye ay} 0} [RIP uay} pue Jola}sod ar] Jeulwopge JOajUe pue upys satjddns—auysesida</td><td>SUIDA DPI{! UOLULWUOD oyu! uresp ‘Yy8iUy JOlWojue pue siqnd pue upys</td><td></td><td>saijddns—oey!</td><td>jue]J ay)</td><td>[jem Jade] pelosejojnosnuu</td><td></td><td>[Jem Je1oseyojnosnu saijddns—oey!</td><td colspan="3">SUIaA I]! UOLULUOD OU! ureip ‘snxajd xajdui0&gt; Woy ‘salaye 0} daaq “euro [ese JO sjua}UOD</td></tr><tr><td></td><td>uls1iQ</td><td>ay) Mojaq ysnf eyoR jo @OLJINS [LAVA WO SASLIY</td><td>s]assan Jeuas ay} JO UIBZLO</td><td></td><td>eyor ay} Wo} Ajaye jeauoyiado.jas papis-yo| paseduy</td><td>sy! oO} WO ¢—-Z suisue</td><td>uonedingiq yeuulxosd</td><td></td><td>ay} JO UOISIAIP peULLWAaL</td><td>Jequun| YWNo} ye eyOR</td><td>ay) ayisoddo suisaq ‘oeI]! UOWULUOD Jo uoneonyig jesaye7</td><td>quiof jessesoquin|</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>st ;essesoquun| ayy ayisoddo sursaq UOWULUOD</td><td>siajad ayy 0} Ajddns pooyq sofew Juiof</td></tr></table>
======================================
<table><tr><td></td><td>aseuresg snoua,</td><td>Yo] JOLIOJUI AY} OJU! sUreIpP apts 1YyBIY uayo jUaWes!| peoig</td><td>UIA [Rudd Yo] ay} Oyu! sureip</td><td></td><td>UldA ay) oyu sandwa UIDA D1Ja}UASALU JOLOJU] ‘ainxalj d1uajds ‘uojoo ‘wg d1Ajad</td><td>SIuUa|ds</td><td>uojoo prowsis Ajddns</td><td>uunygas Om} O|U! saplAIp—(jeployuoway)</td><td>pue ar]</td><td>; ‘sauayse 0} |eIpatu Anysijs Jola}sod</td><td>JOayUe AY} S4a]Ud se Alaye ay} 0} [RIP uay} pue Jola}sod ar] Jeulwopge JOajUe pue upys satjddns—auysesida</td><td>SUIDA DPI{! UOLULWUOD oyu! uresp ‘Yy8iUy JOlWojue pue siqnd pue upys</td><td></td><td>saijddns—oey!</td><td>jue]J ay)</td><td>[jem Jade] pelosejojnosnuu</td><td></td><td>[Jem Je1oseyojnosnu saijddns—oey!</td><td colspan="3">SUIaA I]! UOLULUOD OU! ureip ‘snxajd xajdui0&gt; Woy ‘salaye 0} daaq “euro [ese JO sjua}UOD</td></tr><tr><td></td><td>uls1iQ</td><td>ay) Mojaq ysnf eyoR jo @OLJINS [LAVA WO SASLIY</td><td>s]assan Jeuas ay} JO UIBZLO</td><td></td><td>eyor ay} Wo} Ajaye jeauoyiado.jas papis-yo| paseduy</td><td>sy! oO} WO ¢—-Z suisue</td><td>uonedingiq yeuulxosd</td><td></td><td>ay} JO UOISIAIP peULLWAaL</td><td>Jequun| YWNo} ye eyOR</td><td>ay) ayisoddo suisaq ‘oeI]! UOWULUOD Jo uoneonyig jesaye7</td><td>quiof jessesoquin|</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>st ;essesoquun| ayy ayisoddo sursaq UOWULUOD</td><td>siajad ayy 0} Ajddns pooyq sofew Juiof</td></tr></table>
======================================
<table><thead><th>sajosnuy jeaynys satjddns—yeaynjs</th><th></th><th>9JOSNlW ‘siqnd so1aysod ‘esso} de1! sarjddns—iojeinigQ.</th><th></th><th>[elpaw ayy se ‘saysuesg ‘Maye [OI[IGUUN [ejay JO JURUWAI—/edyIGUi</th><th>94} SaydueIg Jappeq Ajddns—yeoisaa sonayuy</th><th>eUISeApILW ‘uinjoal saljddns—(jeploysoway)</th><th>punog ‘aqny ‘eursen Jaddn ‘x1Ma9 pue sndiod auuayn</th><th>eulsea</th><th>y8iuyy 1014a}s0d ‘sajosnuu jeans saljddns—yeayn/s</th><th>Jeusajqu! Oyu! UleIG Jeue saijddns—(spioysoway)</th><th>SUIOA Jo sajasnuu ‘uns jeauad Jue JO}eAa] ‘ups feueiad 4ayouiyds jeue</th><th>Jeloyedns ‘snsousanesoryps! juawyedtuos</th><th></th><th>eiyjoun pue ‘ging 4ejnqusan ‘SL0y]9</th><th>UIdA UOLULUOD Yo] OU! uresp Ajpensn sulaa Jedoes ajppiw paired Jolaysod jo saumjonujs Jejnosntu</th><th>(slulwopqe eARD Jeusayul/euta}xa) BUDA JOLIOJU! OJUL SUID, |Jem</th></thead><tr><td>€</td><td>JOLIQUY</td><td>1</td><td></td><td></td><td>*</td><td></td><td></td><td></td><td></td><td>ay) ysnoiy) siAjad ayy saneay ‘AUR Delf! [eUJaU]</td><td>BSSOJ [EJPDBJOIYS! BY} SJO}UD pue ‘auids jeryds! ayy punoue sosinod ‘UdLURIO} onelos 4Jayea13 uunaulied ayy 0} Ajddns poojq Jofew ay} sapiaoid</td><td>ay YUM ay) 0} ued Ss} U] “UB@LURIOY nels Jassa] ay} Y8Nosyy</td><td>spPoofy UIYyYIM adiau jepuapnd sal] ‘Wneued</td><td>ajosnu snusayul soyesnyqo AY} JaAO JouUN} JeIDse] e ‘eURD</td><td>satjddng xA0009 pure ‘WMdeS ‘aeIGaLOA JEQWIN] JOMO] JBAO SosINO-) eyoe [eUlUo} Jouaysod wo susie Jassan pasredun aurpiw</td><td>pue JOWajue OU! apIAIp ‘QRIGOUAA sequuN| JoLedNs JOLJa}SOd WO [aAa] Jequun| yore ye Suisue saijddng ay} JO apis ay} punose sseq saypueig jejuawW8as</td></tr></table>
======================================
<table></table>
======================================
<table><thead><th>Primary Artery</th><th>Collateral Arteries</th></thead><tr><td colspan="2">Aorta</td></tr><tr><td>Ovarian artery</td><td>Uterine artery</td></tr><tr><td>Superior rectal artery (inferior mesenteric artery)</td><td>Middle rectal artery</td></tr><tr><td></td><td>Inferior rectal artery (internal pudendal</td></tr><tr><td>Lumbar arteries</td><td>Iliolumbar artery</td></tr><tr><td>Vertebral arteries</td><td>Iliolumbar artery</td></tr><tr><td>Middle sacral artery</td><td>Lateral sacral artery</td></tr><tr><td colspan="2">External Iliac</td></tr><tr><td rowspan="2">Deep iliac circumflex artery</td><td>Iliolumbar artery</td></tr><tr><td></td><td>Superior gluteal artery</td></tr><tr><td>Inferior epigastric artery</td><td>Obturator artery</td></tr><tr><td colspan="2">Femoral</td></tr><tr><td rowspan="2">Medial femoral circumflex artery</td><td>Obturator artery</td></tr><tr><td></td><td>Inferior gluteal artery</td></tr><tr><td>Lateral femoral circumflex artery</td><td>Superior gluteal artery</td></tr></table>
======================================
<table><thead><th>Nodes</th><th>Primary Afferent Connections</th></thead><tr><td>Aortic/paraaortic</td><td>Ovary, fallopian tube, uterine corpus (upper); drainage from common iliac nodes</td></tr><tr><td>Common iliac</td><td>Drainage from external and internal iliac nodes</td></tr><tr><td>External iliac</td><td>Upper vagina, cervix, uterine corpus (upper); drainage from inguinal</td></tr><tr><td>Internal iliac</td><td>Upper vagina, cervix, uterine corpus (lower)</td></tr><tr><td colspan="2">Lateral sacral</td></tr><tr><td colspan="2">Superior gluteal</td></tr><tr><td>nferior gluteal</td><td></td></tr><tr><td colspan="2">Obturator</td></tr><tr><td colspan="2">Vesical</td></tr><tr><td colspan="2">Rectal</td></tr><tr><td colspan="2">Parauterine</td></tr><tr><td colspan="2">Inguinal Vulva, lower vagina; (rare: uterus, tube, ovary)</td></tr><tr><td>Superficial</td><td></td></tr><tr><td>Deep</td><td></td></tr></table>
======================================
<table><thead><th>Nerve</th><th>Spinal Segment</th><th>Innervation</th></thead><tr><td>lliohypogastric</td><td>712, L1</td><td>Sensory—skin near iliac crest, just above symphysis pubis</td></tr><tr><td>Hlioinguinal</td><td>1</td><td>Sensory—upper medial thigh, mons, labia majora</td></tr><tr><td>Lateral femoral cutaneous</td><td>L2, 13</td><td>Sensory—lateral thigh to level of knee</td></tr><tr><td>Femoral</td><td>L2, L3, L4</td><td>Sensory—anterior and medial thigh, medial leg and foot, hip and knee joints Motor—iliacus, anterior thigh muscles</td></tr><tr><td>Genitofemoral</td><td>L1, L2</td><td>Sensory—anterior vulva (genital branch), middle/upper anterior thigh (femoral branch)</td></tr><tr><td>Obturator</td><td>L2, 3, L4 Motor—adductor muscles of thigh</td><td>Sensory—medial thigh and leg, hip and knee joints</td></tr><tr><td>Superior gluteal</td><td>L4,L5, $1</td><td>Motor—gluteal muscles</td></tr><tr><td>Inferior gluteal</td><td>L4, L5, $1, $2</td><td>Motor—gluteal muscles</td></tr><tr><td>Posterior femoral cutaneous</td><td>S1, $2, $3</td><td>Sensory—vulva, perineum, posterior thigh</td></tr><tr><td>Sciatic</td><td>L4, L5, $1, $2, $3 Motor—posterior thigh muscle, leg and foot muscles</td><td>Sensory—much of leg, foot, lower-extremity joints</td></tr><tr><td>Pudendal</td><td>$2, $3, $4 Motor—external anal sphincter, perineal muscles, urogenital</td><td>Sensory—perianal skin, vulva and perineum, clitoris, urethra, vaginal vestibule</td></tr></table>
======================================
<table><thead><th>Weeks of Gestation</th><th>Genital Development</th><th>Urinary Development</th></thead><tr><td rowspan="4">4-6</td><td>Urorectal septum</td><td>Pronephros</td></tr><tr><td></td><td>Formation of cloacal folds, genital tubercle</td><td>Mesonephros/mesonephric duct</td></tr><tr><td></td><td>Ureteric buds, metanephros</td><td></td></tr><tr><td></td><td>Genital ridges</td><td>Exstrophy of mesonephric ducts and ureters into bladder wall</td></tr><tr><td rowspan="4">6-7</td><td></td><td>End of indifferent phase of genital development</td><td>Major, minor calyces form</td></tr><tr><td></td><td>Development of primitive sex cords</td><td rowspan="3">idneys begin to ascend</td><td></td></tr><tr><td></td><td>Formation of paramesonephric ducts</td><td></td></tr><tr><td>Labioscrotal swellings</td></tr><tr><td rowspan="2">8-11</td><td>Distal paramesonephric ducts begin to fuse</td><td>idney becomes functional</td></tr><tr><td></td><td>Formation of sinuvaginal bulbs</td><td></td></tr><tr><td>12</td><td>Development of clitoris and vaginal vestibule</td><td></td></tr><tr><td>20</td><td>Canalization of vaginal plate</td><td></td></tr></table>
======================================
<table><thead><th>Muscle</th><th>Origin</th><th>Insertion</th><th>Action</th></thead><tr><td>External oblique</td><td>Fleshy digitations from the outer surfaces of ribs 5-12</td><td>Fibers radiate inferiorly, anteriorly, and medially, in most cases ending in the aponeurosis of the external muscle and inserting into the anterior half of the iliac crest, the pubic tubercle, and the linea alba. The superficial inguinal ring is located above and lateral to the pubic tubercle at the end of a triangular cleft in the external oblique muscle, bordered by strong fibrous bands that transmit the round ligament</td><td>Compresses and supports abdominal viscera; flexes and rotates vertebral column</td></tr><tr><td>Internal oblique</td><td>Posterior layer of the thoracolumbar fascia, the anterior two thirds of the iliac crest, and the lateral two thirds of the inguinal ligament</td><td>Inferior border of ribs 10-12. The superior fibers of the aponeurosis split to enclose the rectus abdominis muscle and join at the linea alba above the arcuate line. The most inferior fibers join with those of the transverse abdominis muscle to insert into the pubic crest and pecten pubis via the conjoint tendon</td><td>Compresses and supports abdominal viscera</td></tr><tr><td>Transversus abdominus</td><td>Inner aspect of the inferior six costal cartilages, the thoracolumbar fascia, the iliac crest, and the lateral one third of the inguinal ligament</td><td>Linea alba with the aponeurosis of the internal oblique, the pubic crest and the pecten pubis through the conjoint tendon</td><td>Compresses and supports abdominal viscera</td></tr><tr><td>Rectus abdominis</td><td>Superior pubic ramus and the ligaments of the symphysis pubis</td><td>Anterior surface of the xiphoid process and the cartilage of ribs 5-7</td><td>Tenses anterior abdominal wall and flexes trunk</td></tr><tr><td>Pyramidalis</td><td>Small triangular muscle contained within the rectus sheath, anterior to the lower part of the</td><td>On the linea alba, easily recognizable shape, used to locate the midline, particularly in a patient with previous abdominal surgery and scarring of the abdominal wall</td><td>Tenses the linea alba, insignificant in terms of function, and is frequently absent</td></tr></table>
======================================
<table></table>
======================================
<table><thead><th></th><th>sacral nerve and the inferior rectal (hemorrhoidal) nerve.</th></thead><tr><td>Retroperitoneum and Retroperitoneal Spaces</td><td>The subperitoneal area of the true pelvis is partitioned into potential spaces by the various organs and their respective fascial coverings and by the selective thickenings of the endopelvic fascia into ligaments and septa (Fig. 5.23). It is imperative that surgeons operating in the pelvis be familiar with these spaces, as discussed below.</td></tr><tr><td rowspan="2">Prevesical Space</td><td>The prevesical (Retzius) space is a fat-filled potential space bound anteriorly by the pubic bone, covered by the transversalis fascia, and extending to the umbilicus between the medial umbilical ligaments (obliterated umbilical arteries); posteriorly, the space extends to the anterior wall of the bladder. It is separated from the paravesical space by the ascending bladder septum (bladder pillars).</td></tr><tr><td></td><td>Upon entering the prevesical space, the pubourethral ligaments may be seen insert- ing the posterior aspect of the symphysis pubis as a thickened prolongation of the arcus tendineus fascia. With combined abdominal and vaginal bladder neck suspen- sory procedures, the point of entry is usually the Retzius space between the arcus tendineus and the pubourethral ligaments.</td></tr><tr><td>Paravesical Space</td><td>The paravesical spaces are fat filled and limited by the fascia of the obturator inter- nus muscle and the pelvic diaphragm laterally, the bladder pillar medially, the endopelvic fascia inferiorly, and the lateral umbilical ligament superiorly.</td></tr><tr><td>Vesicovaginal Space</td><td>The vesicovaginal space is separated from the Retzius space by the endopelvic fascia. This space is limited anteriorly by the bladder wall (from the proximal urethra to the upper vagina), posteriorly by the anterior vaginal wall, and laterally by the bladder septa (selec- tive thickenings of the endopelvic fascia inserting laterally into the arcus tendineus). A tear in these fascial investments and thickenings medially, transversely, or laterally allows herniation and development of a cystocele.</td></tr></table>
======================================
<table></table>
======================================
<table><thead><th>Protooncogenes</th><th>Gene Product/Function</th></thead><tr><td></td><td>Growth factors</td></tr><tr><td></td><td>Fibroblast growth factor</td></tr><tr><td colspan="2">fgf-5</td></tr><tr><td>Sis</td><td>Platelet-derived growth factor beta</td></tr><tr><td colspan="2">hst, int-2</td></tr><tr><td></td><td>Transmembrane receptors</td></tr><tr><td>erb-B</td><td>Epidermal growth factor (EGF) receptor</td></tr><tr><td>HER-2/neu</td><td>EGF-related receptor</td></tr><tr><td>Fms</td><td>Colony-stimulating factor (CSF) receptor</td></tr><tr><td>Kit</td><td>Stem cell receptor</td></tr><tr><td>Trk</td><td>Nerve growth factor receptor</td></tr><tr><td></td><td>Inner-membrane receptor</td></tr><tr><td>bcl-2</td><td></td></tr></table>
======================================
<table><thead><th></th><th>Table 6.2 Tumor Suppressor Genes</th></thead><tr><td>p53</td><td>Mutated in as many as 50% of solid tumors</td></tr><tr><td>Rb PTEN</td><td>Deletions and mutations predispose to retinoblastoma Dual specificity phosphatase that represses PI3-kinase/Akt pathway</td></tr><tr><td></td><td>activation with negative effect on cell growth</td></tr><tr><td>P16!NK4a</td><td>Binds to cylin-CDK4 complex inhibiting cell cycle progression</td></tr><tr><td>FHIT</td><td>Fragile histidine triad gene with tumor suppressor function via unknown mechanisms</td></tr><tr><td>wit</td><td>Mutations are correlated with Wilms’ tumor</td></tr><tr><td>NF1</td><td>Neurofibromatosis gene</td></tr><tr><td>APC</td><td>Associated with colon cancer development in patients with familial adenomatous</td></tr></table>
======================================
<table><thead><th>Growth Factor</th><th>Sources</th><th>Targets</th><th>Actions</th></thead><tr><td>Platelet-derived growth factor (PDGF)</td><td>Placenta, platelets, preimplantation embryo, endothelial cells</td><td>Endothelial cells Trophoblasts</td><td>Mitogen</td></tr><tr><td>Epidermal growth factor (EGF)</td><td>Submaxillary gland, theca cells Granulosa cells Endometrium</td><td>Mitogen</td><td></td></tr><tr><td>Transforming growth factor-a (TGF-a)</td><td>Embryo, placenta, theca cell, ovarian stromal cel</td><td>Placenta Granulosa cells</td><td>Mitogen</td></tr><tr><td>Transforming growth factor-8 (TGF-B)</td><td>Embryo, theca cells — Endometrium Granulosa cells Theca cells</td><td>Mitogen</td><td></td></tr><tr><td>Insulinlike growth factor 1 (IGF-1)</td><td>Granulosa cells</td><td>Theca cells Granulosa cells</td><td>Mediates growth hormone activity</td></tr><tr><td>Insulinlike growth factor 2 (IGF-2)</td><td>Theca cells</td><td>Theca cells</td><td>Insulinlike</td></tr><tr><td>Fibroblast growth factor (FGF)</td><td>Granulosa cells</td><td>Granulosa cells Angiogenic Mitogen</td><td></td></tr></table>
======================================
<table><thead><th>Hereditary Syndrome</th><th>Gene Mutation</th><th>Tumor Phenotype</th></thead><tr><td>Li-Fraumeni syndrome</td><td>TP53, CHEK2</td><td>Breast cancer, soft tissues sarcoma, adrenal cortical carcinoma, brain tumors</td></tr><tr><td>Cowden syndrome, Bannayan-Zonana syndrome</td><td>PTEN</td><td>Breast cancer, hamartoma, glioma, endometrial cance!</td></tr><tr><td>Hereditary breast and ovarian cancer</td><td>BRCA1, BRCA2</td><td>Cancer of breast, ovary, fallopian tube</td></tr><tr><td>Hereditary nonpolyposis colorectal cancer (HNPCC)</td><td>MLH1, MSH2, MSH3, MSH6, PMS2</td><td>Cancer of colon, endometrium, ovary, stomach, small bowel, urinary tract</td></tr><tr><td>Multiple endocrine neoplasia type |</td><td>Menin</td><td>Cancer of thyroid, pancreas and pituitary, ovarian carcinoid</td></tr><tr><td>Multiple endocrine neoplasia type II</td><td>RET</td><td>Cancer of thyroid and parathyroid, pheochromocytoma, ovarian carcinoid</td></tr><tr><td>Peutz-Jeghers syndrome</td><td>STK11</td><td>Gastrointestinal hamartomatous polyps, tumors of the stomach, duodenum, colon, ovarian sex cord tumor with annular tubules (SCTAT)</td></tr></table>
======================================
<table><thead><th>ACG</th><th>GAA-GGC-CTG-.</th><th>ATG</th></thead><tr><td colspan="3">Point</td></tr><tr><td></td><td></td><td>mutation</td></tr><tr><td colspan="3">GTC</td></tr><tr><td>Thr Glu</td><td>Va]</td><td>Leu Met</td></tr></table>
======================================
<table><thead><th>Cytokine</th><th>Cellular Source</th><th>Target Cells</th><th>Biologic Effects</th></thead><tr><td rowspan="2">IL-1 IL-2</td><td>Monocytes and macrophages</td><td>T cells, B cells Neurons</td><td>Costimulator Pyrogen</td></tr><tr><td></td><td>Tumor cells T cells (T,,1)</td><td>Endothelial cells T cells</td><td>Growth</td></tr><tr><td></td><td></td><td>B cells</td><td>Activation and antibody production</td></tr><tr><td rowspan="2">IL-3</td><td></td><td>NK cells</td><td>Activation and growth</td></tr><tr><td></td><td>T cells</td><td>Immature hemopoietic stem cells</td><td>Growth and differentiation</td></tr><tr><td>IL-4</td><td>T cells (T,,2)</td><td>B cells</td><td>Activation and growth; isotype switch to IgE; increased MHCII expression</td></tr><tr><td rowspan="6">IL-6</td><td></td><td>T cells</td><td>Growth</td></tr><tr><td></td><td>Monocytes and macrophages</td><td>B cells</td><td>Differentiation, antibody production</td></tr><tr><td></td><td>T cells, B cells Ovarian cells</td><td>T cells</td><td>Costimulator Induction of</td></tr><tr><td></td><td>cancer</td><td>Hepatocytes</td><td>acute-phase response</td></tr><tr><td></td><td>Other tumors Tumor cells</td><td>Stem cells Autocrine/paracrine</td><td>Growth and differentiation</td></tr><tr><td></td><td></td><td>growth and viability- enhancing factor</td><td></td></tr><tr><td rowspan="3">IL-10</td><td>T cells (T,,2)</td><td>T cells (T,,1)</td><td>Inhibition of cytokine</td></tr><tr><td></td><td>Monocytes and macrophages</td><td>Monocytes and macrophages</td><td>synthesis Inhibition of Ag presentation and</td></tr><tr><td></td><td></td><td>B cells</td><td>cytokine production Activation</td></tr><tr><td>IL-12</td><td>Monocytes</td><td>NK cells, T cells (T,,1)</td><td>Induction</td></tr><tr><td>IL-13</td><td>T cells (T,,2), mast cells, NK cells</td><td>B cells, T,,2 cells, macrophages</td><td>Regulates IgE secretion by B cell T,,2 development Macrophage activity</td></tr><tr><td>IL-15</td><td>Dendritic cells, monocytes, placenta, kidney, lung, heart, T cells</td><td>Mast cells</td><td>NK cell development and function Mast cell proliferation</td></tr><tr><td>IL-16</td><td>CD4+ and CD8+ T cells, eosinophils, mast cells, dendritic cells</td><td>T cells, monocytes, dendritic cells, eosinophils</td><td>Prevent antigen-induced T-cell death, chemotactic factor for CD4+ T cells, monocytes, eosinophils, dendritic cells</td></tr><tr><td>IL-17</td><td>Activated CD4+ T cells</td><td>T cells, fibroblasts</td><td>T-cell activation Induces secretion of</td></tr></table>
======================================
<table><thead><th>Cytokine</th><th>Cellular Source</th><th>Target Cells</th><th>Biologic Effects</th></thead><tr><td>IL-27</td><td>Monocytes, macrophages</td><td>CD4+ T cells</td><td>Proliferation of naive CD4+ T cells, synergize with IL-12</td></tr><tr><td rowspan="2">IFN-y</td><td>T cells (T,,1)</td><td>Monocytes/ macrophages</td><td>Activation</td></tr><tr><td></td><td>NK cells</td><td>NK cells, T cells, B cells</td><td>Activation Enhances responses</td></tr><tr><td rowspan="2">TNF-a</td><td>Monocytes and macrophages T cells Monokine production Costimulator</td><td>Monocytes/ macrophages T cells, B cells Neurons</td><td></td></tr><tr><td></td><td>Pyrogen</td><td>Endothelial cells Muscle and fat cells</td><td>Activation, inflammation | Catabolism/cachexia</td></tr></table>
======================================
<table><thead><th>Ages 13-18 years</th><th>Ages 40-64 years</th></thead><tr><td>Acne</td><td>Arthritis or osteoarthritis</td></tr><tr><td>Asthma</td><td>Asthma</td></tr><tr><td>Chlamydia</td><td>Back symptoms</td></tr><tr><td>Diabetes mellitus</td><td>Cancer</td></tr><tr><td>Headache</td><td>Cardiovascular disease</td></tr><tr><td>Infective, viral, and parasitic diseases</td><td>Depression</td></tr><tr><td>Mental disorders, including affective and neurotic disorders</td><td>Diabetes mellitus</td></tr><tr><td>Nose, throat, ear, and upper respiratory infections</td><td>Headache/migraine</td></tr><tr><td>Sexual assault</td><td>Hypertension</td></tr><tr><td>Sexually transmitted diseases</td><td>Menopause</td></tr><tr><td>Urinary tract infections</td><td>Mental disorders, including affective and neurotic disorders</td></tr><tr><td>Vaginitis</td><td>Mononeuritis of upper limb and mononeuritis multiples</td></tr><tr><td>Ages 19-39 years</td><td>Nose, throat, ear, and upper respiratory infections</td></tr><tr><td>Acne</td><td>Obesity</td></tr><tr><td>Appendicitis</td><td>Pneumonia</td></tr><tr><td>Arthritis</td><td>Sexually transmitted diseases</td></tr><tr><td>Asthma</td><td>Skin conditions/dermatitis</td></tr><tr><td>Back symptoms</td><td>Ulcers</td></tr><tr><td>Cancer</td><td>Urinary tract infections</td></tr><tr><td>Chlamydia</td><td>Vision impairment</td></tr><tr><td>Depression</td><td>Ages 65 years and older</td></tr><tr><td>Diabetes mellitus</td><td>Arthritis or osteoarthritis</td></tr><tr><td>Gynecologic disorders</td><td>Asthma</td></tr><tr><td>Headache/migraine</td><td>Back symptoms</td></tr><tr><td>Hypertension</td><td>Cancer</td></tr><tr><td>Infective, viral, and parasitic diseases</td><td>Cardiovascular disease</td></tr><tr><td>Joint disorders</td><td>Chronic obstructive pulmonary diseases</td></tr><tr><td>Menstrual disorders</td><td>Diabetes mellitus</td></tr><tr><td>Mental disorders, including affective and neurotic disorders</td><td>Hearing and vision impairment</td></tr><tr><td>Nose, throat, ear, and upper respiratory infections</td><td>Hypertension</td></tr><tr><td>Obesity</td><td>Mental disorders, including affective and neurotic disorders</td></tr><tr><td>Sexual assault/domestic violence</td><td>ose, throat, ear, and upper respiratory infections</td></tr><tr><td>Sexually transmitted diseases</td><td>Obesity</td></tr><tr><td>Skin rash/dermatitis</td><td>Osteoporosis</td></tr><tr><td>Substance abuse</td><td>Pneumonia</td></tr></table>
======================================
<table><thead><th>Ages 65 years and older</th></thead><tr><td>Skin lesions/dermatoses/dermatitis</td></tr><tr><td>Ulcers</td></tr><tr><td>Urinary tract infections</td></tr><tr><td>Urinary tract (other conditions, including urinary incontinence)</td></tr></table>
======================================
<table><thead><th>Screening</th><th>Evaluation and Counseling</th></thead><tr><td colspan="2">History Sexuality</td></tr><tr><td>Reason for visit</td><td>Development</td></tr><tr><td>H ealth status: medical, surgical, family</td><td>High-risk behaviors</td></tr><tr><td>Dietary/nutrition assessment</td><td>Preventing unwanted/unintended pregnancy</td></tr><tr><td>PI ysical activity</td><td>—Postponing sexual involvement</td></tr><tr><td>U se of complementary and alternative medicine</td><td>—Contraceptive options</td></tr><tr><td>Tobacco, alcohol, other drug use</td><td>Sexually transmitted diseases</td></tr><tr><td>A buse/neglect</td><td>—Partner selection</td></tr><tr><td>Sexual practices</td><td>—Barrier protection</td></tr><tr><td>Physical examination</td><td>Fitness and nutrition</td></tr><tr><td>Height</td><td>Dietary/nutrition assessment (including eating disorders)</td></tr><tr><td>Weight</td><td>Exercise: discussion of program</td></tr><tr><td>Blood pressure</td><td>Folic acid supplementation (0.4 mg/d)</td></tr><tr><td>Secondary sexual characteristics (Tanner staging)</td><td>Calcium intake</td></tr><tr><td>Pelvic examination (when indicated by the medical history)</td><td>Psychosocial evaluation</td></tr><tr><td>Skin?</td><td>Interpersonal/family relationships</td></tr><tr><td>Laboratory testing</td><td>Sexual identity</td></tr><tr><td>Periodic</td><td>Personal goal development</td></tr><tr><td>Cervical cytology (annual beginning at approximately 3 years after initiation of sexual intercourse)</td><td>Behavioral/learning disorders</td></tr><tr><td>High-risk groups*</td><td>Abuse/neglect</td></tr><tr><td>H lemoglobin level assessment</td><td>Satisfactory school experience</td></tr><tr><td>Bacteriuria testing</td><td>Peer relationships</td></tr><tr><td>Sexually transmitted disease testing</td><td>Cardiovascular risk factors</td></tr><tr><td>Human immunodeficiency virus (HIV) testing</td><td>Family history</td></tr><tr><td>Genetic testing/counseling</td><td>Hypertension</td></tr><tr><td>Rubella titer assessment</td><td>Dyslipidemia</td></tr><tr><td>Tuberculosis skin testing</td><td>Obesity</td></tr><tr><td>Li pid profile assessment</td><td>Diabetes mellitus</td></tr><tr><td>Fasting glucose testing</td><td>Health/risk behaviors</td></tr><tr><td>H lepatitis C virus testing</td><td>Hygiene (including dental); fluoride supplementation</td></tr><tr><td rowspan="4">Colorectal cancer screening?</td><td></td><td>Injury prevention</td></tr><tr><td>—Safety belts and helmets</td></tr><tr><td></td><td>—Recreational hazards</td></tr><tr><td></td><td>—Firearms</td></tr></table>
======================================
<table><thead><th>Screening</th><th>Evaluation and Counseling</th></thead><tr><td colspan="2">History Sexuality</td></tr><tr><td>Reason for visit</td><td>High-risk behaviors</td></tr><tr><td>H ealth status: medical, surgical, family</td><td>Contraceptive options for prevention of unwanted pregnancy, including emergency contraception</td></tr><tr><td>D ietary/nutrition assessment</td><td>Preconceptional and genetic counseling for desired pregnancy</td></tr><tr><td>PI ysical activity</td><td>Sexually transmitted diseases</td></tr><tr><td>U se of complementary and alternative medicine</td><td>—Partner selection</td></tr><tr><td>Tobacco, alcohol, other drug use</td><td>—Barrier protection</td></tr><tr><td>A buse/neglect</td><td>Sexual function</td></tr><tr><td>Sexual practices</td><td>Fitness and nutrition</td></tr><tr><td>U rinary and fecal incontinence</td><td>Dietary/nutrition assessment (including eating disorders)</td></tr><tr><td>Physical examination</td><td>Exercise: discussion of program</td></tr><tr><td>H eight</td><td>Folic acid supplementation (0.4 mg/d)</td></tr><tr><td>Weight</td><td>Calcium intake</td></tr><tr><td>Blood pressure</td><td>Psychosocial evaluation</td></tr><tr><td>N eck: adenopathy, thyroid</td><td>nterpersonal/family relationships</td></tr><tr><td>Breasts</td><td>Work satisfaction</td></tr><tr><td>Abdomen</td><td>Lifestyle/stress</td></tr><tr><td>Pelvic examination</td><td>Sleep disorders</td></tr><tr><td>Skin?</td><td>Cardiovascular risk factors</td></tr><tr><td>Laboratory testing</td><td>Family history</td></tr><tr><td>Periodic</td><td>Hypertension</td></tr><tr><td>Cervical cytology (annually beginning no later than age 21 years; every 2-3 years after three consecutive negative test results if age 30 years or older with no history of cervical intraepithelial neoplasia 2 or 3, immunosuppression, human immunodeficiency visors [HIV] infection, or diethylstilbestrol exposure in utero)’</td><td>Dyslipidemia</td></tr><tr><td>High-risk groups*</td><td>Obesity</td></tr><tr><td>Hemoglobin level assessment</td><td>Diabetes mellitus</td></tr><tr><td>Bacteriuria testing</td><td>Lifestyle</td></tr><tr><td>Mammography</td><td>Health/Risk Behaviors</td></tr><tr><td>Fasting glucose testing</td><td>Hygiene (including dental); fluoride supplementation</td></tr><tr><td>Sexually transmitted disease testing</td><td>Injury prevention</td></tr><tr><td>H uman immunodeficiency virus (HIV) testing</td><td>—Safety belts and helmets</td></tr><tr><td>Genetic testing/counseling</td><td>—Occupational hazards</td></tr><tr><td>Rubella titer assessment</td><td>—Recreational hazards</td></tr></table>
======================================
<table><thead><th>Screening</th><th>Evaluation and Counseling</th></thead><tr><td>Thyroid-stimulating hormone screening</td><td>—Exercise and sports involvement</td></tr><tr><td>Hepatitis C virus testing</td><td>Breast self-examination®</td></tr><tr><td rowspan="5">Colorectal cancer screening</td><td>Bone density screening</td></tr><tr><td></td><td>Chemoprophylaxis for breast cancer (for high-risk</td></tr><tr><td></td><td>women aged 35 years or older)?</td></tr><tr><td></td><td>Skin exposure to ultraviolet rays</td></tr><tr><td></td><td>Suicide: depressive symptoms</td></tr></table>
======================================
<table><thead><th>Screening</th><th>Evaluation and Counseling</th></thead><tr><td colspan="2">History Sexuality¢</td></tr><tr><td>Reason for visit</td><td>High-risk behaviors</td></tr><tr><td>Health status: medical, surgical, family</td><td>Contraceptive options for prevention of unwanted pregnancy, including emergency contraception</td></tr><tr><td>Dietary/nutrition assessment</td><td>Sexually transmitted diseases</td></tr><tr><td>Physical activity</td><td>—Partner selection</td></tr><tr><td>Use of complementary and alternative medicine</td><td>—Barrier protection</td></tr><tr><td>Tobacco, alcohol, other drug use</td><td>Sexual functioning</td></tr><tr><td>Abuse/neglect</td><td>Fitness and nutrition</td></tr><tr><td>Sexual practices</td><td>Dietary/nutrition assessment</td></tr><tr><td>Urinary and fecal incontinence</td><td>Exercise: discussion of program</td></tr><tr><td>Physical examination</td><td>Folic acid supplementation (0.4 mg/d until age 50 years)</td></tr><tr><td>Height</td><td>Calcium intake</td></tr><tr><td>Weight</td><td>Psychosocial evaluation</td></tr><tr><td>Blood pressure</td><td>Family relationships</td></tr><tr><td></td><td></td></tr><tr><td>Oral cavity</td><td>Domestic violence</td></tr><tr><td>Neck: adenopathy, thyroid</td><td>Work satisfaction</td></tr><tr><td>Breasts, axillae</td><td>Retirement planning</td></tr><tr><td>Abdomen</td><td>Lifestyle/stress</td></tr><tr><td>Pelvic examination</td><td>Sleep disorders</td></tr><tr><td>Skin?</td><td>Cardiovascular risk factors</td></tr><tr><td>Laboratory testing</td><td>Family history</td></tr><tr><td>Periodic Cervical cytology (annually beginning no later than age 21 years; every 2-3 years after three consecutive negative test results if age 30 years or older with no history of cervical intraepithelial neoplasia 2 or 3, immunosuppression, human immunodeficiency visors [HIV] infection, or diethylstilbestrol exposure in utero)’ Mammography (every 1-2 years beginning at age 40 years; yearly beginning at age 50)</td><td>Hypertension Dyslipidemia</td></tr><tr><td>Lipid profile assessment (every 5 years beginning at age 45 years) Yearly fecal occult blood testing or flexible sigmoidoscopy every 5 years or double contrast barium enema every 5 years or colonoscopy every 10 years (beginning at age 50 years)</td><td></td></tr><tr><td>Fasting glucose testing (every 3 years after age 45 years)</td><td>Obesity</td></tr><tr><td>Thyroid-stimulating hormone screening (every 5 years beginning at age 50 years)</td><td>Diabetes mellitus</td></tr></table>
======================================
<table><thead><th>Screening</th><th>Evaluation and Counseling</th></thead><tr><td>Fasting glucose testing</td><td>Injury prevention</td></tr><tr><td>Sexually transmitted disease testing</td><td>—Safety belts and helmets</td></tr><tr><td>Bone density screening</td><td>—Occupational hazards</td></tr><tr><td>Human immunodeficiency virus (HIV) testing</td><td>—Recreational hazards</td></tr><tr><td>Genetic testing/counseling</td><td>—Exercise and sports involvement</td></tr><tr><td>Tuberculosis skin testing</td><td>—Firearms</td></tr><tr><td>Lipid profile assessment</td><td>—Hearing</td></tr><tr><td>Thyroid-stimulating hormone screening</td><td>Breast self-examination?</td></tr><tr><td>Hepatitis C virus testing</td><td>Chemoprophylaxis for breast cancer (for high-risk women)®</td></tr><tr><td>Colorectal cancer screening</td><td>Skin exposure to ultraviolet rays</td></tr><tr><td rowspan="2">Bone density screening</td><td>Suicide: depressive symptoms</td></tr><tr><td></td><td>Tobacco, alcohol, other drug use</td></tr></table>
======================================
<table><thead><th>Screening</th><th>Evaluation and Counseling</th></thead><tr><td>History</td><td>Sexuality©</td></tr><tr><td>Reason for visit</td><td>Sexual functioning</td></tr><tr><td>Health status: medical, surgical, family</td><td>Sexual behaviors</td></tr><tr><td>Dietary/nutrition assessment</td><td>Sexually transmitted diseases</td></tr><tr><td>Physical activity</td><td>—Partner selection</td></tr><tr><td>Use of complementary and alternative medicine</td><td>—Barrier protection</td></tr><tr><td>Tobacco, alcohol, other drug use</td><td>Fitness and nutrition</td></tr><tr><td>Abuse/neglect</td><td>Dietary/nutrition assessment</td></tr><tr><td>Sexual practices</td><td>Exercise: discussion of program</td></tr><tr><td>Urinary and fecal incontinence</td><td>Calcium intake</td></tr><tr><td>Physical examination</td><td>Psychosocial evaluation</td></tr><tr><td>Height</td><td>Neglect/abuse</td></tr><tr><td>Weight</td><td>Lifestyle/stress</td></tr><tr><td>Blood pressure</td><td>Depression/sleep disorders</td></tr><tr><td>Oral cavity</td><td>Family relationships</td></tr><tr><td>Neck: adenopathy, thyroid</td><td>Work/retirement satisfaction</td></tr><tr><td>Breasts, axillae</td><td>Cardiovascular risk factors</td></tr><tr><td>Abdomen</td><td>Hypertension</td></tr><tr><td>Pelvic examination</td><td>Dyslipidemia</td></tr><tr><td>Skin?</td><td>Obesity</td></tr><tr><td>Laboratory testing</td><td>Sedentary lifestyle Health/Risk Behaviors</td></tr><tr><td>Periodic Cervical 2-3 after three consecutive</td><td>dental)</td></tr><tr><td>cytology (every years negative test results if no history of cervical intraepithelial neoplasia 2 or 3, immunosuppression, human immunodeficiency visors [HIV] infection, or diethylstilbestrol exposure in utero)’ Urinalysis Mammography Lipid profile assessment (every 5 years) Yearly fecal occult blood testing or flexible sigmoidoscopy every 5 years or yearly fecal occult blood testing plus flexible sigmoidoscopy every 5 years or double contrast barium enema every 5 years or colonoscopy every 10 years</td><td>Hygiene (including</td></tr><tr><td>Fasting glucose testing (every 3 years after age 45 years)</td><td>Hormone therapy</td></tr><tr><td>Bone density screening®</td><td>Injury prevention</td></tr><tr><td>Thyroid-stimulating hormone screening (every 5 years beginning at age 50 years)</td><td>—Safety belts and helmets</td></tr><tr><td>High-risk groups*</td><td>—Occupational hazards</td></tr><tr><td>Hemoglobin level assessment</td><td>—Recreational hazards</td></tr></table>
======================================
<table><thead><th>Screening</th><th>Evaluation and Counseling</th></thead><tr><td>Thyroid-stimulating hormone screening</td><td>Hearing</td></tr><tr><td>Hepatitis C virus testing</td><td>Breast self-examination?</td></tr><tr><td rowspan="4">Colorectal cancer screening</td><td>Chemoprophylaxis for breast cancer (for high-risk women)*</td></tr><tr><td></td><td>Skin exposure to ultraviolet rays</td></tr><tr><td></td><td>Suicide: depressive symptoms</td></tr><tr><td></td><td>Tobacco, alcohol, other drug use</td></tr></table>
======================================
<table><tr><td>Bone density screening?</td><td>Postmenopausal women younger than 65 years: personal history of fracture as an adult; history of fracture in a first-degree relative; Caucasian; dementia; poor health or frailty; current cigarette smoking; low body weight (&lt;127 Ib); estrogen deficiency caused by early (age &lt;45) menopause, bilateral ovariectomy, or prolonged (&gt;1 year) premenopausal amenorrhea; low lifelong calcium intake; alcoholism; impaired eyesight despite adequate correction; recurrent falls; inadequate physical activity. All women: certain diseases or medical conditions and those who take certain drugs associated with an increased risk of osteoporosis</td></tr><tr><td>Colorectal cancer screening?</td><td>Colorectal cancer or adenomatous polyps in first-degree relative younger than 60 years or in two or more first-degree relatives of any ages; family history of familial adenomatous polyposis or hereditary nonpolyposis colon cancer; history of colorectal cancer, adenomatous polyps, inflammatory bowel disease, chronic ulcerative colitis, or Crohn’s disease</td></tr><tr><td>Fasting glucose testing</td><td>Overweight (body mass index 225 kg/m?); family history of diabetes mellitus; habitual physical inactivity; high-risk race/ethnicity (e.g., African American, Hispanic, Native American, Asian, . Pacific Islander); have given birth to a newborn weighing more than 9 lb or history of gestational diabetes mellitus; hypertension; high-density lipoprotein cholesterol level of at &lt;35 mg/dL; triglyceride level of at 2250 mg/dL; history of impaired glucose tolerance or impaired fasting glucose; polycystic ovary syndrome; history of vascular disease</td></tr><tr><td>Fluoride supplementation</td><td>Live in area with inadequate water fluoridation (&lt;0.7 ppm)</td></tr><tr><td>Genetic testing/counseling</td><td>Considering pregnancy and: will be age 35 or older; patient, partner, or family member with history of genetic disorder or birth defect; exposure to teratogens; or African, Acadian, European Caucasian, Eastern European (Ashkenazi) Jewish, Mediterranean, or Southeast Asian ancestry</td></tr><tr><td>Hemoglobin level assessment</td><td>Caribbean, Latin American, Asian, Mediterranean, or African ancestry; history of excessive menstrual flow</td></tr><tr><td>HAV vaccination</td><td>Chronic liver disease; clotting factor disorders; illegal drug users; individuals who work with HAV-infected nonhuman primates or with HAV in a research laboratory setting; individuals traveling to or working in countries that have high or intermediate endemicity of hepatitis A</td></tr><tr><td>HBV vaccination</td><td>Hemodialysis patients; patients who receive clotting factor concentrates; health care workers and public safety workers who have exposure to blood in the workplace; individuals in training in schools of medicine, dentistry, nursing, laboratory technology, and other allied health professions; injecting drug users; individuals with more than one sexual partner in the previous 6 months; individuals with a recently acquired STD; all clients in STD clinics; household contacts and sexual partners of individuals with chronic HBV infection; clients and staff of institutions for the developmentally disabled; international travelers who will be in countries with high or intermediate prevalence of chronic HBV infection for more than 6 months; inmates of correctional facilities</td></tr><tr><td>HCV testing</td><td>History of injecting illegal drugs; recipients of clotting factor concentrates before 1987; chronic (long-term) hemodialysis; persistently abnormal alanine aminotransferase levels; recipient of blood from a donor who later tested positive for HCV infection; recipient of blood or blood- component transfusion or organ transplant before July 1992; occupational percutaneous or mucosal exposure to HCV-positive blood</td></tr><tr><td>HIV testing</td><td>Seeking treatment for STDs; drug use by injection; history of prostitution; 
======================================
past or present sexual partner who is HIV positive or bisexual or injects drugs; long-term residence or birth in an area with high prevalence of HIV infection; history of transfusion from 1978 to 1985; invasive cervical cancer; pregnancy. Offer to women seeking preconception evaluation.</td></tr><tr><td>Influenza vaccination</td><td>Anyone who wishes to reduce the chance of becoming ill with influenza; chronic cardiovascular or pulmonary disorders, including asthma; chronic metabolic diseases, including diabetes mellitus, renal dysfunction, hemoglobinopathies, and immunosuppression (including immunosuppression caused by medications or by HIV); residents of nursing homes and other</td></tr></table>
======================================
<table><thead><th>Intervention</th><th>High-Risk Factor</th></thead><tr><td></td><td>(e.g., household members and caregivers of elderly, those with medical indications, and adults with high-risk conditions); health care workers; daycare workers</td></tr><tr><td>Lipid profile assessment</td><td>Family history suggestive of hyperlipidemia; family history of premature (age &lt;50 years for men, age &lt;60 years for women) cardiovascular disease; diabetes mellitus; multiple coronary heart disease risk factors (e.g., tobacco use, hypertension)</td></tr><tr><td>Mammography</td><td>Women who have had breast cancer or who have a first-degree relative (i.e., mother, sister, or daughter) or multiple other relatives who have a history of premenopausal breast or breast and ovarian cancer</td></tr><tr><td>MMR vaccination</td><td>Adults born in 1957 or later should be offered vaccination (1 dose of MMR) if there is no proof of immunity or documentation of a dose given after first birthday; persons vaccinated in 1963-1967 should be offered revaccination (2 doses); health care workers, students entering college, international travelers, and rubella-negative postpartum patients should be offered a second dose.</td></tr><tr><td>Pneumococcal vaccination</td><td>Chronic illness, such as cardiovascular disease, pulmonary disease, diabetes mellitus, alcoholism, chronic liver disease, cerebrospinal fluid leaks, functional asplenia (e.g., sickle cell disease) or splenectomy; exposure to an environment where pneumococcal outbreaks have occurred; immunocompromised patients (e.g., HIV infection, hematologic or solid malignancies, chemotherapy, steroid therapy. Revaccination after 5 years may be appropriate for certain high-risk groups.</td></tr><tr><td>Rubella titer assessment</td><td>Childbearing age and no evidence of immunity</td></tr><tr><td>STD testing</td><td>History of multiple sexual partners or a sexual partner with multiple contacts; sexual contact with individuals with culture-proven STD, history of repeated episodes of STDs, attendance at clinics for STDs, routine screening for chlamydial infection for all sexually women aged 25 years or younger and other asymptomatic women at high risk for infection; routine screening or gonorrheal infection for all sexually active adolescents and other asymptomatic women at igh risk for infection</td></tr><tr><td>Skin examination</td><td>Increased recreational or occupational exposure to sunlight; family or personal history of skin cancer; clinical evidence of precursor lesions</td></tr><tr><td>Thyroid-stimulating hormone screening</td><td>Strong family history of thyroid disease; autoimmune disease (evidence of subclinical ypothyroidism may be related to unfavorable lipid profiles)</td></tr><tr><td>Tuberculosis skin testing Varicella vaccination</td><td>Human immunodeficiency virus infection; close contact with persons known or suspected to ave tuberculosis; medical risk factors known to increase risk of disease if infected; born in country with high tuberculosis prevalence; medically underserved; low income; alcoholism; intravenous drug use; resident of long-term care facility (e.g., correctional institutions, mental institutions, nursing homes and facilities); health professional working in high-risk health care acilities All susceptible adults and adolescents, including health-care workers; household contacts of</td></tr><tr><td>Abbreviations: HAV, hepatitis mumps-rubella; STD, sexually</td><td>immunocompromised individuals; teachers; day-care workers; residents and staff of institutional settings, colleges, prisons, or military installations; adolescents and adults living in households with children; international travelers; nonpregnant women of childbearing age A virus; HBV, hepatitis B virus; HCV, hepatitis C virus, HIV, human immunodeficiency virus; MMR, measles- transmitted diseases.</td></tr></table>
======================================
<table><thead><th>Ages 13-18 Years</th><th>Ages 19-39 Years</th><th>Ages 40-64 Years</th><th>Age 65 Years and Older</th></thead><tr><td colspan="4">Periodic</td></tr><tr><td>Tetanus-diphtheria booster (once between ages 11 years and 16 years) Hepatitis B virus vaccine (one series for those not previously immunized)</td><td>Tetanus-diphtheria booster (every 10 years)</td><td>Influenza vaccine (annually beginning at age 50 years) Tetanus-diphtheria booster (every 10 years)</td><td>Tetanus-diphtheria booster (every 10 years) Influenza vaccine (annually) Pneumococcal vaccine (once)</td></tr><tr><td>High-risk groups?</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td></tr><tr><td>Influenza vaccine</td><td>Measles-mumps-rubella vaccine</td><td>Measles-mumps-rubella vaccine</td><td>Hepatitis A vaccine</td></tr><tr><td>Hepatitis A vaccine</td><td>Hepatitis A vaccine</td><td>Hepatitis A vaccine</td><td>Hepatitis B vaccine</td></tr><tr><td>Pneumococcal vaccine</td><td>Hepatitis B vaccine</td><td>Hepatitis B vaccine</td><td>Varicella vaccine</td></tr><tr><td>Measles-mumps-rubella vaccine</td><td>Influenza vaccine</td><td>Influenza vaccine</td><td></td></tr><tr><td>Varicella vaccine</td><td>Pneumococcal vaccine</td><td>Pneumococcal vaccine</td><td></td></tr><tr><td></td><td>Varicella vaccine</td><td>Varicella vaccine</td><td></td></tr></table>
======================================
<table><thead><th>Table 9.6 Blood</th><th>Pressure Classifi ion (Adults 18</th><th>Years and</th><th>Older)</th></thead><thead><th>Category</th><th>Systolic BP (mm Hg)</th><th colspan="2">Diastolic BP (mm H</th></thead><thead><th>Normal</th><th>&lt;120</th><th>and</th><th>&lt;80</th></thead><tr><td>Prehypertension</td><td>120-139</td><td>or</td><td>80-89</td></tr><tr><td>Stage 1 hypertension</td><td>140-159</td><td>or</td><td>90-99</td></tr><tr><td>Stage 2 hypertension</td><td>&gt;160</td><td>or</td><td>&gt;100</td></tr></table>
======================================
<table><thead><th>TABLE 9.7</th><th>Drug Choices</th><th>for</th><th>Hypertension with</th><th>Compelling</th><th>Indications</th><th></th></thead><tr><td>Compelling Indication</td><td>Diuretic</td><td>B-blocker</td><td>ACE inhibitor</td><td>ARB</td><td>CCB</td><td>Aldostero: __antagoni:</td></tr><tr><td>Heart failure</td><td>Vv</td><td>Vv</td><td>Vv</td><td>V</td><td></td><td>Vv</td></tr><tr><td>Post-MI</td><td></td><td>Vv</td><td>Vv</td><td></td><td></td><td>Vv</td></tr><tr><td>High coronary risk</td><td>Vv</td><td>Vv</td><td>Vv</td><td></td><td>V</td><td></td></tr><tr><td>Diabetes</td><td>Vv</td><td>Vv</td><td>Vv</td><td>V</td><td>V</td><td></td></tr><tr><td>Chronic kidney disease</td><td>V</td><td>Vv</td><td></td><td></td><td></td><td></td></tr><tr><td>Recurrent stroke prevention</td><td>Vv</td><td></td><td>v</td><td></td><td></td><td></td></tr></table>
======================================
<table></table>
======================================
<table><tr><td colspan="3">ACE inhibitors</td></tr><tr><td>Enalapril (Vasotec)</td><td>2.5-40</td><td>1-2</td></tr><tr><td>Captopril (Capoten)</td><td>25-100</td><td>2</td></tr><tr><td>Benazepril (Lotensin)</td><td>10-40</td><td>1-2</td></tr><tr><td>Fosinopril (Monopril)</td><td>10-40</td><td></td></tr><tr><td>Lisinopril (Prinivil, Zestril)</td><td>10-40</td><td></td></tr><tr><td>Moexipril (Univasc)</td><td>7.5-30</td><td></td></tr><tr><td colspan="3">Calcium channel blockers nondihydropyridines</td></tr><tr><td>Verapamil, sustained release (Calan SR, Isoptin SR)</td><td>120-360</td><td>1-2</td></tr><tr><td>Diltiazem, sustained release (Cardizem CD, Tiazac)</td><td>180-420</td><td></td></tr><tr><td colspan="3">Calcium channel blockers dihydropyridines</td></tr><tr><td>Amlodipine (Norvasc)</td><td>2.5-10</td><td></td></tr><tr><td>Felodipine (Plendil)</td><td>2.5-20</td><td></td></tr><tr><td>Nifedipine, long-acting (Adalat CC, Procardia XL)</td><td>30-60</td><td></td></tr><tr><td>Nicardipine, sustained release (Cardene SR)</td><td>60-120</td><td>2</td></tr><tr><td colspan="3">a-blockers</td></tr><tr><td>Terazosin (Hytrin)</td><td>1-20</td><td>1-2</td></tr><tr><td>Doxazosin (Cardura)</td><td>1-16</td><td>1</td></tr><tr><td colspan="3">Mixed a- and B-blockers</td></tr><tr><td>Labetalol (Normodyne, Trandate)</td><td>200-800</td><td>2</td></tr><tr><td colspan="3">Thiazide diuretics</td></tr><tr><td>Hydrochlorothiazide (Microzide, HydroDIURIL)</td><td>12.5-50</td><td>1</td></tr><tr><td>Indapamide (Lozol)</td><td>1.25-2.5</td><td>1</td></tr><tr><td colspan="3">Loop diuretics</td></tr><tr><td>Furosemide (Lasix)</td><td>20-80</td><td>2</td></tr><tr><td>Bumetanide (Bumex)</td><td>0.5-2</td><td>2</td></tr><tr><td colspan="3">Potassium-sparing diuretics</td></tr><tr><td>Triamterene (Dyrenium)</td><td>50-100</td><td>1-2</td></tr><tr><td colspan="3">B-blockers</td></tr><tr><td>Atenolol (Tenormin)</td><td>25-100</td><td>1</td></tr><tr><td>Metoprolol (Lopressor)</td><td>50-100</td><td>1-2</td></tr><tr><td>Metoprolol, extended release (Toprol XL)</td><td>50-100</td><td>1</td></tr><tr><td>Angiotensin II receptor antagonists</td><td></td><td></td></tr></table>
======================================
<table><thead><th colspan="3">Table 9.8 Continued</th></thead><thead><th>Medication Class</th><th>Normal Daily Dosage (mg/day)</th><th>Daily Frequency</th></thead><tr><td colspan="3">Central a,-agonist</td></tr><tr><td>Clonidine (Catapres)</td><td>0.1-0.8</td><td>2</td></tr><tr><td>Clonidine patch (Catapres TTS)</td><td>0.1-0.3</td><td>weekly</td></tr><tr><td colspan="3">Direct vasodilators</td></tr><tr><td>Hydralazine (Apresoline)</td><td>25-100</td><td>2</td></tr><tr><td>Minoxidil (Loniten)</td><td>2.5-80</td><td>1-2</td></tr></table>
======================================
<table><tr><td>&lt;200 mg/dL</td><td>Desirable blood cholesterol</td></tr><tr><td>200-239 mg/dL</td><td>Borderline high blood cholesterol</td></tr><tr><td>=240 mg/dL</td><td>High blood cholesterol</td></tr><tr><td colspan="2">LDL cholesterol</td></tr><tr><td>&lt;100 mg/dL</td><td>Optimal cholesterol</td></tr><tr><td>100-129 mg/dL</td><td>ear or above optimal</td></tr><tr><td>130-159 mg/dL</td><td>Borderline high</td></tr><tr><td>160-189 mg/dL</td><td>High</td></tr><tr><td>=190 mg/dL</td><td>Very high</td></tr><tr><td colspan="2">HDL cholesterol</td></tr><tr><td>&lt;40 mg/dL</td><td>Low HDL cholesterol</td></tr><tr><td>=60 mg/dL</td><td>High HDL cholesterol</td></tr><tr><td colspan="2">Triglycerides</td></tr><tr><td>&lt;150 mg/dL</td><td>ormal</td></tr><tr><td>150-199 mg/dL</td><td>Borderline high</td></tr><tr><td>200-499 mg/dL</td><td>High</td></tr><tr><td>&gt;500 mg/dL</td><td>Very high</td></tr></table>
======================================
<table><thead><th>seneric</th><th>Trade Name</th><th>Daily Dose</th><th>Renal Function</th></thead><tr><td>Lovastatin</td><td>Mevacor</td><td>20 mg, 40 mg, 80 mg daily</td><td>Use lower dose for severe renal impairment</td></tr><tr><td>Pravastatin</td><td>Pravachol</td><td>10 mg, 20 mg, 40 mg, 80 mg daily</td><td>Use lower dose for severe or moderate renal impairment</td></tr><tr><td>Simvastatin</td><td>Zocor</td><td>10 mg, 20 mg, 40 mg, 80 mg daily</td><td>Use lower dose for severe renal impairment</td></tr><tr><td>Fluvastatin</td><td>Lescol</td><td>20 mg, 40 mg, 80 mg daily</td><td>No dose adjustment needed for reduced renal function</td></tr><tr><td>Atorvastatin</td><td>Lipitor</td><td>10 mg, 20 mg, 40 mg, 80 mg daily</td><td>No dose adjustment needed for reduced renal function</td></tr></table>
======================================
<table><thead><th></th><th></th><th></th><th></th><th></th><th></th><th></th><th></th><th></th></thead><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr></table>
======================================
<table></table>
======================================
<table><thead><th>OHA</th><th>Trade Name</th><th>Daily Dose</th><th>Duration of Action (Hrs)</th></thead><tr><td>Glyburide</td><td>Glucotrol</td><td>2.5-20 mg variable dose</td><td>10-24</td></tr><tr><td>Glipizide sustained release</td><td>Glucotrol XL</td><td>2.5-20 mg once daily</td><td>24</td></tr><tr><td>Glimepiride</td><td>Amaryl</td><td>1-8 mg once or divided</td><td>12-24</td></tr><tr><td>Metformin</td><td>Glucophage</td><td>500 mg-2.5 grams in two or three divided doses</td><td>6-12</td></tr><tr><td>Pioglitazone</td><td>Actos</td><td>15-45 mg once daily</td><td>24</td></tr><tr><td>Rosiglitazone</td><td>Avandia</td><td>4-8 mg once or divided</td><td>24</td></tr><tr><td>Nateglinide</td><td>Starlix</td><td>60-120 mg before meals</td><td>2-4</td></tr><tr><td>Repaglinide</td><td>Prandin</td><td>0.5-4 mg before meals</td><td>2-4</td></tr><tr><td>Acarbose</td><td>Precose</td><td>25-100 mg before meals</td><td>2-4</td></tr></table>
======================================
<table><thead><th>All women</th><th>54,099,000</th><th>60,201,000</th><th>61,561,001</th></thead><tr><td>Using contraception %</td><td>55.7</td><td>64.2</td><td>61.9</td></tr><tr><td>Female sterilization</td><td>12.9</td><td>17.8</td><td>16.7</td></tr><tr><td>Male sterilization</td><td>6.1</td><td>7.0</td><td>5.7</td></tr><tr><td>Pill</td><td>15.6</td><td>17.3</td><td>18.9</td></tr><tr><td>Implant, Lunelle™ or patch</td><td></td><td>0.9</td><td>0.8</td></tr><tr><td>3-month injectable (DepoProvera)</td><td></td><td>1.9</td><td>3.3</td></tr><tr><td>Intrauterine device</td><td>4.0</td><td>0.5</td><td>1.3</td></tr><tr><td>Condom</td><td>6.7</td><td>13.1</td><td>11.1</td></tr><tr><td>Periodic abstinence—calendar rhythm</td><td>1.8</td><td>13</td><td>0.7</td></tr><tr><td>Periodic abstinence—natural family planning</td><td>0.3</td><td>0.2</td><td>0.2</td></tr><tr><td>Withdrawal</td><td>1.1</td><td>2.0</td><td>2.5</td></tr><tr><td>Other methods?</td><td>2.7</td><td>1.1</td><td>0.6</td></tr></table>
======================================
<table><thead><th></th><th colspan="2">Women Experiencing Accidental Pregnancy within the First Year of Use %</th><th>Women Continuing Use at 1 Year (%)</th></thead><tr><td>Method</td><td>Typical Use</td><td>Perfect Use</td><td></td></tr><tr><td>No method</td><td>85</td><td>85</td><td></td></tr><tr><td>Spermicides</td><td>29</td><td>18</td><td>42</td></tr><tr><td>Periodic abstinence</td><td>25</td><td></td><td>67</td></tr><tr><td>Calendar</td><td></td><td>9</td><td></td></tr><tr><td>Ovulation method</td><td></td><td>3</td><td></td></tr><tr><td>Symptothermal</td><td></td><td>2</td><td></td></tr><tr><td>Postovulation</td><td></td><td>1</td><td></td></tr><tr><td>Withdrawal</td><td>27</td><td>4</td><td>43</td></tr><tr><td colspan="4">Cap</td></tr><tr><td>Parous women</td><td>32</td><td>26</td><td>46</td></tr><tr><td>Nulliparous women</td><td>6</td><td>9</td><td>57</td></tr><tr><td colspan="4">Sponge</td></tr><tr><td>Parous women</td><td>32</td><td>20</td><td>46</td></tr><tr><td>Nulliparous women</td><td>6</td><td>9</td><td>57</td></tr><tr><td>Diaphragm Condom</td><td>6</td><td>6</td><td>57</td></tr><tr><td>Female (Reality)</td><td>21</td><td>5</td><td>49</td></tr><tr><td>Male Combined pill and progestin-only pill</td><td>5 8</td><td>2 0.3</td><td>53 68</td></tr><tr><td>Patch (Evra™)</td><td>8</td><td>0.3</td><td>68</td></tr><tr><td>NuvaRing</td><td>8</td><td>0.3</td><td>68</td></tr><tr><td>Intrauterine devices</td><td></td><td></td><td></td></tr><tr><td colspan="4">ParaGard™ (Copper T 380A) 0.8 0.6 78</td></tr><tr><td>Myrena (levonorgestrel T)</td><td>0.1</td><td>0.1</td><td>81</td></tr><tr><td>DepoProvera</td><td>3</td><td>0.3</td><td>70</td></tr><tr><td>Lunelle</td><td>3</td><td>0.05</td><td>56</td></tr><tr><td>and II</td><td>0.05</td><td>0.05</td><td>84</td></tr><tr><td>Norplant? Norplant Female sterilization</td><td>0.5</td><td>0.5</td><td>100</td></tr></table>
======================================
<table><thead><th>Method</th><th>Advantages</th><th>Disadvantages</th><th>Risks</th><th>Noncontraceptive Benefits</th></thead><tr><td>Coitus interruptus</td><td>Available, free</td><td>Depends on male control</td><td>Pregnancy</td><td>Decreased HIV risk</td></tr><tr><td>Lactation</td><td>Available, free</td><td>Unreliable duration of effect</td><td>Pregnancy</td><td>Decreased breast cancer</td></tr><tr><td>Periodic abstinence</td><td>_ Available, free</td><td>Complex methodology; motivation is essential</td><td>Pregnancy</td><td></td></tr><tr><td>Condoms</td><td>Available, no prescription needed</td><td>Motivation is essential; must be used each time; depends on man</td><td>Pregnancy</td><td>Proven to decrease STDs and cervical cancer</td></tr><tr><td>Spermicides and sponge</td><td>Available, no prescription needed</td><td>Must be used each time</td><td>Pregnancy</td><td></td></tr><tr><td>Diaphragm/cap</td><td>Nonhormonal</td><td>Must be used each time; fitting required</td><td>Pregnancy, cystitis</td><td>Proven to decrease STDs and cervical cancer</td></tr><tr><td>ParaGard IUD</td><td>High efficacy for 10 years, unrelated to coitus</td><td>Initial cost; skilled inserter; pain and bleeding</td><td>nitial mild risk for PID and septic abortion</td><td></td></tr><tr><td>Mirena IUD</td><td>High efficacy for 5 years; unrelated to coitus</td><td>Initial cost; skilled inserter; amenorrhea for some</td><td>nitial mild risk for PID and septic abortion</td><td>Reduced bleeding; can be used to treat menorrhagia</td></tr><tr><td>Oral contraceptives Evra™ patch NuvaRing</td><td>High efficacy</td><td>Motivation to take daily; cost</td><td>Thrombosis; older smokers have increased risk of MI and stroke</td><td>Many benefits (see text)</td></tr><tr><td>DMPA</td><td>High efficacy, convenience</td><td>Injection required; bleeding pattern Osteopenia Weight gain</td><td>Probably none</td><td>Many (see text)</td></tr><tr><td>Lunelle™</td><td>High efficacy, convenience</td><td>Monthly injection</td><td>Probably same as orals</td><td>Probably same as orals</td></tr><tr><td>Implants</td><td>High efficacy, convenience</td><td>Surgical insertion and removal; initial cost; bleeding pattern</td><td>Functional cysts</td><td>Unknown</td></tr><tr><td>Emergency contraception Levonorgestrel</td><td>Moderate efficacy</td><td>Frequent use disrupts menses</td><td>one</td><td>Unknown</td></tr></table>
======================================
<table><thead><th>Method</th><th>Cost ($)</th><th>Cost Multiple ($)</th></thead><tr><td>Vasectomy</td><td>55</td><td>1.0</td></tr><tr><td>Tubal ligation</td><td>118</td><td>2.14</td></tr><tr><td>Intrauterine device</td><td>150</td><td>2.71</td></tr><tr><td>Norplant</td><td>202</td><td>3.66</td></tr><tr><td>Depomedroxyprogesterone acetate</td><td>396</td><td>7.19</td></tr><tr><td>Oral contraceptives</td><td>456</td><td>8.27</td></tr><tr><td>Condoms</td><td>776</td><td>14.08</td></tr><tr><td>Diaphragm</td><td>1,147</td><td>20.81</td></tr></table>
======================================
<table></table>
======================================
<table></table>
======================================
<table></table>
======================================
<table></table>
======================================
<table><thead><th>Estrogen (Dose)</th><th>(Rate/10,000 Person Years)</th><th>Relative Risk (All Cases)</th><th>Relative Risk (Proven Diagnosis,</th></thead><tr><td>&lt;50 ug</td><td>4.2</td><td>1.0</td><td>1.0?</td></tr><tr><td>50 wg</td><td>7.0</td><td>1.5</td><td>2.0 (0.0-4.0)</td></tr><tr><td>&gt;50 wg</td><td>10.0</td><td>1.7</td><td>3.2 (2.4-4.3)</td></tr></table>
======================================
<table><thead><th>Established Benefits</th></thead><tr><td>Menses-related</td></tr><tr><td>Increased menstrual cycle regularity</td></tr><tr><td>Reduced blood loss</td></tr><tr><td>Reduced iron-deficiency anemia</td></tr><tr><td>Reduced dysmenorrhea</td></tr><tr><td>Inhibition of ovulation</td></tr><tr><td>Fewer ovarian cysts</td></tr><tr><td>Fewer ectopic pregnancies</td></tr><tr><td>Other</td></tr><tr><td>Reduced fibroadenomas/fibrocystic breast changes</td></tr><tr><td>Reduced acute pelvic inflammatory disease</td><td></td></tr><tr><td>Reduced endometrial cancer</td></tr><tr><td>Reduced ovarian cancer</td></tr><tr><td>Emerging Benefits</td></tr><tr><td>Increased bone mass</td></tr><tr><td>Reduced acne</td><td></td></tr><tr><td>Reduced colo-rectal cancer</td></tr><tr><td>Reduced uterine leiomyomata</td></tr><tr><td>Reduced rheumatoid arthritis</td></tr><tr><td>Treatment of bleeding disorders</td></tr><tr><td>Treatment of hyperandrogenic anovulation</td></tr><tr><td>Treatment of endometriosis</td></tr><tr><td>Treatment of perimenopausal changes</td></tr></table>
======================================
<table><thead><th>rade Name?</th><th>Progestin</th><th>Estrogen</th></thead><tr><td colspan="3">rogestin-only</td></tr><tr><td>Micronor (Errin, Jolivette, Camila, Nora-BE, NorQD)</td><td>NE 350 pg</td><td>none</td></tr><tr><td>Ovrette</td><td>d,I-NG 75 pg</td><td>none</td></tr><tr><td colspan="3">ombination-monophasic</td></tr><tr><td>orlestrin</td><td>NEA 2.5 mg</td><td>EE 50 wg</td></tr><tr><td>Norlestrin-1</td><td>NEA 1.0 mg</td><td>EE 50 wg</td></tr><tr><td>Loestrin 1.5/30</td><td>NEA 1.5 mg</td><td>EE 30 wg</td></tr><tr><td>Ovral (Ogestrel)</td><td>d,|-NG 0.5 mg</td><td>FE 50 wg</td></tr><tr><td>Lo Ovral (Low-Ogestrel, Cryselle)</td><td>d,|-NG 0.3 mg</td><td>FE 30 wg</td></tr><tr><td>Nordette (Levlen, Levora 0.15/30, Portia) Seasonale contains the same steroids, but provides 84 active pills in each package rather than 21</td><td>levoNG 0.15 mg</td><td>EE 30 wg</td></tr><tr><td>Ortho-Novum 1/50, Norinyl 1/50, Necon 1/50, Nelova 1/50 M)</td><td>NE 1.0 mg</td><td>ME 50 pg</td></tr><tr><td>Ovcon 50</td><td>NE 1.0 mg</td><td>EE 50 ug</td></tr><tr><td></td><td></td><td></td></tr><tr><td>Orthonovum 1/35 (Norinyl 1/35, Necon 1/35, Nelova 1/35E, Nortrel 1/35)</td><td>NE 1.0 mg</td><td>FE 35 wg</td></tr><tr><td>Modicon (Brevicon, Necon 0.5/35, Nelova 0.5/35E, Nortrel 0.5/35)</td><td>NE 0.5 mg</td><td>EE 35 ug</td></tr><tr><td>Ovcon 35</td><td>NE 0.4 mg</td><td>EE 35 wg</td></tr><tr><td>Demulen 1/50 (Zovia 1/50E)</td><td>ED 1.0 mg</td><td>EE 50 ug</td></tr><tr><td>Demulen 1/35 (Zovia 1/35E)</td><td>ED 1.0 mg</td><td>EE 35 wg</td></tr><tr><td>Desogen (Orthocept, Apri, Solia)</td><td>Deso 0.15 mg</td><td>EE 30 wg</td></tr><tr><td>OrthoCyclen (MonoNessa, Previfem, Sprintec)</td><td>Norg 0.25 mg</td><td>EE 35 wg</td></tr><tr><td>Loestrin 1/20</td><td>NEA 1.0 mg</td><td>EE 20 ug</td></tr><tr><td>Alesse (Levlite, Aviane, Lessina)</td><td>levoNG 0.10 mg</td><td>EE 20 wg</td></tr><tr><td colspan="3">lultiphasic</td></tr><tr><td>’thonovum 10/11 (Neocon 10/11, Nelova 10/11)</td><td></td><td></td></tr></table>
======================================
<table><thead><th>Table 10.7 (Continued) Trade Name*</th><th></th></thead><tr><td colspan="2">Progestin Estrogen OrthoTri-Cyclen (TriNessa, Tri-Sprintec, Tri-Previfem)</td></tr><tr><td colspan="2">Norg 0.18 mg and EE 35 yg (first 7 days)</td></tr><tr><td colspan="2">Norg 0.215 mg and EE 35 yg (next 7 days)</td></tr><tr><td colspan="2">Norg 0.250 mg and EE 35 mg (next 7 days)</td></tr><tr><td colspan="2">Ortho Tri-Cyclen Lo</td></tr><tr><td colspan="2">Norg 0.18 mg and EE 25 yg (first 7 days)</td></tr><tr><td colspan="2">Norg 0.215 mg and EE 25 yg (next 7 days)</td></tr><tr><td colspan="2">Norg 0.250 mg and EE 25 mg (next 7 days)</td></tr><tr><td colspan="2">Estrostep</td></tr><tr><td colspan="2">NEA 1.0 mg and EE 20 yg (first 5 days)</td></tr><tr><td colspan="2">NEA 1.0 mg and EE 30 yg (next 7 days)</td></tr><tr><td colspan="2">NEA 1.0 mg and EE 35 yg (next 9 days)</td></tr><tr><td colspan="2">Mircette (Kariva)</td></tr><tr><td colspan="2">Deso 0.15 mg and EE 20 yg (first 21 days)</td></tr><tr><td colspan="2">Placebo and placebo (next 2 days)</td></tr><tr><td>Placebo and EE 10 ug (next 5 days)</td><td></td></tr></table>
======================================
<table></table>
======================================
<table><thead><th>Unipolar coagulation</th><th>7.5</th></thead><tr><td>Postpartum partial salpingectomy</td><td>7.5</td></tr><tr><td>Silastic band (Falope or Yoon)</td><td>17.7</td></tr><tr><td>Interval partial salpingectomy</td><td>20.1</td></tr><tr><td>Bipolar coagulation</td><td>24.8</td></tr><tr><td>Hulka-Clemens clip</td><td>36.5</td></tr><tr><td>Total: all methods</td><td>18.5</td></tr></table>
======================================
<table></table>
======================================
<table><thead><th>Netherlands, 1986</th><th>5.3</th><th colspan="2">Brazil, 1991 36.5</th></thead><tr><td>Canada, 1985</td><td>12.0</td><td>Columbia, 1989</td><td>32.7</td></tr><tr><td>England/Wales, 1987</td><td>14.2</td><td>Chile, 1990</td><td>45.4</td></tr><tr><td>United States, 1985</td><td>28.0</td><td>Mexico, 1990</td><td>22.3</td></tr><tr><td>Cuba, 1988</td><td>58.0</td><td>Peru, 1990</td><td>51.9</td></tr><tr><td>Former USSR, 1987</td><td>181.0</td><td>Dominican Republic</td><td>43.7</td></tr></table>
======================================
<table><thead><th></th><th></th><th></th><th></th><th></th><th></th><th></th></thead><thead><th></th><th></th><th></th><th></th><th></th><th></th><th></th></thead><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr></table>
======================================
<table><thead><th>Number of cases (%)</th><th>Rate</th><th></th></thead><tr><td colspan="3">Minor complications</td></tr><tr><td>Mild infection</td><td>784 (0.46)</td><td>1216</td></tr><tr><td>Resuctioned day of surgery</td><td>307 (0.18)</td><td>553</td></tr><tr><td>Resuctioned subsequently</td><td>285 (0.17)</td><td>1596</td></tr><tr><td>Cervical stenosis?</td><td>28 (0.016)</td><td>16,071</td></tr><tr><td>Cervical tear</td><td>18 (0.01)</td><td>19,444</td></tr><tr><td>Underestimation of gestational age</td><td>11 (0.006)</td><td>115,454</td></tr><tr><td>Convulsive seizure?</td><td>5 (0.004)</td><td>:25,086</td></tr><tr><td>Total minor complications</td><td>1 ,483 (0.846)</td><td>1118</td></tr><tr><td colspan="3">Complications requiring hospitalization</td></tr><tr><td>Incomplete abortion®</td><td>47 (0.28)</td><td>33,617</td></tr><tr><td>Sepsis?</td><td>36 (0.021)</td><td>14,722</td></tr><tr><td>Uterine perforation</td><td>16 (0.009)</td><td>210,625</td></tr><tr><td>Vaginal bleeding</td><td>12 (0.007)</td><td>14,166</td></tr><tr><td>Inability to complete abortion</td><td>6 (0.003)</td><td>128,333</td></tr><tr><td>Combined pregnancy</td><td>4 (0.002)</td><td>:42,500</td></tr><tr><td>Total requiring hospitalization</td><td>121 (0.071)</td><td>21,405</td></tr></table>
======================================
<table></table>
======================================
<table><tr><td>Routine antenatal visit</td><td>enjoyment; any pain? Women’s sexual needs can change during pregnancy. Do you have any problems or questions now? There is no evidence that intercourse or orgasm leads to miscarriage. Of course, any bleeding or spotting will require checking and postponing sexual activity until we have evaluated you. Many women find fatigue and/or nausea reduce their sexual life in the first 3 months, but usually things get back to normal for the middle 3 months and sometimes right up to</td></tr><tr><td>Complicated antenatal visit</td><td>term. These complications may well have already caused you to stop being sexual. Specifically, you should not (have intercourse/have orgasms).</td></tr><tr><td>After one or more miscarriages</td><td>Some women temporarily lose desire for sex after a miscarriage —this is quite normal. Many couples concentrate on affectionate touching while they both grieve about what has happened. Do allow yourselves some time. If any sexual problems persist, we can address them.</td></tr><tr><td>Infertility</td><td>All this testing and timed intercourse and disappointment, plus the financial burdens that are coming up, can be very stressful on your sex life. Try to have times when you and your partner are sexual just for pleasure and intimacy’s sake—not when you are trying to conceive. Do you have any problems now?</td></tr><tr><td>Perimenopause or postmenopause</td><td>We know many women have very rewarding sex after menopause—more time, more privacy. If you find the opposite or you begin to have pain or difficulty getting aroused, these things can be addressed. Do you have any concerns now?</td></tr><tr><td>Woman who is depressed</td><td>| know you are depressed right now, but our studies tell us that sex is still important for many women who are depressed. We also know that some of the medications we prescribe interfere with sexual enjoyment. Do you have any problems right now?</td></tr><tr><td>Chronic illness</td><td>Arthritis/multiple sclerosis can interfere with a woman’s sex life. Are you having any problems?</td></tr><tr><td>Potential damaging surgery</td><td>Obviously the focus right now is to remove your cancer entirely when we do your surgery. The nerves and blood vessels that allow sexual sensations and lubrication may be temporarily and sometimes permanently damaged. If when you have recovered you notice any sexual problems that persist, they can be addressed. Do you have any concerns now?</td></tr><tr><td>Bilateral oophorectomy</td><td>Your surgery will remove a major source of estrogen and approximately one half of the testosterone your body has been making. Testosterone will still be made by adrenal glands (small glands on top of the kidneys), and some of this gets converted into estrogen. Many women find that these reduced amounts of sex hormones are quite sufficient for sexual enjoyment, but others do not. Any sexual problems that do almost certainly be addressed. Do have</td></tr></table>
======================================
<table><thead><th>Sexual problem in patient’s own words</th><th>Clarify further with direct questions; give options rather than leading questions.</th></thead><tr><td>Duration, consistency, priority</td><td>Are problems present in all situations, and which is most severe?</td></tr><tr><td>Context of sexual problems</td><td>Emotional intimacy with partner, activity/behavior just before sexual activity, privacy, safety, birth control, risk of STD, usefulness of sexual stimulation, sexual skills of partner, sexual communication, time of day</td></tr><tr><td>Rest of each partner’s sexual response</td><td>Check this currently and before the onset of the sexual problems—sexual motivation, subjective arousal, enjoyment, orgasm, pain, and erection and ejaculation in male partner</td></tr><tr><td>Reaction of each partner to sexual problems</td><td>How each has reacted emotionally, sexually, and behaviorally</td></tr><tr><td>Previous help</td><td>Compliance with recommendations and effectiveness</td></tr><tr><td>Reason for presenting now</td><td>What has precipitated this request for help</td></tr><tr><td colspan="2">Assessment of Each Partner Alone</td></tr><tr><td>Partner’s own assessment of the situation</td><td>Sometimes it is easier to acknowledge symptoms, e.g., total lack of desire, in the partner’s absence</td></tr><tr><td>Sex response with self-stimulation</td><td>Also ask about sexual thoughts and fantasies</td></tr><tr><td>Past sexual experiences*</td><td>Positive, negative aspects</td></tr><tr><td>Developmental history’</td><td>Relationships to others in the home while growing up, losses, traumas, how they coped. To whom (if anyone) was this person close? Who showed them affection, loved them, respected them? Clarify if some of these themes are playing out now in the current sexual relationship.</td></tr><tr><td>Ask about sexual, emotional, and physical abuse’</td><td>Explain abuse questions are routine and do not necessarily imply causation of the problems.</td></tr></table>
======================================
<table><tr><td>General exam</td><td>Signs of systemic disease leading to low energy, low desire, low arousability, e.g., anemia. Bradycardia and slow relaxing reflexes of hypothyroidism. Signs of connective tissue disease, such as scleroderma or Srdjen’s, which are associated with vaginal dryness. Disabilities that might preclude movements involved in caressing a partner, self-stimulation, intercourse. Disfigurements/presence of stomas; catheters that may decrease sexual self-confidence, leading to low desire; low arousability.</td></tr><tr><td>External genitalia</td><td>Sparsity of pubic hair, suggesting low adrenal androgens. Vulval skin disorders, including lichen sclerosis, which may cause soreness with sexual stimulation (e.g., when it involves the clitoral hood). Cracks/fissures in the interlabial folds suggestive of chronic candidiasis. Labial abnormalities that may cause embarrassment/sexual hesitancy (e.g., particularly long labia or asymmetry).</td></tr><tr><td>Introitus</td><td>Vulval disease involving introitus (e.g., lichen sclerosis). Recurrent splitting of the posterior fourchette manifest as just visible white lines perpendicular to fourchette edge. Abnormalities of the hymen (e.g., hymenal band across the introitus). Adhesions of the labia minora. Swellings in the area of the major vestibular glands. Allodynia (pain sensation from touch stimulus) of the crease between the outer hymenal edge and the inner edge of the labia minora (typical of vulvar vestibulitis). Allodynia of the Skene’s duct openings. Presence of cystocele, rectocele, or prolapse interfering with the woman’s sexual self-image. Inability to tighten and relax perivaginal muscles (often associated with hypertonicity of pelvic muscles and midvaginal dyspareunia). Abnormal vaginal discharge associated with burning dyspareunia.</td></tr><tr><td>Internal exam</td><td>Pelvic muscle tone. Presence of tenderness trigger points on palpating deep levator ani as a result of underlying hypertonicity.</td></tr><tr><td>Full bimanual exam</td><td>Presence of nodules and/or tenderness in the cul-de-sac or vaginal fornix, or along uterosacral ligaments. Retroverted fixed uterus as causes of deep dyspareunia. Tenderness palpating posterior bladder wall from anterior vaginal wall suggestive of bladder pathology.</td></tr></table>
======================================
<table><thead><th>Diagnosis</th><th>Definition</th><th>Comments</th></thead><tr><td>Sexual desire/interest disorder</td><td>Absent or diminished feelings of sexual interest or desire, absent sexual thoughts or fantasies and a lack of responsive desire. Motivations (here defined as reasons/ incentives) for attempting to become sexually aroused are scarce or absent. The lack of interest is beyond a normative lessening with life cycle and relationship duration.</td><td>Minimal spontaneous sexual thinking or desiring of sex ahead of sexual experiences does not necessarily constitute disorder. Additional lack of responsive desire is integral to the diagnosis.</td></tr><tr><td>Combined sexual arousal disorder</td><td>Absent or markedly reduced feelings of sexual arousal (sexual excitement and sexual pleasure) from any type of stimulation and absent or impaired genital sexual arousal (vulval swelling and lubrication).</td><td>There is minimal sexual excitement (subjective arousal) from any type of stimulation—erotic material, stimulating the partner, genital and nongenital stimulation. There is no awareness of the reflexive genital vasocongestion.</td></tr><tr><td>Subjective sexual arousal disorder</td><td>Absent or markedly reduced feelings of sexual arousal (sexual excitement and sexual pleasure) from any type of stimulation. Vaginal lubrication and other signs of physical response still occur.</td><td>Despite lack of sexual excitement/ subjective arousal, lubrication is noted by the woman or partner. Intercourse is comfortable without use of external lubricant.</td></tr><tr><td>Genital arousal disorder</td><td>Absent or impaired genital sexual arousal-minimal vulval swelling or vaginal lubrication from any type of sexual stimulation and reduced sexual sensations from caressing genitalia. Subjective sexual excitement still occurs from nongenital sexual stimuli.</td><td>Subjective arousal (sexual excitement) from nongenital stimuli (erotica, stimulating the partner, receiving breast stimulation, kissing) is key to this diagnosis. Early studies indicate reduced vasocongestion in some but not all cases. Loss of sexual sensitivity of physiologically congested tissues accounts for others.</td></tr><tr><td>Orgasmic disorder</td><td>Despite the self-report of high sexual arousal/excitement, there is either lack of orgasm, markedly diminished intensity of orgasmic sensations, or marked delay of orgasm from any kind of stimulation.</td><td>Women with arousal disorders frequently do not experience orgasm. Their correct diagnosis is one of an arousal disorder.</td></tr><tr><td>Vaginismus</td><td>Persistent or recurrent difficulties of the women to allow vaginal entry of a penis, finger or any object despite the woman’s expressed wish to do so. There is often (phobic) avoidance and anticipation/fear/ experience of pain, along with variable and involuntary pelvic muscle contraction. Structural or other physical abnormalities must be ruled out/addressed.</td><td>Confirmation of this diagnosis is not possible until there has been therapy sufficient to allow a careful introital and vaginal examination. It is a presumptive diagnosis initially.</td></tr><tr><td>Dyspareunia</td><td>Persistent or recurrent pain with attempted or complete vaginal entry and or penile vaginal intercourse</td><td>There are many causes, including localized provoked vestibulodynia (vulvar vestibulitis syndrome) and vulvar atrophy from estrogen deficiency.</td></tr></table>
======================================
<table><thead><th></th><th></th><th></th><th></th><th></th><th></th><th></th><th></th><th></th></thead><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr></table>
======================================
<table><tr><td>Gonorrhea</td><td>Ceftriaxone 125 mg IM or Ciprofloxacin 500 mg PO or Spectinomycin 2 g IM</td></tr><tr><td>Chlamydia</td><td>Azithromycin 1 g PO or Doxycycline 100 mg PO bid X 7 days or Erythromycin 500 mg PO qid X 7 days</td></tr><tr><td>Trichomoniasis and bacterial vaginosis</td><td>Metronidazole 2 g PO</td></tr><tr><td>Hepatitis B</td><td>Vaccine 1.0 mL IM. Repeat in 1 and 6 months.</td></tr><tr><td>Tetanus (if indicated)</td><td>Td 0.5 mL IM</td></tr><tr><td>HIV</td><td>Zidovudine 300 mg and Lamivudine 150 mg (Combivir) PO bid for 28 days. Addition of protease inhibitor should be considered for high-risk exposures.</td></tr><tr><td>Pregnancy</td><td>Plan B (levonorgestrel 0.75 mg) 2 tablets immediately or Ovral 2 tablets immediately, repeat in 12 hours or 35 pig combination birth control pill, 4 tablets immediately, repeat in 12 hours or Mifepristone 10 mg as a single dose or Placement of</td></tr></table>
======================================
<table><thead><th></th><th></th><th></th><th></th><th></th><th></th><th></th><th></th><th></th></thead><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr></table>
======================================
<table><thead><th></th><th>le 12.2 Scientific</th><th>Basis of Selected</th><th>Medications Used to Treat</th><th>PMS</th></thead><tr><td>Treatment Alprazolam</td><td>Scientific Basis Several double-blind, | placebo-controlled, randomized crossover studies. Results were mixed. Placebo was as effective as alprazolam in some studies.</td><td>Advantages Oral medication appears to be more effective in alleviating depression and anxiety symptoms than physical symptoms.</td><td>Disadvantages Potential for dependence; requires tapering; drowsiness reported by many subjects; long-term effects unknown; safety during pregnancy unknown.</td><td>Notes The studies involved highly selective groups of women. There was a high dropout rate in one of the positive studies. In one study that found alprazolam effective, 87% of the women had a _ history of major depression or an anxiety disorder. Different doses were used in the studies (0.75-2.25 mg); the standard effective dosage is unknown.</td></tr><tr><td>Fluoxetine (Prozac)</td><td>Several double-blind, randomized, placebo-controlled, crossover trials. All found fluoxetine effective.</td><td>Well tolerated; single daily oral dose. Significant decrease in psychic and behavioral symptoms.</td><td>Long-term effects unknown. Safety during pregnancy unknown. Appears less effective in controlling physical symptoms.</td><td>Trials involved very small, highly select groups of women. Duration of treatment did not exceed 3 months. All trials used 20 mg orally daily.</td></tr><tr><td>Gonadotropin- releasing hormone agonist</td><td>Several small, double-blind, randomized, placebo-controlled, crossover trials. Most patients experienced improvement.</td><td>Rapidly reversible; many patients report being virtually symptom-free during therapy.</td><td>Produces pseudomenopause; expensive; risk for osteoporosis, hypoestrogenic symptoms. Usually given for only short periods of time.</td><td>An add-back regimen of estrogen-progestin in addition to gonadotropin- releasing hormone agonist has been reported. If replicated, it may have potential for an effective, long-term treatment for premenstrual syndrome.</td></tr><tr><td>Spironolactone</td><td>Several double-blind, randomized, placebo-controlled trials. Mixed results.</td><td>— May alleviate bloating and improve symptoms related to mood. Oral medication taken once or twice a day. Nonaddictive.</td><td>Effectiveness not _ proven consistently across studies.</td><td>Spironolactone is the only diuretic that has shown effectiveness in treating premenstrual syndrome in controlled, randomized trials. Method of action may be antiandrogen properties.</td></tr><tr><td>Vitamin B,</td><td>Ten randomized double-blind trials. About one third of the trials reported positive results, one third reported negative results, and one third reported ambiguous results.</td><td></td><td>No conclusive evidence that vitamin B, is more effective than placebo.</td><td>Doses ranged from 50 to 500 mg. Only one study involved more than 40 subjects. The large multicenter trial (N = 204) reported similar results for placebo and vitamin B,.</td></tr></table>
======================================
<table><thead><th>Drug</th><th>Therapeutic Dosage Range (mg/day)</th><th>Average (range) of Elimination Half-lives (hours)?</th><th>Potentially Fatal Drug Interactions</th></thead><tr><td colspan="4">[ricyclics</td></tr><tr><td>Amitriptyline (Elavil, Endep)</td><td>75-300</td><td>24 (16-46)</td><td>Antiarrhythmics, MAO inhibitors</td></tr><tr><td>Clomipramine (Anafranil)</td><td>75-300</td><td>24 (20-40)</td><td>"</td></tr><tr><td>Desipramine (Norpramin, Pertofrane)</td><td>75-300</td><td>18 (12-50)</td><td>"</td></tr><tr><td>Doxepin (Adapin, Sinequan)</td><td>75-300</td><td>17 (10-47)</td><td>"</td></tr><tr><td>Imipramine (Janimine, Tofranil)</td><td>75-300</td><td>22 (12-34)</td><td>"</td></tr><tr><td>Nortriptyline (Aventyl, Pamelor)</td><td>40-200</td><td>26 (18-88)</td><td>"</td></tr><tr><td>Protriptyline (Vivactil)</td><td>20-60</td><td>76 (54-124)</td><td>"</td></tr><tr><td>Trimipramine (Surmontil)</td><td>75-300</td><td>12 (8-30)</td><td>"</td></tr></table>
======================================
<table><thead><th>Drug</th><th>Therapeutic Dosage Range (mg/day)</th><th>Average (range) of Elimination Half-lives (hours)*</th><th>Potentially Fatal Drug Interactions</th></thead><tr><td colspan="4">Heterocyclics</td></tr><tr><td>Amoxapine (Asendin)</td><td>100-600</td><td>10 (8-14)</td><td>MAO inhibitors</td></tr><tr><td>Maprotiline (Ludiomil)</td><td>100-225</td><td>43 (27-58)</td><td>"</td></tr><tr><td colspan="4">Selective serotonin reuptake inhibitors</td></tr><tr><td>Citalopram (Celexa)</td><td>20-40</td><td>4-6</td><td>"</td></tr><tr><td>Escitalopram (Lexapro)</td><td>20-40</td><td>5</td><td>"</td></tr><tr><td>Fluvoxamine</td><td>100-200</td><td>2-8</td><td>"</td></tr><tr><td>Fluoxetine (Prozac) (now available in a once-a-week preparation)</td><td>10-40</td><td>168 (72-360)?</td><td>"</td></tr><tr><td>Paroxetine (Paxil)</td><td>20-50</td><td>24 (3-65)</td><td>MAO inhibitors®</td></tr><tr><td>Sertraline (Zoloft)</td><td>50-150</td><td>24 (10-30)</td><td>"</td></tr><tr><td colspan="4">Monoamine oxidase inhibitors (MAO inhibitors)¢</td></tr><tr><td>Isocarboxazid (Marplan)</td><td>30-50</td><td>Unknown</td><td>For all three MAO inhibitors: vasoconstrictors,® decongestants,® meperidine, and possibly other narcotics</td></tr><tr><td>Phenelzine (Nardil)</td><td>45-90</td><td>2 (1.5-4.0)</td><td></td></tr><tr><td>Tranylcypromine (Parnate)</td><td>20-60</td><td>2 (1.5-3.0)</td><td></td></tr><tr><td colspan="4">5-HT2 Antagonists</td></tr><tr><td>Trazodone (Desyrel)</td><td>150-600</td><td>8 (4-14)</td><td></td></tr><tr><td>Nefazodone (Serzone)</td><td>300-500</td><td>3</td><td></td></tr><tr><td colspan="4">Others</td></tr><tr><td>Bupropion (Wellbutrin, Wellbutrin SR, Wellbutrin XL)</td><td>225-450</td><td>14 (8-24)</td><td>MAO inhibitors (possibly)</td></tr><tr><td>Mirtazapine (Remeron)</td><td>15-45</td><td>20-40</td><td></td></tr><tr><td>Venlafaxine (Effexor, Effexor-XR)</td><td>75-375</td><td>5</td><td></td></tr><tr><td>Duloxetine (Cymbalta)</td><td>20-60 bid</td><td>8-17</td><td></td></tr></table>
======================================
<table><thead><th></th><th rowspan="2">Anticholinergic?</th><th colspan="2">Central Nervous System</th><th colspan="2">Cardiovascular</th><th rowspan="2">Gastrointestinal _ Distress</th><th rowspan="2">Weight Gair (more than 6 kg)</th></thead><thead><th></th><th></th><th>Drowsiness</th><th>Insomnia Agitation</th><th>Orthostatic Hypotension</th><th>Cardiac Arrhythmia</th><th></th><th></th></thead><tr><td>\mitriptyline</td><td>4+</td><td>At</td><td>0</td><td>At</td><td>3+</td><td>0</td><td>At</td></tr><tr><td>italopram</td><td>0.5</td><td>0.5</td><td>0.5</td><td>0</td><td>0</td><td>1.5</td><td>0</td></tr><tr><td>desipramine</td><td>1+</td><td>1+</td><td>1+</td><td>2+</td><td>2+</td><td>0</td><td>1+</td></tr><tr><td>Joxepin</td><td>3+</td><td>A+</td><td>0</td><td>2+</td><td>2+</td><td>0</td><td>3+</td></tr><tr><td>mipramine</td><td>3+</td><td>3+</td><td>1+</td><td>4+</td><td>3+</td><td>1+</td><td>3+</td></tr><tr><td>Airtazapine</td><td>0.5-1</td><td>4</td><td>0.5</td><td>0.5</td><td>0</td><td>0</td><td>4</td></tr><tr><td>Vortriptyline</td><td>1+</td><td>1+</td><td></td><td>2+</td><td>2+</td><td>0</td><td>1+</td></tr><tr><td>rotriptyline</td><td>2+</td><td>1+</td><td>1+</td><td>2+</td><td>2+</td><td>0</td><td>0</td></tr><tr><td>rimipramine</td><td>1+</td><td>A+</td><td>0</td><td>2+</td><td>2+</td><td>0</td><td>3+</td></tr><tr><td>fenlafaxine</td><td>0.5</td><td>0.5</td><td>2</td><td>0</td><td>0.5</td><td>3</td><td>0</td></tr><tr><td>\moxapine</td><td>2+</td><td>2+</td><td>2+</td><td>2+</td><td>3+</td><td>0</td><td>1+</td></tr><tr><td>Aaprotiline</td><td>2+</td><td>At</td><td>0</td><td>0</td><td>1+</td><td>0</td><td>2+</td></tr><tr><td>Vefazodone</td><td>0.5</td><td>0.5</td><td>0</td><td>2</td><td>0.5</td><td>2</td><td>0.5</td></tr><tr><td>razodone</td><td>0</td><td>At</td><td>0</td><td>1+</td><td>1+</td><td>1+</td><td>1+</td></tr><tr><td>jupropion</td><td>0</td><td>0</td><td>2+</td><td>0</td><td>1+</td><td>1+</td><td>0</td></tr><tr><td>Juoxetine</td><td>0</td><td>0</td><td>2+</td><td>0</td><td>0</td><td>3+</td><td>0</td></tr><tr><td>aroxetine</td><td>0</td><td>0</td><td>2+</td><td>0</td><td>0</td><td>3+</td><td>0</td></tr><tr><td>ertraline</td><td>0</td><td>0</td><td>2+</td><td>0</td><td>0</td><td>3+</td><td>0</td></tr><tr><td>Aonoamine</td><td>1</td><td>1+</td><td>2+</td><td>2+</td><td>0</td><td>1+</td><td>2+</td></tr></table>
======================================
<table><thead><th>Medication</th><th>Trade Name</th><th>Rate of Absorption?</th><th>Half-Life?</th><th>Active Long- Acting Metabolite</th><th>Comments</th></thead><tr><td>Benzodiazepines</td><td></td><td></td><td></td><td></td><td>Metabolism of benzodiazepines is inhibited by cimetidine, disulfiram, isoniazid, and oral contraceptives. Metabolism of benzodiazepines is enhanced by rifampin.</td></tr><tr><td>Alprazolam</td><td>Xanax</td><td>Intermediate</td><td>Intermediate</td><td>No</td><td>Preferred in elderly patients or patients with poor hepatic functions.</td></tr><tr><td>Chlordiazepoxide</td><td>_ Librium, others</td><td>Intermediate</td><td>Intermediate</td><td>Yes</td><td></td></tr><tr><td>Clonazepam</td><td>Klonopin</td><td>Long</td><td>Long</td><td>No</td><td></td></tr><tr><td>Clorazepate</td><td>Tranxene, others</td><td>— Short</td><td>Short</td><td>Yes</td><td></td></tr><tr><td>Diazepam</td><td>Valium, others</td><td>Short</td><td>Long</td><td>Yes</td><td>Half-life increased 3 or 4 times in elderly patients.</td></tr><tr><td>Lorazepam</td><td>Ativan, others</td><td>Intermediate</td><td>Intermediate</td><td>No</td><td>Preferred in elderly patients or patients with poor hepatic function.</td></tr><tr><td>Oxazepam</td><td>Serax</td><td>Long</td><td>ntermediate</td><td>No</td><td>Preferred in elderly patients or patients with poor hepatic function.</td></tr><tr><td>Prazepam</td><td>Centrax</td><td>Long</td><td>Short</td><td>Yes</td><td></td></tr><tr><td colspan="6">Atypical agent</td></tr><tr><td>Buspirone</td><td>BuSpar</td><td></td><td></td><td></td><td>Not effective in panic disorder, little sedation, little risk of dependence or tolerance.</td></tr></table>
======================================
<table><tr><td>Alternative Medical Systems</td><td>Homeopathic medicine, naturopathic medicine, traditional Chinese medicine, Ayurveda</td></tr><tr><td>Mind-body Interventions</td><td>Meditation, prayer, mental healing, creative outlets (art, music, dance)</td></tr><tr><td>Biologically Based Therapies</td><td>Dietary supplements, herbal products</td></tr><tr><td>Manipulative and Body-based</td><td>Chiropractic or osteopathic manipulation, massage</td></tr><tr><td>Methods Energy Therapies</td><td>Biofield therapies, such as qi gong, Reiki,</td></tr><tr><td></td><td>Bioelectromagnetic therapies, such as pulsed fields, magnetic fields, AC or DC fields</td></tr></table>
======================================
<table><thead><th>Chiropractic</th><th>Must complete a 4-year chiropractic college program of study accredited by the Council on Chiropractic Education (CCE)</th><th>National</th></thead><tr><td>Massage therapy and bodywork</td><td>The American Massage Therapy Association (AMTA) accredits 25% of massage training schools. The National Certification Board for Therapeutic Massage and Bodywork (NCBTMB) administers a certification examination used by 24 states. Certification from ICBTMB requires passing this exam and the completion of a minimum of 500 in-class hours of formal education and training.</td><td>Offered at the state level in 30 states.</td></tr><tr><td>Hypnotherapy</td><td></td><td>The International Medical and Dental Hypnotherapy Association will certify hypnotherapists if they meet the minimum eligibility requirements and provide referrals.</td></tr><tr><td>Clinical hypnosis</td><td>Basic certification requires a minimum of 40 hours of ASCH approved workshop training, 20 hours of individualized training, and a minimum of 2 years of independent practice using clinical hypnosis. The advanced level, called approved consultant, requires a minimum of 60 additional hours of ASCH-approved workshop training and 5 years of independent practice using clinical hypnosis.</td><td>American Society of Clinical Hypnosis (ASCH) Certification in clinical hypnosis ensures that the certified individual is a bona fide health care professional who is licensed in that state or province to provide medical, dental, or psychotherapeutic services.</td></tr><tr><td>Meditation and stress reduction</td><td></td><td></td></tr></table>
======================================
<table><thead><th colspan="3">Table 13.2 Continued</th></thead><thead><th>Therapy</th><th>Training</th><th>Licensure</th></thead><tr><td rowspan="3">Acupuncture</td><td>Schools provide 3- or 4-year training programs in oriental medicine that consist of about 2,500 to 3,200 hours.</td><td>In most states, the practitioné must provide proof that he/she has attended and graduated from an accredite school or from a school that is in the process of being accredited by the Accreditation Commission fc Acupuncture and Oriental Medicine (ACAOM). Forty states either license or</td></tr><tr><td></td><td>The National Certification Commission for Acupuncture and Oriental Medicine (NCCAOM) tests entry-level capabilities with a comprehensive written exam, point location exam, and clean needle technique.</td><td>An acupuncturist must pass this exam and meet continuing education requirements every 4 years t retain certification and licensure.</td></tr><tr><td></td><td>Medical doctors can be certified by the American Board of Medical Acupuncture by taking a minimum 300 hours in training.</td><td></td></tr></table>
======================================
<table><thead><th>Rank/Herb</th><th>Dollar Sales</th><th>% Change vs. 1 Year Age</th></thead><tr><td>1. Garlic</td><td>27,013,420</td><td>=11.2</td></tr><tr><td>2. Echinacea</td><td>23,782,640</td><td>-14.9</td></tr><tr><td>3. Saw palmetto</td><td>20,334,030</td><td>—10.5</td></tr><tr><td>4. Ginkgo</td><td>9,334,010</td><td>=12.9</td></tr><tr><td>5. Soy</td><td>7,419,530</td><td>26.6</td></tr><tr><td>6. Cranberry</td><td>3,445,670</td><td>+6.8</td></tr><tr><td>7. Ginseng</td><td>2,165,220</td><td>—10.2</td></tr><tr><td>8. Black cohosh</td><td>1,984,960</td><td>—22.3</td></tr><tr><td>9. St. John’s wort</td><td>9,087,829</td><td>—12.5</td></tr><tr><td>10. Milk thistle</td><td>7,775,529</td><td>+0.8</td></tr><tr><td>11. Evening primrose</td><td>6,088,103</td><td>—3.6</td></tr><tr><td>12. Valerian</td><td>3,449,297</td><td>-9.2</td></tr><tr><td>13. Green tea</td><td>2,794,783</td><td>+22.1</td></tr><tr><td>14. Bilberry</td><td>2,341,301</td><td>—-17.6</td></tr><tr><td>15. Grape seed</td><td>2,330,281</td><td>-11.9</td></tr><tr><td>16. Horny goat weed</td><td>2,203,555</td><td>—12.2</td></tr><tr><td>17. Yohimbe</td><td>1,835,313</td><td>—21.9</td></tr><tr><td>18. Horse chestnut</td><td>1,564,550</td><td>—35.8</td></tr><tr><td>19. Eleuthero</td><td>$992,286</td><td>—64.4</td></tr><tr><td>20. Ginger</td><td>$814,789</td><td>-13.8</td></tr><tr><td>Multiherbs</td><td>$52,049,290</td><td>+291</td></tr><tr><td>All other herbs</td><td>$11,841,120</td><td>-7.5</td></tr></table>
======================================
<table><thead><th>Botanical</th><th>Drug Class</th><th>Type of Interaction</th><th>Signs and Symptoms</th><th>Type of Evidence</th></thead><tr><td rowspan="3">Aloe gel Aloe vera Aloe barbadensis</td><td>Diuretics</td><td>Potentiation caused by potassium-depleting effects</td><td>Confusion, weakness, irregular heartbeat</td><td>Case reports</td></tr><tr><td></td><td>Hypoglycemic agents</td><td>Potentiation</td><td></td><td>Traditional</td></tr><tr><td></td><td>All drugs</td><td>Reduced effectiveness towing to binding with drug</td><td></td><td>Traditional</td></tr><tr><td>Bilberry Vaccinium myrtillus</td><td>Anticoagulants</td><td>Potentiation at high doses</td><td>Increased bleeding time</td><td>Case reports</td></tr><tr><td>Borage</td><td>Anticonvulsants</td><td>Decreased seizure threshold</td><td>Epileptic events</td><td>Case reports</td></tr><tr><td>Cascara sagrada Rhamnus purshianus</td><td>Diuretics</td><td>Potentiation caused by potassium-depleting effects</td><td>Confusion, weakness, irregular heartbeat</td><td>Case reports</td></tr><tr><td rowspan="2">Chamomile, German Matricaria recutita</td><td></td><td>Sedatives (e.g., chlorpheniramine, trazodone, diazepam)</td><td>Potentiation</td><td>Excessive drowsiness, loss of coordination, trouble driving</td><td>eoretical</td></tr><tr><td>Anticoagulants.</td><td>Potentiation</td><td>Increased bleeding time</td><td>Theoretical</td></tr><tr><td>Chaparral Larrea tridentata</td><td>Phenobarbital</td><td>Potentiation of liver toxicity</td><td>Liver toxicity</td><td>Theoretical</td></tr><tr><td rowspan="2">Chasteberry, chaste tree Vitex agnuscastus</td><td>Oral contraceptives and hormone replacement</td><td>Reduced effectiveness owing to herb’s effect on progesterone</td><td></td><td>Theoretical</td></tr><tr><td></td><td>Anticancer agents for hormone-sensitive cancers</td><td>Reduced effectiveness caused by herb’s estrogenic activity</td><td></td><td>Theoretical</td></tr><tr><td>Co-enzyme Q10</td><td>Anticoagulants</td><td>Procoagulant effect</td><td>Decreased clotting time</td><td>Theoretical</td></tr><tr><td>Comfrey Symphytum officinale</td><td>Phenobarbital</td><td>Potentiation of liver toxicity</td><td>Liver toxicity</td><td>Case reports</td></tr><tr><td>Danshen Salvia miltiorrhiza</td><td>Warfarin</td><td>Potentiation caused by presence of coumarins in herb</td><td>Increased bleeding</td><td>Case reports</td></tr><tr><td>Dong quai Angelica sinensis</td><td>Anticoagulants.</td><td>Potentiation caused by presence of coumarins in herb</td><td>Increased bleeding</td><td>Case reports</td></tr><tr><td rowspan="2">Echinacea Echinacea purpurea, E, angustifolia, E. pallida</td><td>Immunosuppressive agents (e.g., cyclosporin)</td><td>Reduced effectiveness</td><td>Shivering, fever, muscle weakness</td><td>Theoretical</td></tr><tr><td></td><td>Drugs metabolized by cytochrome P450 3A4</td><td>Potentiation caused by inhibition of</td><td>Liver dysfunction</td><td>In vitro studies</td></tr></table>
======================================
<table><thead><th>Botanical</th><th>Drug Class</th><th>Type of Interaction</th><th>Signs and Symptoms</th><th>Type of Evidence</th></thead><tr><td rowspan="5">Ephedra Ma huang Ephedra sinica</td><td>MAO inhibitors</td><td>Potentiation caused by sympathomimetic action</td><td>Excitability, restlessness, hypertension</td><td>Case reports</td></tr><tr><td></td><td>Caffeine and other stimulants</td><td>Potentiation</td><td>Excitability, hypertension, stroke, death</td><td>Case reports</td></tr><tr><td></td><td>Antihypertensive agents</td><td>Reduced effectiveness caused by herb’s sympathomimetic actions</td><td>Hypertension</td><td>Case reports</td></tr><tr><td></td><td>Theophylline</td><td>Potentiation caused by sympathomimetic action</td><td>Rapid heart rate, anxiety, hypertension</td><td>Theoretical</td></tr><tr><td></td><td>Cardiac glycosides</td><td>Reduced effectiveness</td><td>Cardiac arrhythmia</td><td>Theoretical</td></tr><tr><td>Evening primrose oil (EPO) Oenothera biennis</td><td>Phenothiazines, anesthetics, anticonvulsants</td><td>Increased risk of seizures as drug and herb lower the seizure threshold leve</td><td>Epileptic events</td><td>Case reports</td></tr><tr><td>Feverfew Tanacetum parthenium</td><td>Anticoagulants</td><td>Potentiation caused by inhibition of platelet aggregation</td><td>ncreased bleeding</td><td>Case reports</td></tr><tr><td>Garlic Allium sativa</td><td>Anticoagulants</td><td>Potentiation caused by inhibition of platelet aggregation</td><td>ncreased bleeding</td><td>Case reports</td></tr><tr><td rowspan="2">Ginger Zingiber officinalis</td><td>Anticoagulants</td><td>Potentiation caused by inhibition of platelet aggregation</td><td>ncreased bleeding</td><td>Case reports</td></tr><tr><td></td><td>Antacids</td><td>Reduced effectiveness owing to increased gastric secretion</td><td>Heartburn</td><td>Case reports</td></tr><tr><td rowspan="3">Ginkgo Ginkgo biloba</td><td>Anticoagulants</td><td>Potentiation caused by inhibition of platelet aggregation factor</td><td>ncreased bleeding, spontaneous bleeding</td><td>Case reports, animal study</td></tr><tr><td></td><td>Trazodone</td><td>Potentiation caused by inhibition of drug metabolism</td><td>Sedation, coma</td><td>Case report</td></tr><tr><td></td><td>Thiazide diuretics</td><td>Unclear interaction</td><td>Hypertension</td><td>Case report</td></tr><tr><td rowspan="2">Ginseng (Asian) Panax ginseng</td><td>Hypoglycemic agents</td><td>Potentiation</td><td>Hypoglycemia</td><td>Case reports, clinical study</td></tr><tr><td></td><td>MAO inhibitors</td><td>Potentiation</td><td>Insomnia, headache, tremors</td><td>Case reports</td></tr></table>
======================================
<table><thead><th>Botanical</th><th>Drug Class</th><th>Type of Interaction</th><th>Signs and Symptoms</th><th>Type of Evidence</th></thead><tr><td></td><td>Sildenafil</td><td>Potentiation caused by herb’s stimulation of nitric oxide release</td><td></td><td>Theoretical</td></tr><tr><td></td><td>Antiestrogens</td><td>Reduced effectiveness owing to estrogenlike activity of herb</td><td></td><td>Theoretical</td></tr><tr><td>Ginseng (Siberian) Eleutherococcus Senticosus</td><td>Digoxin</td><td>Elevated digoxin levels, probably caused by interference with digoxin assay</td><td></td><td>Case reports</td></tr><tr><td rowspan="5">Guarana Paullinia cupana</td><td>Antihypertensives</td><td>Reduced effectiveness owing to herb’s CNS stimulant effects</td><td>Increased blood pressure</td><td>Case report</td></tr><tr><td></td><td>Halothane</td><td>Interaction</td><td>Dysrhythmias</td><td>Case reports</td></tr><tr><td></td><td>Cardiac glycosides</td><td>Increased sensitivity to drug caused by increased potassium secretion</td><td></td><td>Case reports</td></tr><tr><td></td><td>Diuretics</td><td>Increased sensitivity to drug caused by increased potassium secretion</td><td>Diuresis</td><td>Case reports</td></tr><tr><td></td><td>CNS stimulants</td><td>Potentiation caused by herb’s caffeine content (up to 5%)</td><td>Restlessness, insomnia, excitability</td><td>Theoretical</td></tr><tr><td rowspan="2">Hawthorn Crataegus laevigata</td><td>Cardiac glycosides</td><td>Potentiation caused by similar mechanism of action</td><td>Cardiac glycoside toxicity</td><td>Theoretical</td></tr><tr><td></td><td>CNS depressant</td><td>Potentiation caused by similar activities</td><td>CNS depression</td><td>Theoretical</td></tr><tr><td rowspan="4">Kava Piper methysticum</td><td>Anxiolytics</td><td>Potentiation</td><td>Tremors, somnolence</td><td>Case reports</td></tr><tr><td></td><td>Alcohol</td><td>Potentiation</td><td>Increased impairment, hypnotic effects</td><td>Clinical study</td></tr><tr><td></td><td>Anticoagulants.</td><td>Potentiation</td><td>Increased bleeding</td><td>Theoretical</td></tr><tr><td></td><td>MAO inhibitors</td><td>Potentiation</td><td>Hypertension</td><td>Theoretical</td></tr><tr><td>Kelp, bladderwrack Fucus vesiculosus</td><td>Thyroid-hormone replacement therapy</td><td>Interference as the herb contains iodine</td><td></td><td>Theoretical</td></tr><tr><td rowspan="2">Licorice Glycyrrhiza glabra</td><td>Prednisolone, hydrocortisone</td><td>Potentiation caused by reduced plasma clearance</td><td>Hypertension, edema</td><td>Case reports, clinical studies</td></tr><tr><td></td><td>Thiazide diuretics</td><td>Increased risk of</td><td></td><td>Case reports</td></tr></table>
======================================
<table><thead><th>Botanical</th><th>Drug Class</th><th>Type of Interaction</th><th>Signs and Symptoms</th><th>Type of Evidence</th></thead><tr><td rowspan="2"></td><td>Antihypertensives (e.g., spironolactone)</td><td>Reduced effectiveness after 4 weeks of herb owing to inhibition of rennin-angiotensin system</td><td>Hypertension</td><td>Case reports, in vitro studies</td></tr><tr><td></td><td>Cardiac glycosides</td><td>Increased sensitivity to drugs after 4 weeks owing to hypokalemic effect of herb</td><td>Dysrhythmias, hypertension</td><td>Theoretical</td></tr><tr><td>Psyllium Plantago ovata</td><td>Lithium</td><td>Reduced effectiveness caused by interference with lithium ionization</td><td></td><td>Case reports</td></tr><tr><td>Red yeast rice Monascus purpureus</td><td>Statin drugs</td><td>Potentiation as both contain the same class of drugs</td><td>Liver damage</td><td>Theoretical</td></tr><tr><td rowspan="2">Saw palmetto Serenoa repens</td><td>Hormone replacement therapy and oral contraceptives</td><td>Potentiation caused by herb’s steroidal content</td><td></td><td>Theoretical</td></tr><tr><td></td><td>Anticoagulants</td><td>Potentiation</td><td>Bleeding risk</td><td>Theoretical</td></tr><tr><td>Senna Senna alexandrina, Cassia angustifolia</td><td>Diuretics</td><td>Potentiation caused by potassium-depleting effects</td><td>Confusion, weakness, irregular heartbeat</td><td>Case reports</td></tr><tr><td rowspan="2">Stinging nettle Urtica dioica</td><td>Hypoglycemic agents</td><td>Reduced effectiveness</td><td>Hyperglycemia</td><td>Clinical study</td></tr><tr><td></td><td>NSAIDs</td><td>Potentiation</td><td></td><td>Theoretical</td></tr><tr><td rowspan="5">St. John’s wort Hypericum perforatum</td><td>Other antidepressants</td><td>Potentiation caused by increased serotonin levels</td><td>Euphoria, drowsiness, muscle twitching, seating, diarrhea, loss of consciousness</td><td>Case studies</td></tr><tr><td></td><td>Various drugs metabolized via cytochrome P450 (e.g., cyclosporin, oral contraceptives, theophylline, HIV protease inhibitors)</td><td>Reduced plasma levels of drugs caused by induction of cytochrome P450 metabolizing enzymes</td><td>Reduced effectiveness of drugs taken concomitantly</td><td>Case reports, clinical studies</td></tr><tr><td></td><td>Anticoagulants</td><td>Reduced effectiveness</td><td>Loss of anticoagulant effect</td><td>Case reports</td></tr><tr><td></td><td>Digoxin</td><td>Reduced effectiveness</td><td>Loss of cardioprotective effect</td><td>Clinical study</td></tr><tr><td></td><td>MAO inhibitors</td><td>Potentiation</td><td>Elevated blood pressure</td><td>In vitro studies</td></tr></table>
======================================
<table><thead><th>Botanical</th><th>Drug Class</th><th>Type of Interaction</th><th>Signs and Symptoms</th><th>Type of Evidence</th></thead><tr><td>Yohimbine Pausinystalia Yohimbe, Corynanthe yohimbe</td><td>Tricyclic _ antidepressants</td><td>Potentiation of hypertension by drug</td><td>Hypertension, especially in hypertensive patients</td><td>Case reports</td></tr><tr><td></td><td>Spironolactone</td><td>Reduced effectiveness caused by potassium- depleting effects</td><td>Hypertension</td><td>Theoretical</td></tr></table>
======================================
<table><tr><td>Meditation and Stress Reduction</td><td>Meditation is a self-directed practice for relaxing the body and calming the mind. Most meditative techniques have to the West from religious practices in the East,</td></tr></table>
======================================
<table><thead><th>Fish (3.5 ounce portion)</th><th>EPA (mg)</th><th>DHA (mg)</th><th>Total EPA + DHA (g)</th><th>Total Fat</th></thead><tr><td>Bass (striped)</td><td>184</td><td>637</td><td>0.8</td><td>2.5</td></tr><tr><td>Catfish—wild</td><td>85</td><td>116</td><td>0.2</td><td>2.4</td></tr><tr><td>Catfish—farmed</td><td>42</td><td>109</td><td>0.2</td><td>6.8</td></tr><tr><td>Clams (about 9 small)</td><td>117</td><td>124</td><td>0.2</td><td>1.1</td></tr><tr><td>Cod—Pacific</td><td>88</td><td>147</td><td>0.2</td><td>0.1</td></tr><tr><td>Cod—Atlantic</td><td>3</td><td>131</td><td>0.1</td><td>0.8</td></tr><tr><td>Crab—Alaska king (about 7/3 leg)</td><td>251</td><td>100</td><td>0.4</td><td>1.3</td></tr><tr><td>Crab—Dungeness (about °/4 crab)</td><td>239</td><td>96</td><td>0.3</td><td>1.1</td></tr><tr><td>Fish sticks (about 3)</td><td>72</td><td>108</td><td>0.2</td><td>10.2</td></tr><tr><td>Flounder and sole</td><td>207</td><td>219</td><td>0.4</td><td>1.3</td></tr><tr><td>Haddock</td><td>65</td><td>138</td><td>0.2</td><td>0.8</td></tr><tr><td>Halibut</td><td>77</td><td>318</td><td>0.4</td><td>2.5</td></tr><tr><td>Herring—kippered</td><td>825</td><td>1003</td><td>1.8</td><td>10.5</td></tr><tr><td>Herring—pickled</td><td>711</td><td>464</td><td>1.2</td><td>15.3</td></tr><tr><td>Lobster (Northern)</td><td>45</td><td>26</td><td>0.1</td><td>0.5</td></tr><tr><td>Mackerel—Pacific and Jack</td><td>855</td><td>1016</td><td>1.6</td><td>8.6</td></tr><tr><td>Mackerel—Atlantic</td><td>428</td><td>594</td><td>1.0</td><td>15.1</td></tr><tr><td>Mackerel—King</td><td>148</td><td>193</td><td>0.3</td><td>2.2</td></tr><tr><td>Mahi mahi (dolphin fish)</td><td>22</td><td>96</td><td>0.1</td><td>0.8</td></tr><tr><td>Oysters—Pacific, raw (about 1.5)</td><td>312</td><td>212</td><td>0.6</td><td>2.0</td></tr><tr><td>Oysters—Eastern, wild, raw (about 6)</td><td>228</td><td>248</td><td>0.5</td><td>21</td></tr><tr><td>Oysters—Eastern, wild (about 12)</td><td>221</td><td>247</td><td>0.5</td><td>6</td></tr><tr><td>Oysters—farmed (about 9)</td><td>195</td><td>119</td><td>0.4</td><td>8</td></tr><tr><td>Oysters—farmed, raw (about 6)</td><td>160</td><td>113</td><td>0.3</td><td>3</td></tr><tr><td>Perch (Atlantic)</td><td>88</td><td>230</td><td>0.3</td><td>8</td></tr><tr><td>Pollock—Atlantic</td><td>11</td><td>383</td><td>0.5</td><td>J</td></tr><tr><td>Pollock—walleye</td><td>157</td><td>241</td><td>0.4</td><td>0</td></tr><tr><td>Rockfish</td><td>154</td><td>223</td><td>0.4</td><td>Jl</td></tr><tr><td>Salmon—Atlantic, farmed</td><td>587</td><td>1238</td><td>1.8</td><td>10.5</td></tr><tr><td>Salmon—Atlantic, wild</td><td>349</td><td>1215</td><td>1.6</td><td>6.9</td></tr><tr><td>Salmon—Coho, farmed</td><td>347</td><td>140</td><td>11</td><td>0</td></tr><tr><td>Salmon—Coho, wild</td><td>341</td><td>559</td><td>0.9</td><td>3.1</td></tr><tr><td>Salmon—sockeye, canned, drained</td><td>418</td><td>564</td><td>1.0</td><td>6.2</td></tr><tr><td>Sardines—Pacific, canned in tomato sauce, drained</td><td>520</td><td>845</td><td>1.4</td><td>2</td></tr><tr><td>Sardines—Atlantic, canned in oil</td><td>402</td><td>432</td><td>0.8</td><td>9.1</td></tr></table>
======================================
<table><thead><th></th><th>Table 13.7</th><th>Continued</th><th></th><th></th></thead><thead><th>Fish (3.5 ounce portion)</th><th>EPA (mg)</th><th>DHA (mg)</th><th>Total EPA + DHA (g)</th><th>Total Fat (g)</th></thead><tr><td>Shrimp (about 16 large)</td><td>145</td><td>122</td><td>0.3</td><td>0.9</td></tr><tr><td>Swordfish</td><td>111</td><td>579</td><td>0.1</td><td>44</td></tr><tr><td>Tilefish</td><td>146</td><td>623</td><td>0.8</td><td>4.0</td></tr><tr><td>Trout—rainbow, farmed</td><td>284</td><td>697</td><td>1.0</td><td>6.1</td></tr><tr><td>Trout—rainbow, wild</td><td>398</td><td>442</td><td>0.8</td><td>4.9</td></tr><tr><td>Trout—mixed species</td><td>220</td><td>575</td><td>0.8</td><td>7.2</td></tr><tr><td>Tuna—bluefin</td><td>309</td><td>910</td><td>1.3</td><td>5.3</td></tr><tr><td>Tuna—canned in water, drained</td><td>198</td><td>535</td><td>0.1</td><td>2.5</td></tr><tr><td>Tuna—skipjack</td><td>11</td><td>201</td><td>0.3</td><td>11</td></tr><tr><td>Tuna—yellowfin</td><td>40</td><td>191</td><td>0.2</td><td>1.0</td></tr><tr><td>Tuna—light, canned in water, drained</td><td>40</td><td>190</td><td>0.2</td><td>0.1</td></tr><tr><td>Tuna—canned in oil, drained</td><td>23</td><td>86</td><td>0.1</td><td>1.0</td></tr><tr><td>Whiting</td><td>241</td><td>200</td><td>0.4</td><td>1.4</td></tr></table>
======================================
<table></table>
======================================
<table><tr><td rowspan="5">400-700 mg progesterone per ounze</td><td>Pro-Gest</td></tr><tr><td></td><td>Bio Balance</td></tr><tr><td></td><td>Progonol</td></tr><tr><td></td><td>Ostaderm</td></tr><tr><td></td><td>Pro-Alo</td></tr><tr><td rowspan="9">2-15 mg progesterone per ounze</td><td>PhytoGest</td></tr><tr><td></td><td>Pro-Dermex</td></tr><tr><td></td><td>Endocreme</td></tr><tr><td></td><td>Life Changes</td></tr><tr><td></td><td>Yamcon</td></tr><tr><td></td><td>Wild Yam Extract</td></tr><tr><td></td><td>PMS Formula</td></tr><tr><td></td><td>Menopause Formula</td></tr><tr><td></td><td>Femarone-Nutri-Gest</td></tr><tr><td rowspan="3">Less than 2 mg progesterone per ounze</td><td></td><td>Progerone</td></tr><tr><td></td><td>Wild Yam Cream</td></tr><tr><td>Progestone-HP</td></tr></table>
======================================
<table></table>
======================================
<table><thead><th>Substance</th><th>Potential Negative Effects</th></thead><tr><td>Chaparral</td><td>Hepatotoxicity</td></tr><tr><td>Chondroitin</td><td>Anticoagulative properties</td></tr><tr><td>Chromium</td><td>Hypoglycemia</td></tr><tr><td>Dong quai</td><td>Anticoagulative properties</td></tr><tr><td>Echinacea</td><td>Hepatotoxicity</td></tr><tr><td>Feverfew</td><td>Anticoagulative properties</td></tr><tr><td>Garlic</td><td>Anticoagulative properties</td></tr><tr><td>Ginger</td><td>Anticoagulative properties</td></tr><tr><td>Ginkgo</td><td>Anticoagulative properties</td></tr><tr><td rowspan="3">Ginseng</td><td>Anticoagulative properties</td></tr><tr><td></td><td>Hypertension</td></tr><tr><td></td><td>Hypoglycemia</td></tr><tr><td>Goldenseal</td><td>Can reduce effect of antihypertensives</td></tr><tr><td rowspan="2">Kava</td><td>Potentiates the sedative effects of anesthetics</td></tr><tr><td></td><td>Hepatotoxicity</td></tr><tr><td rowspan="5">Licorice root</td><td>Hypertension</td></tr><tr><td></td><td>Hyperkalemia</td></tr><tr><td></td><td>Hypokalemia</td></tr><tr><td></td><td>Hypernatremia</td></tr><tr><td></td><td>Edema</td></tr><tr><td rowspan="2">Ma Huang (ephedra)</td><td>Arrhythmias</td></tr><tr><td></td><td>Hypertension</td></tr><tr><td>Red yeast rice</td><td>Hepatotoxicity</td></tr><tr><td rowspan="2">St. John’s wort</td><td>Prolongation of anesthetic effects</td></tr><tr><td></td><td>nhibits reuptake of serotonin, dopamine, and noradrenaline</td></tr><tr><td rowspan="2">Valerian</td><td>Prolongation of anesthetic effects</td></tr><tr><td></td><td>Hepatotoxicity</td></tr><tr><td>Vitamin E</td><td>Anticoagulative properties</td></tr></table>
======================================
<table><tr><td>Skin conditions</td></tr><tr><td>Pigmented lesions</td></tr><tr><td>Tumors and cysts</td></tr><tr><td>Ulcers</td></tr><tr><td>Nonneoplastic epithelial disorders</td></tr><tr><td>Vagina</td></tr><tr><td>Embryonic origin</td></tr><tr><td>Mesonephric, paramesonephric, and urogenital sinus cysts</td></tr><tr><td>Adenosis (related to diethylstilbestrol)</td></tr><tr><td>Vaginal septa or duplications</td></tr><tr><td>Disorders of pelvic support</td></tr><tr><td>Anterior vaginal prolapse</td><td></td></tr><tr><td>Cystourethrocele</td></tr><tr><td>Cystocele</td></tr><tr><td>Apical vaginal prolapse</td></tr><tr><td>Uterovaginal</td></tr><tr><td>Vaginal vault</td><td></td></tr><tr><td>Posterior vaginal prolapse</td></tr><tr><td>Enterocele</td></tr><tr><td>Rectocele</td></tr><tr><td>Other</td></tr><tr><td>Condyloma</td></tr><tr><td>Urethral diverticula</td></tr><tr><td>Fibroepithelial polyp</td></tr><tr><td>Vaginal endometriosis</td></tr><tr><td>Cervix</td></tr><tr><td>Infectious</td><td></td></tr><tr><td>Condyloma</td></tr><tr><td>Herpes simplex virus ulceration</td></tr><tr><td>Chlamydial cervicitis</td></tr><tr><td>Other cervicitis</td></tr><tr><td>Other</td></tr><tr><td>Endocervical polyps</td></tr><tr><td>Nabothian cysts</td></tr><tr><td>Columnar epithelium eversion</td></tr></table>
======================================
<table><thead><th>Functional</th></thead><tr><td>Follicular</td></tr><tr><td>Corpus luteum</td></tr><tr><td>Theca lutein</td></tr><tr><td>Inflammatory</td></tr><tr><td>Tubo-ovarian abscess or complex</td></tr><tr><td>Neoplastic</td></tr><tr><td>Germ cell</td></tr><tr><td>Benign cystic teratoma</td></tr><tr><td>Other and mixed</td></tr><tr><td>Epithelial</td><td></td></tr><tr><td>Serous cystadenoma</td></tr><tr><td>Mucinous cystadenoma</td></tr><tr><td>Fibroma</td></tr><tr><td>Cystadenofibroma</td></tr><tr><td>Brenner tumor</td></tr><tr><td>Mixed tumor</td></tr><tr><td>Other</td></tr></table>
======================================
<table><thead><th>Vulvar and external</th></thead><tr><td>Vulvitis with excoriation</td></tr><tr><td>Trauma (e.g., accidental injury [straddle injury] or sexual abuse)</td></tr><tr><td>Lichen sclerosus</td></tr><tr><td>Condylomas</td></tr><tr><td>Molluscum contagiosum</td></tr><tr><td>Urethral prolapse</td></tr><tr><td>Vaginal</td></tr><tr><td>Vaginitis</td></tr><tr><td>Vaginal foreign body</td></tr><tr><td>Trauma (abuse, penetration)</td></tr><tr><td>Vaginal tumor</td><td></td></tr><tr><td>Uterine</td></tr><tr><td>Precocious puberty</td></tr><tr><td>Ovarian tumor</td></tr><tr><td>Granulosa cell tumor</td></tr><tr><td>Germ cell tumor</td></tr><tr><td>Exogenous estrogens</td></tr><tr><td>Topical</td></tr></table>
======================================
<table><thead><th>Vulvovaginitis</th><th>Anovulation</th><th>Exogenous hormone use</th><th>Anovulation</th><th>Exogenous hormone use</th></thead><tr><td>Vaginal foreign body</td><td>Exogenous hormone use</td><td>Pregnancy</td><td>Fibroids</td><td>Endometrial lesions, including cancer</td></tr><tr><td>Precocious puberty</td><td>Pregnancy</td><td>Anovulation</td><td>Cervical and endometrial polyps</td><td>Atrophic vaginitis</td></tr><tr><td>Tumor</td><td>Coagulopathy</td><td>Fibroids</td><td>Thyroid dysfunction</td><td>Other tumor—</td></tr></table>
======================================
<table><thead><th>Functional cyst</th><th>Prepubertal — Functional cyst</th><th>Adolescent — Functional cyst</th><th>Reproductive Functional cyst</th><th>Perimenopausal Fibroids</th><th>Ovarian tumor (malignant or benign)</th></thead><tr><td rowspan="3">Germ cell tumor</td><td>Germ cell tumor</td><td>Pregnancy</td><td>Pregnancy</td><td>Epithelial ovarian tumor</td><td>Functional cyst</td></tr><tr><td></td><td></td><td>Dermoid/other germ cell tumors</td><td>Uterine fibroids</td><td>Functional cyst</td><td>Bowel, malignant tumor or inflammatory</td></tr><tr><td></td><td></td><td>Obstructing vaginal or uterine anomalies Epithelial ovarian tumor</td><td>Epithelial ovarian tumor</td><td></td><td>Metastases</td></tr></table>
======================================
<table></table>
======================================
<table></table>
======================================
<table><thead><th>Eating disorders</th></thead><tr><td>Anorexia nervosa</td></tr><tr><td>Bulimia nervosa</td></tr><tr><td>Excessive physical exercise</td></tr><tr><td>Chronic illness</td></tr><tr><td>Ovarian insufficiency/premature ovarian failure</td></tr><tr><td>Alcohol and other drug abuse</td></tr><tr><td>Stress</td></tr><tr><td>Thyroid disease</td></tr><tr><td>Hypothyroidism</td></tr><tr><td>Hyperthyroidism</td></tr><tr><td>Diabetes mellitus</td></tr></table>
======================================
<table><thead><th>Term</th><th>Table 14.6 Abnormal Interval</th><th>Menses—Termin Duration</th><th>Amount</th></thead><tr><td>Menorrhagia</td><td>Regular</td><td>Prolonged</td><td>Excessive</td></tr><tr><td>Metrorrhagia</td><td>Irregular</td><td>+Prolonged</td><td>Normal</td></tr><tr><td>Menometrorrhagia</td><td>Irregular</td><td>Prolonged</td><td>Excessive</td></tr><tr><td>Hypermenorrhea</td><td>Regular</td><td>Normal</td><td>Excessive</td></tr><tr><td>Hypomenorrhea</td><td>Regular</td><td>Normal or less</td><td>Less</td></tr><tr><td>Oligomenorrhea</td><td>Infrequent or irregular</td><td>Variable</td><td>Scanty</td></tr><tr><td>Amenorrhea</td><td>Absent</td><td>No menses for 90 d</td><td>Absent</td></tr></table>
======================================
<table><thead><th>Full urinary bladder</th></thead><tr><td>Urachal cyst</td></tr><tr><td>Sharply anteflexed or retroflexed uterus</td></tr><tr><td>Pregnancy (with or without concomitant leiomyomas)</td></tr><tr><td>Intrauterine</td></tr><tr><td>Tubal</td></tr><tr><td>Abdominal</td></tr><tr><td>Ovarian or adnexal masses</td></tr><tr><td>Functional cysts</td></tr><tr><td>Inflammatory masses</td></tr><tr><td>Tubo-ovarian complex</td><td></td></tr><tr><td>Diverticular abscess</td><td></td></tr><tr><td>Appendiceal abscess</td></tr><tr><td>Matted bowel and omentum</td></tr><tr><td>Peritoneal cyst</td><td></td></tr><tr><td>Stool in sigmoid</td></tr><tr><td rowspan="2">Neoplastic tumors</td><td></td></tr><tr><td>Benign</td><td></td></tr><tr><td>Malignant</td><td></td></tr><tr><td>Paraovarian or paratubal cysts</td><td></td></tr><tr><td>Intraligamentous myomas</td></tr><tr><td>Less common conditions that must be excluded:</td></tr><tr><td>Pelvic kidney</td></tr><tr><td>Carcinoma of the colon, rectum, appendix</td></tr><tr><td>Carcinoma of the fallopian tube</td></tr><tr><td>Retroperitoneal tumors (anterior sacral meningocele)</td></tr><tr><td>Uterine sarcoma or other malignant tumors</td></tr></table>
======================================
<table><thead><th>That May Be Useful In Predicting Malignancy</th></thead><tr><td>Unilocular cyst vs. multilocular vs. solid components</td></tr><tr><td>Regular contour vs. irregular border</td></tr><tr><td>Smooth walls vs. nodular vs. irregular</td></tr><tr><td>Presence or absence of ascites</td></tr><tr><td>Unilateral vs. bilateral</td></tr><tr><td>Wall thickness</td></tr><tr><td>Internal echogenicity</td></tr><tr><td>Presence of other intra-abdominal pathology (liver, etc.)</td></tr><tr><td>Vascular characteristics and color flow Doppler pattern</td></tr></table>
======================================
<table><thead><th>Acanthosis nigricans</th><th>Cellulitis</th></thead><tr><td>Atopic dermatitis</td><td>Folliculitis</td></tr><tr><td>Behcet's disease</td><td>Furuncle/carbuncle</td></tr><tr><td>Contact dermatitis</td><td>Insect bites (e.g., chiggers, fleas)</td></tr><tr><td>Crohn’s disease</td><td>Necrotizing fasciitis</td></tr><tr><td>Diabetic vulvitis*</td><td>Pubic lice</td></tr><tr><td>Hidradenitis suppurativa?</td><td>Scabies</td></tr><tr><td>Squamous cell hypertrophy</td><td>Tinea</td></tr><tr><td colspan="2">Lichen sclerosus</td></tr><tr><td colspan="2">Paget's disease</td></tr><tr><td colspan="2">“Razor bumps”—folliculitis or pseudofolliculitis</td></tr><tr><td colspan="2">Psoriasis</td></tr><tr><td colspan="2">Seborrheic dermatitis</td></tr><tr><td colspan="2">Vulvar aphthous ulcer</td></tr><tr><td>Vulvar intraepithelial neoplasia</td><td></td></tr></table>
======================================
<table><thead><th>1. Cystic lesions</th><th>3. Anatomic</th></thead><tr><td>Bartholin duct cyst</td><td>Hernia</td></tr><tr><td>Cyst in the canal of Nuck (hydrocele)</td><td>Urethral diverticulum</td></tr><tr><td>Epithelial inclusion cyst</td><td>Varicosities</td></tr><tr><td>Skene duct cyst</td><td>. Infections</td></tr><tr><td>. Solid tumors</td><td>Abscess—Bartholin, Skene, periclitoral, other</td></tr><tr><td>Acrochordon (skin tag)</td><td>Condyloma lata</td></tr><tr><td>Angiokeratoma</td><td>Molluscum contagiosum</td></tr><tr><td>Bartholin gland adenoma</td><td>Pyogenic granuloma</td></tr><tr><td>Cherry angioma</td><td>. Ectopic</td></tr><tr><td>Fibroma</td><td>Endometriosis</td></tr><tr><td>Hemangioma</td><td>Ectopic breast tissue</td></tr><tr><td colspan="2">Hidradenoma</td></tr><tr><td colspan="2">Lipoma</td></tr><tr><td colspan="2">Granular cell myoblastoma</td></tr><tr><td colspan="2">Neurofibroma</td></tr><tr><td>Papillomatosis</td><td></td></tr></table>
======================================
<table><thead><th>Exogenous estrogens</th><th>30</th></thead><tr><td>Atrophic endometritis/vaginitis</td><td>30</td></tr><tr><td>Endometrial cancer</td><td>15</td></tr><tr><td>Endometrial or cervical polyps</td><td>10</td></tr><tr><td>Endometrial hyperplasia</td><td>5</td></tr><tr><td colspan="2">Miscellaneous (e.g., cervical cancer, uterine</td></tr><tr><td>sarcoma, urethral caruncle, trauma)</td><td>10</td></tr></table>
======================================
<table><tr><td>Acute Pain</td></tr><tr><td>1. Complication of pregnancy</td></tr><tr><td>a. Ectopic pregnancy</td></tr><tr><td>b. Abortion, threatened or incomplete</td></tr><tr><td>2. Acute infections</td></tr><tr><td>a. Endometritis</td></tr><tr><td>b. Pelvic inflammatory disease (acute PID) or salpingo-oophoritis</td></tr><tr><td>c. Tubo-ovarian abscess</td></tr><tr><td>3. Adnexal disorders</td></tr><tr><td>a. Hemorrhagic functional ovarian cyst</td></tr><tr><td>b. Torsion of adnexa</td></tr><tr><td>c. Rupture of functional, neoplastic, or inflammatory ovarian cyst</td><td></td></tr><tr><td>Recurrent Pelvic Pain</td></tr><tr><td>1. Mittelschmerz (midcycle pain)</td></tr><tr><td>2. Primary dysmenorrhea</td></tr><tr><td>3. Secondary dysmenorrhea</td></tr><tr><td>Gastrointestinal</td></tr><tr><td>. Gastroenteritis 1</td></tr><tr><td>. Appendicitis 2.</td></tr><tr><td>. Bowel obstruction 3</td></tr><tr><td>4. Diverticulitis</td></tr><tr><td>. Inflammatory bowel disease 5</td></tr><tr><td>6. . Irritable bowel syndrome</td></tr><tr><td>Genitourinary</td></tr><tr><td>1. Cystitis</td><td></td></tr><tr><td>2. Pyelonephritis</td></tr><tr><td>3. Ureteral lithiasis</td><td></td></tr><tr><td>Musculoskeletal</td></tr><tr><td>1. Abdominal wall hematoma</td></tr><tr><td>2. Hernia</td></tr><tr><td>Other</td></tr><tr><td>1. Acute porphyria</td></tr><tr><td>2. Pelvic thrombophlebitis</td></tr><tr><td>3. Aortic aneurysm</td></tr><tr><td>4. Abdominal angina</td></tr></table>
======================================
<table><thead><th>Organ</th><th>Spinal Segments</th><th>Nerves</th></thead><tr><td>Abdominal wall</td><td>T12-L1</td><td>lliohypogastric, ilioinguinal, genitofemoral</td></tr><tr><td>Lower abdominal wall, anterior vulva, urethra, and clitoris</td><td>L1-L2</td><td>llioinguinal, genitofemoral</td></tr><tr><td>Lower back</td><td>LI-L2</td><td></td></tr><tr><td>Pelvic floor, anus, perineum, and lower vagina</td><td>S2-S4</td><td>Pudendal, inguinal, genitofemora posterofemoral cutaneous</td></tr><tr><td>Upper vagina, cervix, uterine corpus, inner third of fallopian tube, broad ligament, upper bladder, terminal ileum, and terminal large bowel</td><td>T11-L2 S2-S4</td><td>Thoracolumbar autonomics (sympathetics) via hypogastric plexus; sacral autonomics (parasympathetics) via pelvic nerve</td></tr><tr><td>Ovaries, outer two thirds of fallopian tubes, and upper ureter</td><td>T9-T10</td><td>Thoracic autonomics (sympathetics) via renal and aortic plexus and celiac and mesenteric ganglia, aortic and superior mesenteric plexuses</td></tr></table>
======================================
<table><thead><th>Gynecologic</th><th>Genitourinary</th></thead><tr><td>Non-cyclic</td><td>Recurrent or relapsing cystourethritis</td></tr><tr><td>Adhesions</td><td>Urethral syndrome</td></tr><tr><td>Endometriosis</td><td>Interstitial cystitis</td></tr><tr><td>Salpingo-oophoritis</td><td>Ureteral diverticuli or polyps</td></tr><tr><td>Ovarian remnant or retained ovary syndrome</td><td>Carcinoma of the bladder</td></tr><tr><td>Pelvic congestion</td><td>Ureteral obstruction</td></tr><tr><td>Ovarian neoplasm benign or malignant</td><td>Pelvic kidney</td></tr><tr><td>Pelvic relaxation</td><td>Neurologic</td></tr><tr><td>Cyclic</td><td>Nerve entrapment syndrome, neuroma , or other neuropathies</td></tr><tr><td>Primary dysmenorrhea</td><td>Trigger points</td></tr><tr><td>Mittelschmerz</td><td>Musculoskeletal</td></tr><tr><td>Secondary dysmenorrhea</td><td>Low-back-pain syndrome</td></tr><tr><td>Endometriosis</td><td>Congenital anomalies</td></tr><tr><td>Uterine or vaginal anomalies with obstruction of menstrual outflow</td><td>Scoliosis and kyphosis</td></tr><tr><td>ntrauterine synechiae (Asherman’s syndrome)</td><td>Spondylolysis</td></tr><tr><td>Endometrial polyps or intrauterine device (IUD)</td><td>Spondylolisthesis</td></tr><tr><td>Uterine leiomyomata</td><td>Spinal injuries</td></tr><tr><td>Adenomyosis</td><td>Inflammation</td></tr><tr><td>Pelvic congestin syndrome</td><td>Tumors</td></tr><tr><td>Atypical cyclic</td><td>Osteoporosis</td></tr><tr><td>Endometriosis</td><td>Degenerative changes</td></tr><tr><td>Adenomyosis</td><td>Coccydynia</td></tr><tr><td>Ovarian remnant syndrome</td><td>Myofascial syndrome</td></tr><tr><td>Chronic functional cyst formation</td><td>Hernia</td></tr><tr><td>Gastrointestinal</td><td>Systemic</td></tr><tr><td>Irritable bowel syndrome</td><td>Fibromyalgia</td></tr><tr><td>Ulcerative colitis</td><td>Acute intermittent porphyria</td></tr><tr><td>Granulomatous colitis (Crohn's disease)</td><td>Abdominal migraine</td></tr><tr><td>Carcinoma</td><td>Connective tissue disease including systemic lupus erythematosus</td></tr><tr><td>Infection</td><td>Lymphoma</td></tr><tr><td>Recurrent partial bowel obstruction</td><td>Neurofibromatosis</td></tr><tr><td>Diverticulitis</td><td></td></tr></table>
======================================
<table><thead><th></th><th></th><th></th><th></th><th></th><th></th><th></th><th></th></thead><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr></table>
======================================
<table><thead><th>Table 16.1 Classifi ion of</th><th>Vulvovaginal Can</th></thead><tr><td>Uncomplicated</td><td>Complicated</td></tr><tr><td>Sporadic or infrequent in occurrence</td><td>Recurrent symptoms</td></tr><tr><td>Mild to moderate symptoms</td><td>Severe symptoms</td></tr><tr><td>Likely to be Candida albicans</td><td>Non-albicans Candida</td></tr><tr><td>Immunocompetent women</td><td>Immunocompromised, e.g., diabetic</td></tr><tr><td></td><td>women</td></tr></table>
======================================
<table><thead><th>Outpatient Treatment</th><th></th></thead><tr><td colspan="2">Regimen A</td></tr><tr><td colspan="2">Cefoxitin, 2 g intramuscularly, plus probenecid, 1 g orally concurrently, or</td></tr><tr><td colspan="2">Ceftriaxone, 250 mg intramuscularly, or</td></tr><tr><td colspan="2">Equivalent cephalosporin</td></tr><tr><td colspan="2">Plus:</td></tr><tr><td colspan="2">Doxycycline, 100 mg orally 2 times daily for 14 days</td></tr><tr><td colspan="2">With or without:</td></tr><tr><td colspan="2">Metronidazole, 500 mg orally 2 times daily for 14 days*</td></tr><tr><td colspan="2">Regimen B</td></tr><tr><td>Ofloxacin, 400 mg orally 2 times daily for 14 days, or</td><td></td></tr><tr><td colspan="2">Levofloxacin, 500 mg orally once daily for 14 days</td></tr><tr><td colspan="2">With or without:</td></tr><tr><td colspan="2">Metronidazole, 500 mg orally 2 times daily for 14 days*</td></tr><tr><td colspan="2">Inpatient Treatment</td></tr><tr><td colspan="2">Regimen A</td></tr><tr><td colspan="2">Cefoxitin, 2 g intravenously every 6 hours, or</td></tr><tr><td colspan="2">Cefotetan, 2 g intravenously every 12 hours,</td></tr><tr><td colspan="2">Plus:</td></tr><tr><td colspan="2">Doxycycline, 100 mg orally or intravenously every 12 hours</td></tr><tr><td colspan="2">Regimen B</td></tr><tr><td colspan="2">Clindamycin, 900 mg intravenously every 8 hours</td></tr><tr><td colspan="2">Plus:</td></tr><tr><td>Gentamicin, loading dose intravenously or intramuscularly (2 mg/kg of body followed by a maintenance dose (1.5 mg/kg) every 8 hours</td><td>weight)</td></tr></table>
======================================
<table><thead><th>Modality</th><th>Efficacy (%)</th><th>Recurrence Risl</th></thead><tr><td>Cryotherapy</td><td>63-88</td><td>21-39</td></tr><tr><td>Imiquimod 5% cream?</td><td>33-72</td><td>13-19</td></tr><tr><td>Podophyllin 10%-25%</td><td>32-79</td><td>27-65</td></tr><tr><td>Podofilox 0.5%?</td><td>45-88</td><td>33-60</td></tr><tr><td>Trichloroacetic acid 80%-90%</td><td>81</td><td>36</td></tr><tr><td>Electrodesiccation or cautery</td><td>94</td><td>22</td></tr><tr><td>Laser?</td><td>43-93</td><td>29-95</td></tr><tr><td>Interferon</td><td>44-61</td><td>0-67</td></tr></table>
======================================
<table><thead><th>Bethesda System</th><th>Dysplasia/CIN System</th><th>Papanicolaou System</th></thead><tr><td>Within normal limits</td><td>Normal</td><td></td></tr><tr><td>Infection (organism should be specified)</td><td>Inflammatory atypia (organism)</td><td></td></tr><tr><td colspan="3">Reactive and reparative changes</td></tr><tr><td>high-grade</td><td>HPV atypia</td><td></td></tr><tr><td>Low-grade squamous intraepithelial lesion (LSIL)</td><td>Mild dysplasia CIN 1</td><td></td></tr><tr><td>High-grade squamous intraepithelial lesion (HSIL)</td><td>Moderate dysplasia CIN 2</td><td>I</td></tr><tr><td>Squamous cell carcinoma</td><td>Squamous cell carcinoma</td><td>Vv</td></tr></table>
======================================
<table><thead><th>Guideline</th><th>American Cancer Society</th><th>and Gynecologists</th></thead><tr><td>Initial screening</td><td>¢ Age 21 or 3 y after vaginal sex</td><td>¢ Age 21 or 3 y after vaginal sex</td></tr><tr><td>Interval</td><td>¢ Every year for conventional Pap ¢ Every 2 years for liquid-based Pap ¢ Every 2-3 y after age 30 with 3 consecutive normals</td><td>¢ Every year for either liquid-based Pap or conventional ¢ Every 2-3 y after age 30 with 3 consecutive normals</td></tr><tr><td>Discontinue</td><td>¢ Age 70 if 3 consecutive normals in 10 y</td><td>¢ No upper limit of age</td></tr></table>
======================================
<table><thead><th>Author (ref. no.)</th><th>No.</th><th>Failure (%)</th><th>No.</th><th>Failure (%)</th><th>No.</th><th>Failure (%,</th></thead><tr><td>Ostergard (77)</td><td>13/205</td><td>6.3</td><td>7/93</td><td>7.5</td><td>9/46</td><td>19.6</td></tr><tr><td>Creasman et al. (78)</td><td>15/276</td><td>5.4</td><td>17/235</td><td>7.2</td><td>46/259</td><td>17.8</td></tr><tr><td>Benedet et al. (79)</td><td>7/143</td><td>4.9</td><td>19/448</td><td>4.2</td><td>65/1,003</td><td>6.5</td></tr><tr><td>Anderson and Hartley (81)</td><td></td><td></td><td>9/123</td><td>7.3</td><td>17/74</td><td>23.0</td></tr><tr><td>TOTAL</td><td>35/624</td><td>5.6</td><td>50/899</td><td>5.6</td><td>137/1,382</td><td>9.9</td></tr></table>
======================================
<table><thead><th rowspan="2">Author (ref. no.)</th><th colspan="2">CIN 1</th><th colspan="2">CIN 2</th><th colspan="2">CIN 3</th></thead><thead><th></th><th>No.</th><th>NED (%)</th><th>No.</th><th>NED (%)</th><th>No.</th><th>NED (%)</th></thead><tr><td>Burke (93)</td><td>49</td><td>41 (83.6)</td><td>42</td><td>36 (85.7)</td><td>40</td><td>31 (77.5)</td></tr><tr><td>Wright et al. (94)</td><td>110</td><td>108 (98.2)</td><td>140</td><td>133 (95)</td><td>190</td><td>179 (94.2)</td></tr><tr><td>Rylander et al. (95)</td><td>22</td><td>21 (95.5)</td><td>49</td><td>48 (97.9)</td><td>133</td><td>116 (87.2)</td></tr><tr><td>Jordan et al. (96)</td><td>142</td><td>140 (98.6)</td><td>153</td><td>145 (94.7)</td><td>416</td><td>390 (93.8)</td></tr><tr><td>Benedet et al. (98)</td><td>312</td><td>301 (96.5)</td><td>472</td><td>428 (90.7)</td><td>773</td><td>702 (90.8)</td></tr><tr><td>Baggish et al. (101)</td><td>741</td><td>675 (91.1)</td><td>1,048</td><td>978 (93.3)</td><td>1,281</td><td>1,228 (96)</td></tr><tr><td>TOTAL</td><td>1,376</td><td>1,286 (93.5)</td><td>1,904</td><td>1,768 (92.9)</td><td>2,833</td><td>2,646 (93.4)</td></tr></table>
======================================
<table><thead><th>Wright et al. (94)</th><th>96.2</th><th>Larsson et al. (99)</th><th>94.0</th></thead><tr><td>Baggish et al. (97)</td><td>97.5</td><td>Bostofte et al. (100)</td><td>90.2</td></tr><tr><td>Larsson et al. (99)</td><td>95.6</td><td>Bjerre et al.2 (102)</td><td>94.8</td></tr><tr><td>Bostofte et al. (100)</td><td>93.2</td><td>Kolstad et al.? (103)</td><td>97.6</td></tr></table>
======================================
<table><thead><th>Author (ref. no.)</th><th>Laser (%)</th><th>Author (ref. no.)</th><th>Knife (%)</th></thead><tr><td>Wright et al. (94)</td><td>12.2</td><td>Larsson et al. (99)</td><td>14.8</td></tr><tr><td>Baggish (97)</td><td>25</td><td>Bostofte et al. (100)</td><td>17.0</td></tr><tr><td>Larsson et al. (99)</td><td>2.3</td><td>Jones (104)</td><td>10.0</td></tr><tr><td>Bostofte (100)</td><td>5.0</td><td>Luesley et al. (106)</td><td>13.0</td></tr></table>
======================================
<table><thead><th>Complications</th><th>No. of Patients</th><th>Operative Hemorrhage</th><th>Postoperative Hemorrhage</th><th>Cervical Stenosis</th></thead><tr><td>Prendiville et al. (82)</td><td>111</td><td>2</td><td>2</td><td>—</td></tr><tr><td>Whiteley et al. (83)</td><td>80</td><td>0)</td><td>3</td><td>—</td></tr><tr><td>Mor-Yosef et al. (84)</td><td>50</td><td>1</td><td>3</td><td>—</td></tr><tr><td>Bigrigg et al. (85)</td><td>1,000</td><td>0</td><td>6</td><td>—</td></tr><tr><td>Gunasekera et al. (86)</td><td>98</td><td>0</td><td>0</td><td>—</td></tr><tr><td>Howe et al. (87)</td><td>100</td><td>0</td><td>1</td><td>_—</td></tr><tr><td>Minucci et al. (88)</td><td>130</td><td>0</td><td>1</td><td>2</td></tr><tr><td>Wright et al. (89)</td><td>432</td><td>0</td><td>8</td><td>2</td></tr><tr><td>Luesley et al. (90)</td><td>616</td><td>0</td><td>24</td><td>7</td></tr><tr><td>TOTAL</td><td>2,617</td><td>3 (0.001%)</td><td>48 (1.8%)</td><td>11/6178 (1.0%)</td></tr></table>
======================================
<table><thead><th>Table 17.9</th><th>Unsuspected</th><th>Invasion in Electrosurgical</th><th>Excision Specimens</th></thead><thead><th>Author (ref. no.)</th><th>Patients</th><th>Microinvasive</th><th>Invasive</th></thead><tr><td>Prendiville et al. (82)</td><td>02</td><td>1</td><td>—_</td></tr><tr><td>Bigrigg et al. (85)</td><td>1,000</td><td>5</td><td>—</td></tr><tr><td>Gunasekera et al. (86)</td><td>98</td><td>—</td><td>1</td></tr><tr><td>Howe et al. (87)</td><td>00</td><td>1</td><td>—</td></tr><tr><td>Wright et al. (89)</td><td>41</td><td>3</td><td>a</td></tr><tr><td>Luesley et al. (90)</td><td>616</td><td>1</td><td>—</td></tr><tr><td>Chappatte et al. (92)</td><td>00</td><td>4</td><td>6 (adenocarcinoma in situ)</td></tr><tr><td>TOTAL</td><td>2,157</td><td>15 (0.7%)</td><td>1 (0.04%)</td></tr></table>
======================================
<table><thead><th>Side Effect</th><th>Loop Excision (n = 98)</th><th>Laser (n = 101)</th></thead><tr><td>Not unpleasant</td><td>80 (92%)</td><td>32 (32%)</td></tr><tr><td>Moderately unpleasant</td><td>16 (16%)</td><td>50 (50%)</td></tr><tr><td>Very unpleasant</td><td>2 (2%)</td><td>19 (18%)</td></tr><tr><td>Operative time</td><td>20-50 sec (mean, 16 sec)</td><td>4-15 min (mean, 6.5 mii</td></tr></table>
======================================
<table><thead><th>Table 17.11</th><th>Results of Loop Electrosurgical</th><th>Excision</th></thead><tr><td>Author (ref. no.)</td><td>Patients Treated</td><td>Patients Recurred</td></tr><tr><td>Prendiville et al. (82)</td><td>102</td><td>2</td></tr><tr><td>Whiteley et al. (83)</td><td>80</td><td>4</td></tr><tr><td>Bigrigg et al. (85)</td><td>1,000</td><td>41</td></tr><tr><td>Gunasekera et al. (86)</td><td>98</td><td>7</td></tr><tr><td>Luesley et al. (90)</td><td>616</td><td>27</td></tr><tr><td>Murdoch et al. (91)</td><td>600</td><td>16</td></tr><tr><td>TOTAL</td><td>2,496</td><td>97 (3.9%)</td></tr></table>
======================================
<table><thead><th>Author (ref. no.)</th><th>No. of Patients</th><th>Negative Margins</th><th>Positive Margins</th></thead><tr><td>Larsson et al. (99)</td><td>683</td><td>56</td><td>246</td></tr><tr><td>Bjerre et al. (102)</td><td>1,226</td><td>64</td><td>429</td></tr><tr><td>Kolstad et al. (103)</td><td>1,121</td><td>27</td><td>291</td></tr><tr><td>TOTAL</td><td>3,030</td><td>147 (4.9%)</td><td>966 (31.9%)</td></tr></table>
======================================
<table><thead><th>Tubal pregnancy</th><th>A pregnancy occurring in the fallopian tube—most often these are located in the ampullary portion of the fallopian tube</th></thead><tr><td>Interstitial pregnancy</td><td>A pregnancy that implants within the interstitial portion of the fallopian tube</td></tr><tr><td rowspan="2">Abdominal pregnancy</td><td>Primary abdominal pregnancy—the first and only implantation occurs on a peritoneal surface</td></tr><tr><td></td><td>Secondary abdominal pregnancy—implantation originally in the tubal ostia, subsequently aborted, and then reimplanted onto a peritoneal surface</td></tr><tr><td>Cervical pregnancy</td><td>Implantation of the developing conceptus in the cervical canal</td></tr><tr><td>Ligamentous pregnancy</td><td>A secondary form of ectopic pregnancy in which a primary tubal pregnancy erodes into the mesosalpinx and is located between the leaves of the broad ligament</td></tr><tr><td>Heterotopic pregnancy</td><td>A condition in which ectopic and intrauterine pregnancies coexist</td></tr><tr><td>Ovarian pregnancy</td><td>A condition in which an ectopic pregnancy implants within the ovarian cortex</td></tr><tr><td colspan="2">Abnormal Intrauterine Pregnancy</td></tr><tr><td>Incomplete abortion</td><td>Expulsion of some but not all of the products of conception before 20 completed weeks of gestation</td></tr><tr><td>Complete abortion</td><td>Spontaneous expulsion of all fetal and placental tissue from the uterine cavity before 20 weeks of gestation</td></tr><tr><td>Inevitable abortion</td><td>Uterine bleeding from a gestation of less than 20 weeks, accompanied by cervical dilation but without expulsion of placental or fetal tissue through the cervix</td></tr><tr><td>Anembryonic gestation</td><td>An intrauterine sac without fetal tissue present at more than 7.5 weeks of gestation</td></tr><tr><td>First-trimester fetal death</td><td>Death of the fetus in the first 12 weeks of gestation</td></tr><tr><td>Second-trimester fetal death</td><td>Death of the fetus between 13 and 24 weeks of gestation</td></tr></table>
======================================
<table><tr><td>Pathologic (blighted) ovum—anembryonic gestation</td></tr><tr><td>Embryonic anomalies</td></tr><tr><td>Chromosomal anomalies</td></tr><tr><td>Increased maternal age</td></tr><tr><td>Uterine anomalies</td></tr><tr><td>Intrauterine device</td></tr><tr><td>Teratogen</td></tr><tr><td>Mutagen</td></tr><tr><td>Maternal disease</td></tr><tr><td>Placental anomalies</td></tr></table>
======================================
<table><thead><th>Day</th><th>Therapy?</th></thead><tr><td>lo</td><td>D&amp;C, hCG</td></tr><tr><td>[la</td><td>CBC, SGOT, BUN, creatinine, blood type and Rh</td></tr><tr><td></td><td>Methotrexate 50 mg/m? IM</td></tr><tr><td>N</td><td>hCG</td></tr></table>
======================================
<table><tr><td>Echo-free uterine cavity or the presence of a false gestational sac only</td></tr><tr><td>Decidual transformation of the endometrium with dense echo structure</td></tr><tr><td>Diffuse uterine wall structure</td></tr><tr><td>Hourglass uterine shape</td></tr><tr><td>Ballooned cervical canal</td></tr><tr><td>Gestational sac in the endocervix</td></tr><tr><td>Placental tissue in the cervical canal</td></tr></table>
======================================
<table><thead><th>Aspiration FNAC, aspirated (usually 22-gauge) and examined by a pathologist. Precise guidelines for this technique are available (72). It</th></thead></table>
======================================
<table></table>
======================================
<table><thead><th>Change covers a spectrum of clinical signs and symptoms and histologic changes (76). The</th></thead></table>
======================================
<table><tr><td>Analysis Investigators electrolyte protein cyst been of little significance in the clinical management of fibrocystic disease. The potassium-</td></tr></table>
======================================
<table><thead><th>cyclic, or extramammary (116). Cyclic mastalgia is related to exaggerated premenstrual</th></thead></table>
======================================
<table><tr><td>Lactational Abscesses</td><td>Infection in the breast is rare unless the patient is lactating. Lactational mastitis must be distinguished from lactational abscess (191). During lactation, an area of redness, tender- ness, and induration frequently develops in the breast. Lactational mastitis is caused by transmission of bacteria during nursing and poor hygiene. The organism most commonly found in lactational mastitis and abscesses is Staphylococcus aureus (192). If mastitis is diagnosed, manual pressure, antibiotics, and continued breastfeeding are recommended. In its early stages, the infection often can be treated while breastfeeding is continued by administering an antibiotic such as dicloxacillin 250 mg four times daily, or oxacillin, 500 mg four times daily for 7 to 10 days. If the lesion progresses to a localized mass with local and systemic signs of infection, an abscess is present. It should be drained, and breastfeeding should be discontinued.</td></tr></table>
======================================
<table><tr><td></td><td>Table 20.2 Causes of Metabolic</td><td>Acidosis</td></tr><tr><td>Disorder</td><td>Source of Alkali</td><td>Cause of Renal HCO Retention</td></tr><tr><td>Gastric alkalosis</td><td>Gastric mucosa</td><td>WECF, JK</td></tr><tr><td colspan="3">Nasogastric suction</td></tr><tr><td colspan="3">Vomiting</td></tr><tr><td>Renal alkalosis Diuretics Respiratory acidosis and diuretics</td><td>Renal epithelium</td><td>ECF, JK LEC, JK, TPCO,</td></tr><tr><td>Exogenous base</td><td>NaHCO,, Na citrate, Na lactate</td><td>Coexisting disorder of ECF, kK, Paco,</td></tr></table>
======================================
<table><thead><th></th><th>Hyperkalemic</th><th>Hypokalemic</th></thead><tr><td>Uremia</td><td>Hyporeninism</td><td>Diarrhea</td></tr><tr><td>Ketoacidosis</td><td>Primary adrenal failure</td><td>Renal tubular acidosis</td></tr><tr><td>Lactic acidosis</td><td>NH,Cl</td><td>Ileal and sigmoid bladder:</td></tr><tr><td>Aspirin</td><td>Sulfur poisoning</td><td>Hyperalimentation</td></tr><tr><td>Paraldehyde</td><td>Early chronic renal failure</td><td></td></tr><tr><td>Methanol</td><td>Obstructive uropathy</td><td></td></tr><tr><td colspan="3">Ethylene glycol</td></tr><tr><td colspan="3">Methyl malonic aciduria</td></tr><tr><td>NH,CI (chloramine)</td><td></td><td></td></tr></table>
======================================
<table><thead><th>Primary Disorder</th><th>Defect</th><th>Common Causes</th><th>Compensation</th><th>Treatment</th></thead><tr><td>Respiratory acidosis</td><td>| Carbon dioxide (hypoventilation)</td><td>Central nervous system depression Airway and lung impairment</td><td>Renal excretion of acid salts Bicarbonate retention Chloride shift into red blood cells</td><td>Restoration ventilation Control of excess dioxide production</td></tr><tr><td>Respiratory alkalosis</td><td>Hyperventilation</td><td>Central nervous excitation system Excess ventilator support</td><td>Renal excretion of sodium, potassium bicarbonate Absorption of hydrogen and chloride ions Lactal red b te release from ood cells</td><td>Correction hyperventilation</td></tr><tr><td></td><td>Increased nonvolatile acids</td><td>versus sodium Increased bicarbonate loss Lactic, ketoacidosis Uremia Dilution acidosis</td><td>Rena excretion of hydrogen and chloride ions Resorption of potassium bicarbonate</td><td>give bicarbonate for pH &lt;7.2 Restore buffers, protein, hemoglobin</td></tr><tr><td>Metabolic acidosis</td><td>Excess loss of chloride and potassium Increased bicarbonate</td><td>Gastrointestinal losses of chloride Excess intake of bicarbonate Diuretics Hypokalemia Extracellular fluid volume contraction</td><td>Respiratory acidosis May be hypoxia Renal excretion of bicarbonate and potassium Absorption of hydrogen and chloride ions</td><td>Increased chloride content Potassium replacement Acetazolamide (Diamox) to waste _ bicarbonate Vigorous volume replacement Occasional 0.1 NaHCl as needed</td></tr></table>
======================================
<table><tr><td>Hysterectomy (vaginal/abdominal)</td><td>1 to 2 g IV cefazolin 2 g IV cefoxitin 1 to 2 g IV cefotetan 1 g IV cefotaxime</td></tr><tr><td>Abortion/dilation &amp; curettage</td><td>100 mg doxycycline PO 1 hour before procedure, then 200 mg po after the procedure</td></tr><tr><td>Cervical conization</td><td>No clear recommendations; doxycycline suggested by some authors</td></tr><tr><td>Colporrhaphy</td><td>No clear recommendations, cephalosporins suggested by some authors</td></tr><tr><td>Laparoscopy (clean)</td><td></td></tr><tr><td>Laparotomy (clean)</td><td></td></tr><tr><td>Hysterosocopy</td><td></td></tr></table>
======================================
<table><thead><th></th><th>Genitourinary and Gastrointestinal</th><th>Procedures</th></thead><thead><th>High-Risk Patients</th><th>Agents</th><th>Regimen</th></thead><tr><td rowspan="2">Standard regimen</td><td>Ampicillin and</td><td>2.0 g IM or IV within 30 min of starting 1.0 IM IV hr later</td></tr><tr><td></td><td>Gentamicin</td><td>procedure; g or 6 1.5 mg/kg (not to exceed 120 mg) within 30 min of starting procedure</td></tr><tr><td rowspan="2">Penicillin-allergic</td><td>Vancomycin and</td><td>1.0 g IV over 1-2 h completed within 30 min of procedure</td></tr><tr><td></td><td>Gentamicin</td><td>starting 1.5 mg/kg (not to exceed 120 mg) within 30 min of starting procedure</td></tr><tr><td>Moderate-Risk Patients</td><td>Agents</td><td>Regimen</td></tr><tr><td rowspan="2">Standard regimen</td><td></td><td>Ampicillin or</td><td>2.0 g IM or IV within 30 min of starting procedure</td></tr><tr><td>Amoxicillin</td><td>2.0 g orally 1 h before procedure</td></tr><tr><td>Penicillin-allergic</td><td>Vancomycin</td><td>1.0 g IV over 1-2 h completed within 30 min of starting procedure</td></tr></table>
======================================
<table><thead><th>Operative Site</th><th>Nonoperative Site</th></thead><tr><td>Vaginal cuff</td><td>Urinary tract</td></tr><tr><td>Pelvic cellulitis</td><td>Asymptomatic bacteriuria</td></tr><tr><td>Pelvic abscess</td><td>Cystitis</td></tr><tr><td>Supervaginal, extraperitoneal</td><td>Pyelonephritis</td></tr><tr><td>Intraperitoneal</td><td>Respiratory</td></tr><tr><td>Adnexa</td><td>Atelectasis</td></tr><tr><td>Cellulitis</td><td>Pneumonia</td></tr><tr><td>Abscess</td><td>Vascular</td></tr><tr><td>Abdominal incision</td><td>Phlebitis</td></tr><tr><td>Cellulitis</td><td>Septic pelvic thrombophlebit</td></tr><tr><td colspan="2">Simple</td></tr><tr><td colspan="2">Progressive bacterial synergistic</td></tr><tr><td>Necrotizing fascitis</td><td></td></tr></table>
======================================
<table><tr><td>APTT &lt;35 seconds (&lt;1.2 X control)</td><td>80-U/kg bolus, then 4 U/kg/h</td></tr><tr><td>APTT 35-45 seconds (1.2-1.5 X control)</td><td>40-U/kg bolus, then 2 U/kg/h</td></tr><tr><td>APTT 46-70 seconds (1.5-2.3 X control)</td><td>No change</td></tr><tr><td>APTT 71-90 seconds (2.3—3 X control)</td><td>Decrease infusion rate by 2 U/kg/h</td></tr><tr><td>APTT &gt;90 seconds (&gt;3 X control)</td><td>Hold infusion for 1h, then decrease infusion rate by 3 U/kg/h</td></tr></table>
======================================
<table><thead><th>Medical or Surgical Stress</th><th>Corticosteroid Dosage</th></thead><tr><td colspan="2">Minor</td></tr><tr><td>Moderate Open cholecystectomy Hemicolectomy Significant febrile illness Pneumonia</td><td>50-75 mg of hydrocortisone or 10-15 mg of methylprednisolone !V on day of procedure Taper quickly over 1-2 days to usual dose</td></tr><tr><td>Severe gastroenteritis</td><td></td></tr><tr><td>Major cardiothoracic surgery Whipple procedure Liver resection Pancreatitis II</td><td>100-150 mg of hydrocortisone or 20-30 mg of methylprednisolone !V on day of procedure Rapid taper to usual dose over next 1-2 days</td></tr><tr><td>Critically Sepsis-induced hypotension or shock</td><td>50-100 mg of hydrocortisone IV every 6-8 h or 0.18 mg/kg/h as a continuous infusion + 50 pg/d of fludrocortisone until shock resolved. May take several days to a week or more, then gradually taper, following vital signs and serum sodium.</td></tr></table>
======================================
<table><thead><th>Class</th><th>(number of risk factors)</th><th>Events/Patient</th><th>Event Rate % (95% Cl)</th></thead><tr><td>|</td><td>(0)</td><td>2/488</td><td>0.4 (0.05, 1.5)</td></tr><tr><td>Il</td><td>(1)</td><td>5/567</td><td>0.9 (0.3, 2.1)</td></tr><tr><td>Il</td><td>(2)</td><td>17/258</td><td>6.6 (3.9, 10.3)</td></tr><tr><td>IV</td><td>(3)</td><td>12/109</td><td>11.0 (5.8, 18.4)</td></tr></table>
======================================
<table><thead><th>Table 20.16 Signs and Symptoms of Congestive Heart Failure Presence of an S, gallop</th></thead><tr><td>Jugular venous distention</td></tr><tr><td>Lateral shift of the point of maximal impulse</td></tr><tr><td>Lower-extremity edema</td></tr><tr><td>Basilar rales</td></tr><tr><td>Increased voltage on electrocardiogram</td></tr><tr><td>Evidence of pulmonary edema or cardiac enlargement on chest radiograph</td></tr></table>
======================================
<table><tr><td>. Precordial heave</td></tr><tr><td>. Diastolic murmur at apex</td></tr><tr><td>. Mitral opening snap</td><td></td></tr><tr><td>. Suffused face and lips</td></tr><tr><td>. Chest radiograph with left atrial dilation Electrocardiogram with large P waves and right axis deviation</td></tr></table>
======================================
<table><thead><th>Drug</th><th>Route</th><th>Initial Dose</th><th>Onset</th><th>Duration</th><th>Side Effects</th></thead><tr><td>Nitroprusside</td><td>IV infusion</td><td>0.5 wg/min</td><td>Immediate</td><td>2-5 min</td><td>Tachycardia, nausea</td></tr><tr><td>Labetalol</td><td>IV infusion</td><td>20 mg</td><td>5-10 min</td><td>4h</td><td>Bronchospasm, dizziness, nausea</td></tr><tr><td>Esmolol</td><td>IV infusion</td><td>50 pg/min</td><td>2h</td><td>9 min</td><td>Headache, somnolence, dizziness, hypotension</td></tr><tr><td>Nifedipine</td><td>Sublingual</td><td>10 mg</td><td>5 min</td><td>2 min</td><td>Hypotension, headache, dizziness, nausea, peripheral edema</td></tr><tr><td>Verapamil</td><td>IV infusion</td><td>5-10 mg</td><td>3-5 min</td><td>25h</td><td>Nausea, headache, hypotension, dizziness, pulmonary edema</td></tr></table>
======================================
<table><thead><th>Parameter</th><th>Value</th></thead><tr><td>Maximal breathing capacity</td><td>&lt;50% predicted</td></tr><tr><td></td><td>&lt;1L</td></tr><tr><td>FVC</td><td>&lt;70% predicted</td></tr><tr><td>FEV ,/FVC</td><td>&lt;65% predicted</td></tr><tr><td>Pao,</td><td>&lt;60 mm Hg</td></tr><tr><td>Paco,</td><td>&gt;45 mm Hg</td></tr></table>
======================================
<table><thead><th rowspan="2">Parameter</th><th colspan="3">Child Classification</th></thead><thead><th></th><th>A</th><th>B</th><th>c</th></thead><tr><td>Bilirubin</td><td>&lt;2.0</td><td>2.0-3.0</td><td>&gt;3.0</td></tr><tr><td>Albumin</td><td>&gt;3.5</td><td>3.0-3.5</td><td>&lt;3.0</td></tr><tr><td>Ascites</td><td></td><td>Easily controlled</td><td>Poor controlled</td></tr><tr><td>Encephalopathy</td><td></td><td>Mild</td><td>Advanced</td></tr><tr><td>Nutritional status</td><td>Excellent</td><td>Good</td><td>Poor</td></tr></table>
======================================
<table></table>
======================================
<table></table>
======================================
<table></table>
======================================
<table><tr><td>and Communication</td><td>hysteroscopy is usually performed in an operating room or hospital surgicenter. The</td></tr><tr><td></td><td>should understand the rationale for either procedure, as well as the anticipated discom.</td></tr><tr><td></td><td>potential risks, and the expectant, medical, and surgical alternatives. The nature of the</td></tr><tr><td></td><td>and the chance of therapeutic success should be explained to the patient, and she</td></tr></table>
======================================
<table><thead><th></th><th>Indication</th><th rowspan="3">No. of Patients 27</th><th rowspan="3">Percentage 1.5</th><th rowspan="3">Percentage Confirmed! 93</th></thead><thead><th>Acute</th><th>condition (emergencies)</th><th></th><th></th><th></th></thead><thead><th>A-1</th><th>Pregnancy catastrophe!</th><th></th><th></th><th></th></thead><tr><td>A-2</td><td>Severe infection?</td><td>2</td><td>&lt;1</td><td>100</td></tr><tr><td>A-3</td><td>Operative complication!</td><td>1</td><td>&lt;1</td><td>100</td></tr><tr><td colspan="5">Benign disease</td></tr><tr><td>B-1</td><td>Leiomyomas?</td><td>522</td><td>29</td><td>86</td></tr><tr><td>B-2</td><td>Endometriosis*</td><td>95</td><td>5.3</td><td>92</td></tr><tr><td>B-3</td><td>Adenomyosis”</td><td>27</td><td>1.5</td><td>44</td></tr><tr><td>B-4</td><td>Chronic infection?</td><td>29</td><td>1.6</td><td>00</td></tr><tr><td>B-5</td><td>Adnexal mass?</td><td>46</td><td>8.1</td><td>00</td></tr><tr><td>B-6</td><td>Other?</td><td>1</td><td>&lt;i</td><td>00</td></tr><tr><td colspan="5">Cancer or premalignant disease (known)</td></tr><tr><td>C-1__</td><td>Invasive cancer?</td><td>64</td><td>9.1</td><td>00</td></tr><tr><td>C-2</td><td>Preinvasive disease”</td><td>37</td><td>7.6</td><td>00</td></tr><tr><td>C-3</td><td>Adjacent or distant cancer?</td><td>6</td><td>&lt;i</td><td>00</td></tr><tr><td colspan="5">Discomfort (chronic or recurrent)</td></tr><tr><td>D-1</td><td>Chronic pelvic pain!</td><td>44</td><td>8</td><td>80</td></tr><tr><td>D-2</td><td>Pelvic relaxation!</td><td>89</td><td>10.5</td><td>00</td></tr><tr><td>D-3</td><td>Stress urinary incontinence!</td><td>86</td><td>4.8</td><td>00</td></tr><tr><td>D-4</td><td>Abnormal uterine bleeding!</td><td>225</td><td>12.5</td><td>94</td></tr><tr><td colspan="5">Extenuating circumstances (peer reviewed)</td></tr><tr><td></td><td>Sterilization?</td><td>3</td><td>&lt;1</td><td>00</td></tr><tr><td>E-2</td><td>Cancer prophylaxis’</td><td>5&lt;1</td><td>100</td><td></td></tr><tr><td>E-3.</td><td>Other’</td><td>2</td><td>&lt;i</td><td>00</td></tr><tr><td>TOTAL</td><td></td><td>1,811</td><td>100</td><td>92</td></tr></table>
======================================
<table><thead><th>Neoplasia</th><th>Intraepithelial past, hysterectomy performed primary intraepithelial neoplasia. However, the maximum depth of dysplasia at the squamocolumnar junction</th></thead></table>
======================================
<table><thead><th>Neurologic</th></thead><tr><td>Mental status</td></tr><tr><td>Perineal sensation</td></tr><tr><td>Perineal reflexes</td></tr><tr><td>Patellar reflexes</td></tr><tr><td>Abdominal examination</td></tr><tr><td>Masses</td></tr><tr><td>Cardiovascular</td></tr><tr><td>Congestive heart failure</td></tr><tr><td>Lower extremity edema</td><td></td></tr><tr><td>Mobility</td></tr><tr><td>Gait assessment</td></tr><tr><td>Pelvic examination</td></tr><tr><td>Prolapse</td></tr><tr><td>Atrophy</td></tr><tr><td>Levator muscle palpation (symmetry, ability to squeeze)</td></tr><tr><td>Anal sphincter function</td></tr><tr><td>Test of urethral mobility (e.g., Q-tip test)</td></tr></table>
======================================
<table><thead><th>|.</th><th>Bladder sensation</th></thead><tr><td colspan="2">A. First sensation First becomes aware of bladder filling</td></tr><tr><td></td><td>B. First desire to void Feeling that would lead the person to void at next convenient moment, but voiding can be delayed if necessary</td></tr><tr><td colspan="2">C. Strong desire to void Persistent desire to void without the fear of leakage</td></tr><tr><td colspan="2">D. Sensation classified as:</td></tr><tr><td></td><td>1. Increased</td></tr><tr><td colspan="2">2. Reduced</td></tr><tr><td colspan="2">3. Absent</td></tr><tr><td></td><td>4. Nonspecific bladder sensations (other symptoms make person aware of bladder filling, like abdominal fullness)</td></tr><tr><td></td><td>5. Bladder pain (is abnormal)</td></tr><tr><td></td><td>6. Urgency (sudden compelling desire to void)</td></tr><tr><td>Il.</td><td>Detrusor function</td></tr></table>
======================================
<table><thead><th>Pressure flow studies</th></thead><tr><td>Urine flow is defined as</td></tr><tr><td>Continuous</td></tr><tr><td>Intermittent</td></tr><tr><td>Flow rate Volume voided/unit time a.</td></tr><tr><td>b. Voided volume Total volume voided</td></tr><tr><td>. Maximum flow rate c.</td></tr><tr><td>d. Voiding time Includes interruptions</td></tr><tr><td>e. Flow time Time over which measurable flow actually occurs</td></tr><tr><td>f. Average flow rate Voided volume/flow time</td></tr><tr><td>. Closing pressure Pressure measured at end of measured flow</td></tr><tr><td>= |go Detrusor function during voiding can be classified as:</td></tr><tr><td>1. Normal</td></tr><tr><td>2. Detrusor underactivity Contraction of reduced strength resulting in prolonged bladder emptying and/or a failure to achieve complete bladder emptying</td></tr><tr><td>3. Acontractile Cannot be demonstrated to contract</td></tr><tr><td>i. Urethral function during voiding can be classified as:</td></tr><tr><td>1. Normal Continuously relaxed</td></tr><tr><td>2. Dysfunctional voiding Intermittent and/or fluctuating flow rate that is due to involuntary intermittent contractions of the periurethral striated muscle during voiding in neurologically normal people</td></tr><tr><td>3. Detrusor sphincter dyssynergia Detrusor contraction concurrent with an involuntary contraction of the urethral and/or periurethral striated muscle</td></tr><tr><td>4. Nonrelaxing urethral sphincter obstruction Usually occurs in people with a neurologic lesion</td></tr></table>
======================================
<table><thead><th>Drug</th><th>Oral Dose Range</th></thead><tr><td colspan="2">Generic and Brand Names</td></tr><tr><td colspan="2">Oxybutynin</td></tr><tr><td>Ditropan*</td><td>2.5—5 mg tid-qid</td></tr><tr><td>Ditropan syrup</td><td>tsp (5 mg)</td></tr><tr><td>Ditropan XL&gt;</td><td>5, 10, or 15 mg qd</td></tr><tr><td>Oxytrol patch®</td><td>patch 2 times per week</td></tr><tr><td colspan="2">Hyoscyamine</td></tr><tr><td>Levsin®</td><td>0.125-0.25 mg qid</td></tr><tr><td>Levbid, Levsinex</td><td>tab bid</td></tr><tr><td>Levsin elixir</td><td>tsp (0.25 mg qid)</td></tr><tr><td>Levsin/SL</td><td>sublingual pill</td></tr><tr><td>Cystospaz®</td><td>0.15-0.3 mg qid</td></tr><tr><td>Cystospaz-M</td><td>tab bid</td></tr><tr><td>Dicyclomine</td><td>20</td></tr><tr><td>BentyP Probantheline</td><td>mg qid</td></tr><tr><td>ProBanthine'</td><td>5-30 mg qid</td></tr><tr><td colspan="2">Tolteridene</td></tr><tr><td>Detrol</td><td>-2 mg bid (immediate release)</td></tr><tr><td>Detrol LA&amp;</td><td>4 mg qd (extended release)</td></tr><tr><td>Trospium chloride" Sanctura</td><td>20 mg bid</td></tr><tr><td>Solifenacin succinate! Vesicare</td><td>5-20 mg qd (one daily dose; usual dosing is 5-10 mg qd)</td></tr></table>
======================================
<table><tr><td>Sling</td><td>Pubovaginal approach (Fig. 23.11). The anterior vagina is opened, the space of Retzius is dissected</td></tr></table>
======================================
<table><tr><td>do occur in women and can be defined as emptying dysfunction resulting from relaxation</td></tr></table>
======================================
<table><thead><th></th><th>Description</th><th>Range</th></thead><tr><td>Aa</td><td>Anterior wall 3 cm from hymen</td><td>—3 cmto +3 cm</td></tr><tr><td>Ba</td><td>Most dependent portion of rest of anterior wall</td><td>—3 cm to +TVL</td></tr><tr><td>C</td><td>Cervix or vaginal cuff</td><td>+TVL</td></tr><tr><td>D</td><td>Posterior fornix (if no prior hysterectomy)</td><td>*+TVL or omitted</td></tr><tr><td>Ap</td><td>Posterior wall 3 cm from hymen</td><td>—3 cmto +3 cm</td></tr><tr><td>Bp</td><td>Most dependent portion of rest of posterior wall</td><td>—3 cm to +TVL</td></tr></table>
======================================
<table><thead><th></th><th>Table 24.2. Stages of Pelvic Organ Prolapse</th></thead><tr><td>Stage 0</td><td>No prolapse is demonstrated. Points Aa, Ap, Ba, Bp are all at —3 cm, and point C is between total vaginal length (TVL) and (TVL —2 cm).</td></tr><tr><td>Stage |</td><td>The most distal portion of the prolapse is &gt;1 cm above the level of the hymen.</td></tr><tr><td>Stage Il</td><td>The most distal portion of the prolapse is &lt;1 cm proximal or distal to the plane of the hymen.</td></tr><tr><td>Stage III</td><td>The most distal portion of the prolapse is &lt;1 cm below the plane of the hymen but no further than 2 cm less than the total vaginal length.</td></tr><tr><td>Stage IV</td><td>Complete to nearly complete eversion of the vagina. The most distal portion of the prolapse protrudes to &gt; +(TVL —2) cm.</td></tr></table>
======================================
<table></table>
======================================
<table><thead><th>Metabolic/Endocrine</th><th rowspan="2">Diabetes mellitus Thyroid disease Hypercalcemia Hypokalemia</th></thead><thead><th></th></thead><tr><td>Neurological</td></tr><tr><td>Central Nervous System</td></tr><tr><td>Multiple sclerosis, Parkinson disease, stroke, tumor, dementia</td></tr><tr><td>Peripheral Nervous System Hirschsprung disease, spina bifida, autonomic neuropathy,</td></tr><tr><td>pudendal neuropathy</td></tr><tr><td>Infectious</td></tr><tr><td>Bacterial, viral, parasitic diarrhea</td></tr><tr><td>Collagen Vascular/Muscle Disorder Systemic sclerosis, amyloidosis,</td></tr><tr><td>myotonic dystrophy, dermatomyositis</td></tr><tr><td>Idiopathic/Autoimmune nflammatory bowel disease</td></tr><tr><td>Food allergy</td></tr><tr><td>Medications</td></tr><tr><td>over the counter</td></tr><tr><td>Prescription,</td></tr><tr><td>Anatomical/Structural Abnormalities</td></tr><tr><td>Pelvic Outlet Obstruction</td></tr><tr><td>Pelvic organ prolapse</td></tr><tr><td>Descending perineum syndrome Anismus/rectosphincteric dyssynergia</td></tr><tr><td>ntussusception, rectal prolapse Volvulus</td></tr><tr><td>Neoplasia</td></tr><tr><td>Benign strictures Hemorrhoids</td></tr><tr><td>Anal Sphincter Disruption/Fistula</td></tr><tr><td>Obstetrical trauma Surgical trauma Anal intercourse radiation</td></tr></table>
======================================
<table><thead><th>Global motility disorder</th></thead><tr><td>Colonic inertia/slow-transit constipation</td></tr><tr><td>Irritable bowel syndrome</td></tr><tr><td>Functional constipation</td></tr><tr><td>Functional diarrhea</td></tr><tr><td>Functional Limitations</td></tr><tr><td>Decreased mobility</td></tr><tr><td>Decreased cognition</td></tr></table>
======================================
<table><thead><th>Antidepressants</th><th>Iron</th></thead><tr><td>Antipsychotics</td><td>Barium sulfate</td></tr><tr><td>Antispasmodics</td><td>Metallic intoxication (arsenic, lead, mercury)</td></tr><tr><td>Antiparkinsonian drugs</td><td>Opiates</td></tr><tr><td>Antihypertensives</td><td>Nonsteroidal anti-inflammatory agents</td></tr><tr><td>Calcium channel blockers</td><td>Anticonvulsants</td></tr><tr><td>Beta-blockers</td><td>Vinca alkaloids</td></tr><tr><td>Diuretics</td><td>5-HT, antagonists (ondansetron, granisetron)</td></tr></table>
======================================
<table><thead><th>Laxatives</th><th></th></thead><tr><td colspan="2">Antacids (with magnesium)</td></tr><tr><td colspan="2">Prescription Medications</td></tr><tr><td>Laxatives</td><td>Chemotherapy</td></tr><tr><td>Diuretics</td><td>Colchicine</td></tr><tr><td>Thyroid preparations</td><td>Cholestyramine</td></tr><tr><td>Cholinergics</td><td>Neomycin</td></tr><tr><td>Prostaglandins</td><td>Para-aminosalicylic acid</td></tr><tr><td colspan="2">Dietary Items</td></tr><tr><td colspan="2">Dietetic foods, candy or chewing gum, and elixirs with sorbitol, mannitol, or xylitol</td></tr><tr><td colspan="2">Olestra</td></tr><tr><td colspan="2">Caffeine</td></tr><tr><td>Ethanol</td><td></td></tr></table>
======================================
<table></table>
======================================
<table><tr><td>Tire Test</td><td>performed independently or during colonoscopy, flexible sigmoidoscopy, and flat tire test.</td></tr></table>
======================================
<table><thead><th colspan="4">Table 25.7 Fiber Sources</th></thead><thead><th>Cereals</th><th></th><th>Fiber Supplements</th><th></th></thead><tr><td>All-Bran Extra Fiber (1/2 c)</td><td>15g</td><td>Konsyl (tsp)</td><td>6.0¢g</td></tr><tr><td>Fiber One (1/2 c)</td><td>14g</td><td>Perdiem (1tsp)</td><td>40g</td></tr><tr><td>Raisin Bran (1/2 c)</td><td>78</td><td>Metamucil (1tsp)</td><td>3.48</td></tr><tr><td>All Bran (1/2 c)</td><td>6g</td><td>Maalox w/fiber (1 tbs)</td><td>3.48</td></tr><tr><td>Fruit &amp; Fiber (2/3 c)</td><td>5g</td><td>Mylanta w/fiber (1tsp)</td><td>3.48</td></tr><tr><td>Frosted Mini Wheats (1/2 c)</td><td>3g</td><td>Citrucel (1tbs)</td><td>2.0¢g</td></tr><tr><td>Breads</td><td></td><td>Vegetables</td><td></td></tr><tr><td>Whole wheat (1 slice)</td><td>2.0g</td><td>Lettuce (1 c)</td><td>14¢8</td></tr><tr><td>White (1 slice) Bagel (1)</td><td>0.5 g 10g</td><td>Celery (1) Tomato, raw (1)</td><td>0.5 g 10g</td></tr></table>
======================================
<table><thead><th colspan="4">Table 25.8 Laxatives fo 't of Disordered Defecation</th></thead><thead><th>Type of Laxative</th><th>Adult Dose</th><th>Onset of Action</th><th>Side Effects</th></thead><tr><td colspan="4">Bulk-Forming Laxatives</td></tr><tr><td>Natural (psy/lium)</td><td>7gPO</td><td>12-72 h</td><td>Impaction above strictures</td></tr><tr><td>Synthetic (methylcellulose)</td><td>4-6 g PO</td><td>12-72 h</td><td>Fluid overload</td></tr><tr><td colspan="4">Emollient Laxatives</td></tr><tr><td>Docusate salts</td><td>50-500 mg PO</td><td>24-72 h</td><td>Skin rashes</td></tr><tr><td>Mineral oil</td><td>15-45 ml PO</td><td>6-8h</td><td>Decreased vitamin absorption</td></tr><tr><td></td><td></td><td></td><td>Lipid pneumonia</td></tr><tr><td colspan="4">Hyperosmolar Laxatives</td></tr><tr><td>Polyethylene glycol</td><td>3-22 L PO</td><td>Th</td><td>Abdominal bloating</td></tr><tr><td>Lactulose</td><td>15-60 mL PO</td><td>24-48 h</td><td>Abdominal bloating</td></tr><tr><td>Sorbitol</td><td>120 mL 25% solution PO</td><td>24-48 h</td><td>Abdominal bloating</td></tr><tr><td>Glycerine</td><td>3 g suppository</td><td>15-60 min</td><td>Rectal irritation</td></tr><tr><td></td><td>5-15 mL enema</td><td>15-30 min</td><td>Rectal irritation</td></tr><tr><td colspan="4">Saline Laxatives</td></tr><tr><td>Magnesium sulfate</td><td>15gPO</td><td>0.5-3 h</td><td>Magnesium toxicity</td></tr><tr><td>Magnesium phosphate</td><td>10gPO</td><td>0.5-3 h</td><td></td></tr><tr><td>Magnesium citrate</td><td>200 mL PO</td><td>0.5-3 h</td><td></td></tr><tr><td colspan="4">Stimulant Laxatives</td></tr><tr><td>Castor oil</td><td>15-60 mL PO</td><td>2-6h</td><td>Nutrient malabsorption</td></tr><tr><td colspan="4">Diphenylmethanes</td></tr><tr><td>Phenolphthalein</td><td>60-100 mg PO</td><td>6-8h</td><td>Skin rashes</td></tr><tr><td>Bisacodyl</td><td>30 mg PO</td><td>6-10h</td><td>Gastric irritation</td></tr><tr><td></td><td>10 mg PR</td><td>0.25-1h</td><td>Rectal stimulation</td></tr><tr><td colspan="4">Anthraquinones</td></tr><tr><td>Cascara sagrada</td><td>1 mL PO</td><td>6-12h</td><td>Melanosis coli</td></tr><tr><td>Senna</td><td>2 mL PO</td><td>6-12h</td><td>Degeneration of Meissner and Auerbach plexuses</td></tr><tr><td>Aloe (Casanthrol)</td><td>250 mg PO</td><td>6-12 h</td><td></td></tr><tr><td>Danthron</td><td>75-150 mg PO</td><td>6-12h</td><td>Hepatotoxicity (w/docusate)</td></tr></table>
======================================
<table><tr><td>Inertia</td><td>to be the surgical treatment of choice for slow-transit constipation refractory to medical management. Most surgeons restrict the use of this surgical procedure to the most extreme cases and typically operate on fewer than 10% of patients. Strict criteria for surgery include the following: chronic, severe, disabling symptoms unresponsive to medical therapy; slow transit in the proximal colon; no evidence of pseudo-obstruction; and normal anorectal function (144). Success rates are variable and depend on several factors. An extensive review of colectomy for slow-transit constipation analyzed 32 studies from 1981 to 1988 and found satisfaction rates ranged from 39% to 100% (157). Higher success rates occurred in studies in the United States (n = 11, median 94%, range 75%-100%) and prospective studies (n = 16, median 90%, range 50%-—100%). Superior outcomes occurred in those who had a complete physiologic eval- uation and proven slow-transit constipation. Patients with anismus had higher rates of recurrent symptoms and lower satisfaction levels (158). Poorer outcomes occurred with ileosigmoid and cecorectal anastomosis than with ileorectal anastomosis. Those with segmental resection (hemicolectomy) had the worst outcome. of the studies had a comparison group, and outcomes were variable and lacking validated measures. Morbidity associated with the operation included small bowel obstruction (median 18%, range 2%-71%), need for reoperation (median 14%, range 0%—-50%), diarrhea (median 14%, range 0%-46%), fecal incontinence (median 14%, range 0%-52%), recurrent constipation (median 9%, range 0%-—33%), persistent abdominal pain (median 41%, range 0%-90%), and permanent ileostomy (median 5%, range 0%-—28%). Mortality ranged from 0%-6% (159). A quality-of-life study revealed that the score correlated poorly with frequency of bowel movements. However, a lower score was seen in those patients who had persistent abdominal pain, diarrhea, fecal incontinence, and permanent ileostomies. Overall satisfaction with the procedure was very high and correlated with the quality-of-life (160).</td></tr></table>
======================================
<table><thead><th></th><th colspan="2">Arnold (164)</th><th colspan="2">Mellgren (165)?</th><th colspan="2">Kahn (166)</th><th colspan="2">Weber (167)?</th><th colspan="2">Sand (168)?</th></thead><thead><th></th><th>Preop</th><th>Postop</th><th>Preop</th><th>Postop</th><th>Preop</th><th>Postop</th><th>Preop</th><th>Postop</th><th>Preop</th><th>Postop</th></thead><tr><td>N</td><td>29</td><td></td><td>25</td><td>25</td><td>231</td><td>171</td><td>53</td><td>53</td><td>70</td><td>67</td></tr><tr><td>Follow-up (mean) months</td><td></td><td></td><td></td><td>12</td><td></td><td>42</td><td></td><td>12</td><td></td><td>12</td></tr><tr><td>Levator plication</td><td></td><td>Yes</td><td></td><td>Yes</td><td></td><td>Yes</td><td></td><td>No</td><td></td><td>No</td></tr><tr><td>Anatomical cure (%)</td><td></td><td>80</td><td></td><td>96</td><td></td><td>76</td><td></td><td></td><td></td><td>90</td></tr><tr><td>Constipation (%)</td><td>75</td><td>54</td><td>100</td><td>88</td><td>22</td><td>33</td><td></td><td></td><td></td><td></td></tr><tr><td>Protrusion (%)</td><td></td><td></td><td>21</td><td>4</td><td>64</td><td>31</td><td></td><td></td><td></td><td></td></tr><tr><td>Splinting/digitations (%)</td><td>20</td><td></td><td>50</td><td>0</td><td></td><td>33</td><td></td><td></td><td></td><td></td></tr><tr><td>Fecal incontinence %</td><td></td><td>36</td><td>8</td><td>8</td><td>4</td><td>11</td><td></td><td></td><td></td><td></td></tr></table>
======================================
<table><thead><th></th><th>Preop</th><th>Postop</th><th>Preop</th><th>Postop</th><th></th><th>Preop</th><th>Postop</th><th>Preop</th><th>Postop</th><th colspan="2">Preop Postop</th></thead><tr><td>N</td><td>69</td><td>61</td><td>125</td><td>72</td><td></td><td>66</td><td>46</td><td>67</td><td>67</td><td>42</td><td>33</td></tr><tr><td>Follow-up (mean) months</td><td></td><td>2</td><td></td><td>6</td><td></td><td></td><td>12</td><td></td><td>3</td><td></td><td>18</td></tr><tr><td>Anatomic cure</td><td></td><td>82</td><td></td><td>82</td><td></td><td></td><td>90</td><td></td><td>100</td><td></td><td>92</td></tr><tr><td>Constipation (%)</td><td>46</td><td>3</td><td>60</td><td>50</td><td></td><td>41</td><td>57</td><td></td><td></td><td></td><td></td></tr><tr><td>Difficult defecation</td><td>32</td><td>5</td><td>61</td><td>44</td><td></td><td>53</td><td>46</td><td>40</td><td>4</td><td>57</td><td>27</td></tr><tr><td>Protrusion (%)</td><td>100</td><td>8</td><td>38</td><td>14</td><td></td><td>86</td><td>9</td><td></td><td></td><td>78</td><td>7</td></tr><tr><td>Splinting/digitations (%)</td><td>39</td><td>25</td><td>24</td><td>14</td><td></td><td>30</td><td>15</td><td></td><td></td><td></td><td></td></tr><tr><td>Fecal incontinence (%)</td><td>13</td><td>8</td><td>24</td><td>21</td><td></td><td>30</td><td></td><td></td><td></td><td>9</td><td>5</td></tr><tr><td>Dyspareunia (%)</td><td>29</td><td>9</td><td>67</td><td>46</td><td></td><td>28</td><td>8</td><td>12</td><td>3</td><td>31</td><td>15</td></tr><tr><td>De novo dyspareunia ® (%)</td><td></td><td>2</td><td></td><td>4</td><td></td><td></td><td>7</td><td></td><td>3</td><td></td><td>(0)</td></tr></table>
======================================
<table><thead><th></th><th colspan="2">Oster (174)</th><th colspan="2">Sand (168)*</th><th colspan="2">Goh (175)?</th><th colspan="2">Kohli (176) —</th><th colspan="2">Mercer-Jones (177)?</th></thead><thead><th></th><th colspan="2">Preop Postop</th><th>Preop</th><th>Postop</th><th>Preop</th><th>Postop</th><th colspan="2">Preop Postop</th><th colspan="2">Preop _ Postop</th></thead><tr><td></td><td></td><td>Autologous</td><td colspan="2">Polygalactin mesh</td><td colspan="2">Polypropylene</td><td colspan="2" rowspan="2">Transvaginal</td><td colspan="2">Porcine dermis</td><td colspan="2">Polypropylene</td></tr><tr><td>Graft route</td><td></td><td>Transvaginal</td><td></td><td>Transvaginal</td><td colspan="2"></td><td></td><td>Transvaginal</td><td colspan="2">Transperineal</td></tr><tr><td>N</td><td>15</td><td>15</td><td>73</td><td>65</td><td>43</td><td>43</td><td>43</td><td>30</td><td>22</td><td>22</td></tr><tr><td>Follow-up (mean) months</td><td></td><td>30</td><td></td><td>12</td><td></td><td>12</td><td></td><td>12</td><td></td><td>12</td></tr><tr><td>Anatomic cure</td><td></td><td>100</td><td></td><td>92</td><td></td><td>100</td><td></td><td>93</td><td></td><td>95</td></tr><tr><td>Constipation (%)</td><td></td><td>33</td><td></td><td></td><td></td><td></td><td></td><td></td><td>50</td><td>14</td></tr><tr><td>Difficult defecation</td><td>47</td><td>0</td><td></td><td></td><td></td><td></td><td></td><td></td><td>95</td><td>32</td></tr><tr><td>Protrusion (%)</td><td>80</td><td>10)</td><td></td><td></td><td>100</td><td>10)</td><td></td><td></td><td>86</td><td>23</td></tr><tr><td>Splinting/digitations (%)</td><td>100</td><td>12</td><td></td><td></td><td></td><td></td><td></td><td></td><td>64</td><td>23</td></tr><tr><td>Fecal incontinence (%)</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>5</td></tr><tr><td>Dyspareunia (%)</td><td></td><td>20</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr></table>
======================================
<table><thead><th></th><th colspan="2">Sullivan (178)</th><th colspan="2">Sehapavak (179)</th><th colspan="2">Jenssen (180)?</th><th colspan="2">Van Dam (181)*°</th><th colspan="2">— Ayabaca (182)?</th></thead><thead><th></th><th>Preop</th><th>Postop</th><th>Preop</th><th>Postop</th><th>Preop</th><th>Postop</th><th>Preop</th><th>Postop</th><th>Preop</th><th>_ Postop</th></thead><tr><td>N</td><td>137</td><td>117</td><td>355</td><td>204</td><td>64</td><td>64</td><td>89</td><td>89</td><td>49</td><td>34</td></tr><tr><td>Follow-up (mean) months</td><td></td><td>18</td><td></td><td></td><td></td><td>12</td><td></td><td>52</td><td></td><td>48</td></tr><tr><td>Anatomic cure</td><td></td><td>96</td><td></td><td>98</td><td></td><td>70</td><td></td><td>72</td><td></td><td>90</td></tr><tr><td>Constipation (%)</td><td></td><td></td><td>82</td><td>15</td><td></td><td></td><td>63</td><td>33</td><td>83</td><td>32</td></tr><tr><td>Difficult defecation</td><td>58</td><td>2</td><td></td><td></td><td>72</td><td>16</td><td>92</td><td>27</td><td></td><td></td></tr><tr><td>Protrusion (%)</td><td>27</td><td></td><td></td><td></td><td>38</td><td>3</td><td>40</td><td>28</td><td></td><td></td></tr><tr><td>Splinting/digitations (%)</td><td></td><td></td><td>26</td><td></td><td>26</td><td>4</td><td>23</td><td>0</td><td>38</td><td></td></tr><tr><td>Fecal incontinence (%)</td><td>39</td><td>3</td><td></td><td></td><td>40</td><td>9</td><td>10</td><td>16</td><td>71</td><td>27</td></tr><tr><td>Dyspareunia (%)</td><td></td><td>0</td><td></td><td>20</td><td></td><td></td><td>28</td><td>44</td><td></td><td></td></tr></table>
======================================
<table><tr><td colspan="2">A. Complete androgen insensitivity syndrome (testicular feminization)</td></tr><tr><td colspan="2">B. Incomplete androgen insensitivity syndrome</td></tr><tr><td colspan="2">II. Precocious puberty</td></tr><tr><td colspan="2">A. Central (true) precocious puberty</td></tr><tr><td colspan="2">1. Constitutional (idiopathic) precocious puberty</td></tr><tr><td colspan="2">. Hypothalamic neoplasms (most commonly hamartomas) wlrn</td></tr><tr><td colspan="2">. Congenital malformations |</td></tr><tr><td colspan="2">. Infiltrative processes (Langerhans cell-type histiocytosis) ale</td></tr><tr><td colspan="2">. After irradiation NTO]</td></tr><tr><td colspan="2">. Trauma</td></tr><tr><td colspan="2">. Infection</td></tr><tr><td colspan="2">B. Precocious puberty of peripheral origin (precocious pseudopuberty)</td></tr><tr><td colspan="2">1. Gonadotropin-secreting neoplasms</td></tr><tr><td colspan="2">a. Human chorionic gonadotropin secreting</td></tr><tr><td colspan="2">i. Ectopic germinomas (pinealomas)</td></tr><tr><td colspan="2">ii. Choriocarcinomas</td></tr><tr><td colspan="2">iii. Teratomas</td></tr><tr><td colspan="2">iv. Hepatoblastomas</td></tr><tr><td colspan="2">b. Luteinizing hormone-secreting (pituitary adenomas)</td></tr><tr><td colspan="2">2. Gonadal neoplasms</td></tr><tr><td colspan="2">a. Estrogen-secreting</td></tr><tr><td colspan="2">i. Granulosa-theca cell tumors</td></tr><tr><td colspan="2">ii. Gonadal sex-cord tumors</td></tr><tr><td colspan="2">b. Androgen-secreting</td></tr><tr><td colspan="2">i. Arrhenoblastomas</td></tr><tr><td colspan="2">ii. Teratomas</td></tr><tr><td colspan="2">3. Congenital adrenal hyperplasia</td></tr><tr><td colspan="2">a. 21-Hydroxylase (P450c21) deficiency</td></tr><tr><td colspan="2">b. 11B-Hydroxylase (P450c11) deficiency</td></tr><tr><td colspan="2">c. 3B-Hydroxysteroid dehydrogenase deficiency</td></tr><tr><td>4. Adrenal neoplasms</td><td></td></tr></table>
======================================
<table><thead><th>Proved</th><th>No Effect</th><th>Insufficient Data</th></thead><tr><td>Testosterone enanthate</td><td>Progesterone</td><td>Ethynodiol diacetate</td></tr><tr><td>lestosterone propionate</td><td>17a-Hydroxyprogesterone</td><td>Dimethisterone</td></tr><tr><td>Vethylandrostenediol</td><td>Medroxyprogesterone</td><td>Norgestrel</td></tr><tr><td>5a-Methyltestosterone</td><td>Norethynodrel</td><td>Desogestrel</td></tr><tr><td>thisterone</td><td></td><td>Gestodene</td></tr><tr><td>Vorethindrone</td><td></td><td>Norgestimate</td></tr><tr><td>Danazol</td><td></td><td></td></tr></table>
======================================
<table><tr><td>Abnormal physical examination</td></tr><tr><td>5a-reductase deficiency in XY individual</td></tr><tr><td>17, 20-desmolase deficiency in XY individual</td></tr><tr><td>17a-hydroxylase deficiency in XY individual</td></tr><tr><td>Hypergonadotropic hypogonadism</td></tr><tr><td>Gonadal dysgenesis</td></tr><tr><td>Pure gonadal dysgenesis</td></tr><tr><td>Partial deletion of X chromosome</td></tr><tr><td>Sex chromosome mosaicism</td></tr><tr><td>Environmental and therapeutic ovarian toxins</td></tr><tr><td>17a-hydroxylase deficiency in XX individual</td></tr><tr><td>Galactosemia</td></tr><tr><td>Other</td></tr><tr><td>Hypogonadotropic hypogonadism</td></tr><tr><td>Physiologic delay</td></tr><tr><td>Kallmann’s syndrome</td></tr><tr><td>Central nervous system tumors</td></tr></table>
======================================
<table><thead><th>Table 27.3 Causes of Ovarian Failure after Development of</th><th>Secondary</th></thead><tr><td colspan="2">Chromosomal etiology</td></tr><tr><td colspan="2">latrogenic causes</td></tr><tr><td colspan="2">Radiation</td></tr><tr><td colspan="2">Chemotherapy</td></tr><tr><td colspan="2">Surgical alteration of ovarian blood supply</td></tr><tr><td colspan="2">Infections</td></tr><tr><td colspan="2">Autoimmune disorders</td></tr><tr><td colspan="2">Galactosemia (mild form or heterozygote)</td></tr><tr><td colspan="2">Savage syndrome</td></tr><tr><td colspan="2">Cigarette smoking</td></tr></table>
======================================
<table><thead><th>Pituitary and hypothalamic</th></thead><tr><td>Craniopharyngioma</td></tr><tr><td>Germinoma</td></tr><tr><td>Tubercular granuloma</td></tr><tr><td>Sarcoid granuloma</td></tr><tr><td>Dermoid cyst</td></tr><tr><td>Pituitary</td></tr><tr><td>Nonfunctioning adenomas</td></tr><tr><td>Hormone-secreting adenomas</td></tr><tr><td>Prolactinoma</td></tr><tr><td>Cushing's disease</td></tr><tr><td>Acromegaly</td></tr><tr><td>Primary hyperthyroidism</td></tr><tr><td>Infarction</td></tr><tr><td>Lymphocytic hypophysitis</td></tr><tr><td>Surgical or radiologic ablations</td></tr><tr><td>Sheehan's syndrome</td></tr></table>
======================================
<table><thead><th>Anorexia nervosa</th></thead><tr><td>Exercise-induced</td></tr><tr><td>Stress-induced</td></tr><tr><td>Pseudocyesis</td></tr><tr><td>Malnutrition</td></tr><tr><td>Chronic diseases</td></tr><tr><td>Diabetes mellitus</td></tr><tr><td>Renal disorders</td></tr><tr><td>Pulmonary disorders</td></tr><tr><td>Liver disease</td></tr><tr><td>Chronic infections</td><td></td></tr><tr><td>Addison’s disease</td><td></td></tr><tr><td>Hyperprolactinemia</td></tr><tr><td>Thyroid dysfunction</td><td></td></tr><tr><td>Euestrogenic states</td></tr><tr><td>Obesity</td><td></td></tr><tr><td>Hyperandrogenism</td><td></td></tr><tr><td>Polycystic ovary syndrome</td></tr><tr><td>Cushing's syndrome</td></tr><tr><td>Congenital adrenal hyperplasia</td></tr><tr><td>Androgen-secreting adrenal tumors</td></tr><tr><td>Androgen-secreting ovarian tumors</td></tr><tr><td>Granulosa cell tumor</td></tr><tr><td>Idiopathic</td></tr></table>
======================================
<table><thead><th>Table 28.1 Normal Values</th><th>for Serum Androgens?</th></thead><tr><td>Testosterone (total)</td><td>20-80 ng/dL</td></tr><tr><td>Free testosterone (calculated)</td><td>0.6-6.8 pg/mL</td></tr><tr><td>Percent free testosterone</td><td>0.4-2.4%</td></tr><tr><td>Bioavailable testosterone</td><td>1.6-19.1 ng/dL</td></tr><tr><td>SHBG</td><td>18-114 nmol/L</td></tr><tr><td>Albumin</td><td>3,300-4,800 mg/dL.</td></tr><tr><td>Androstenedione</td><td>20-250 ng/dL</td></tr><tr><td>Dehydroepiandrosterone sulfate</td><td>100-350 g/dL</td></tr><tr><td>17-hydroxyprogesterone (follicular phase)</td><td>30-200 ng/dL</td></tr></table>
======================================
<table><thead><th colspan="2">le 28.3 Medical Treatment of Hirsutism</th></thead><tr><td>Treatment Category</td><td>Specific Regimens</td></tr><tr><td colspan="2">Weight loss</td></tr><tr><td rowspan="4">Hormonal suppression</td><td>Oral contraceptives</td></tr><tr><td></td><td>Medroxyprogesterone</td></tr><tr><td></td><td>Gonadotropin-releasing hormone analogs</td></tr><tr><td></td><td>Glucocorticoids</td></tr><tr><td>Steroidogenic enzyme inhibitors</td><td>Ketoconazole</td></tr><tr><td>5a-reductase inhibitors</td><td>Finasteride</td></tr><tr><td rowspan="3">Antiandrogens</td><td>Spironolactone</td></tr><tr><td></td><td>Cyproterone acetate</td></tr><tr><td></td><td>Flutamide</td></tr><tr><td>Insulin Sensitizer</td><td>Metformin</td></tr><tr><td rowspan="4">Mechanical</td><td></td><td>Temporary</td></tr><tr><td></td><td>Permanent</td></tr><tr><td></td><td>Electrolysis</td></tr><tr><td>Laser hair removal</td></tr></table>
======================================
<table><tr><td>Laparoscopic Electrocautery</td><td>Laparoscopic electrocautery wedge patients with severe PCOS whose condition is resistant to clomiphene citrate. In</td></tr></table>
======================================
<table><thead><th>Category</th><th>Cause</th><th>Relative Incidence</th></thead><tr><td rowspan="3">ACTH-dependent</td><td>Cushing syndrome</td><td>60%"</td></tr><tr><td></td><td>Ectopic ACTH-secreting tumors</td><td>15%</td></tr><tr><td></td><td>Ectopic CRH-secreting tumors</td><td>Rare</td></tr><tr><td rowspan="4">ACTH-independent</td><td>Adrenal cancer</td><td>15%</td></tr><tr><td></td><td>Adrenal adenoma</td><td>10%</td></tr><tr><td></td><td>Micronodular adrenal hyperplasia</td><td>Rare</td></tr><tr><td></td><td>latrogenic/factitious</td><td>Common</td></tr></table>
======================================
<table><tr><td>Screening</td><td>Women with hirsutism who are suspected of having Cushing syndrome should be tested for urinary free cortisol in a 24-hour collection and should undergo an overnight dexamethasone suppression test. Two consecutive collections are recommended with creatinine determination. Normal urinary free cortisol should range from 30 to 80 yg/day. The overnight dexamethasone suppression test is an 8:00 AM cortisol determination after the patient is given 1 mg of dexamethasone at 11:00 pm the previous night.</td></tr><tr><td>Confirmation of diagnosis</td><td>Confirmation of diagnosis at this stage can be performed by the 2-day, low- dose dexamethasone suppression test of Liddle (117). The patient is given 0.5 mg of dexamethasone every 6 hours for 2 days. A 24-hour urine specimen is collected during the second day. Cushing syndrome is ruled out if there is suppression of urinary 17-hydroxycorticosteroids to &lt;3 mg/24 hr (or to 0% of baseline), suppression of plasma cortisol to &lt;4 g/day, or suppression of urinary free cortisol to &lt;25 .g/24 hr.</td></tr><tr><td>Differentiation of Cushing syndrome</td><td>The high-dose dexamethasone suppression test is used to differentiate Cushing syndrome from other causes (2 mg every 6 hours). Normally, urinary 17-hydroxycorticoids should be 40% of baseline after 2 days. This test partially suppresses ACTH section with a resulting decrease in cortisol production in most patients with Cushing syndrome; however, it has no effect on the majority of patients with ectopic or adrenal Cushing syndrome.</td></tr><tr><td>Differentiation of ectopic ACTH syndrome</td><td>High plasma ACTH (&gt;4.5 pmol/L or &gt;20 pg/mL) is consistent with ectopic ACTH production from adrenal glands. A low ACTH level (&lt;1.1 pmol/L or &lt;5 pg/mL) identifies a patient who most likely has adrenal Cushing syndrome.</td></tr><tr><td>ACTH-independent and -dependent</td><td>A patient with ACTH-independent Cushing syndrome should undergo an adrenal scan by MRI and should be prepared for adrenal surgery. A patient with ACTH-dependent Cushing syndrome should initially receive an administration of cortical-releasing hormone (1 g/kg IV over 1 minute), which is followed 3-5 minutes later by simultaneous sampling of both the inferior petrosal sinuses and of the peripheral vein. The ratio of ACTH levels from the inferior petrosal sinuses to peripheral plasma is then calculated. An inferior petrosal sinus is virtually diagnostic of a pituitary tumor. Moreover, 95% of patients with Cushing syndrome are found to have ratios higher than 2. If the test indicates a patient has Cushing syndrome, a pituitary MRI with gadolinium enhancement should be obtained in preparation for transsphenoidal surgery. If the results indicate ectopic ACTH secretion, a</td></tr></table>
======================================
<table><thead><th>Diagnosis</th><th>24-Hour Urinary Cortisol</th><th>DEX Low-Dose</th><th>DEX High-Dose</th><th>ACTH</th></thead><tr><td colspan="5">ACTH-dependent</td></tr><tr><td>Cushing syndrome (60%)</td><td>Increased</td><td>Increased</td><td>Decreased</td><td>Normal</td></tr><tr><td colspan="5">Pituitary adenoma</td></tr><tr><td colspan="5">Basophil hyperplasia</td></tr><tr><td colspan="5">Nodular adrenal hyperplasia</td></tr><tr><td colspan="5">Cyclic Cushing syndrome</td></tr><tr><td>Ectopic ACTH (15%)</td><td>Increased</td><td>Increased</td><td>Increased</td><td>Increased</td></tr><tr><td>Ectopic CRH (rare)</td><td>Increased</td><td>Increased</td><td>Increased or decreased</td><td>Increased</td></tr><tr><td colspan="5">ACTH-independent</td></tr><tr><td>Adrenal neoplasia</td><td>Increased</td><td>Increased</td><td>Increased</td><td>Decreased</td></tr><tr><td>Adenoma (10%)</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="5">Carcinoma (15%)</td></tr><tr><td colspan="5">Primary adrenocorticoid nodular dysplasia (&lt;1%)</td></tr><tr><td>Pseudo-Cushing syndrome (alcohol-related, &lt;1%)</td><td>Increased</td><td>Increased</td><td>Decreased</td><td>Normal</td></tr><tr><td>Exogenous glucocorticoids/</td><td>Increased or</td><td>Decreased</td><td>Decreased</td><td>Decreased</td></tr></table>
======================================
<table><thead><th>Inhibitory factors</th></thead><tr><td>Dopamine</td></tr><tr><td>y-Aminobutyric acid</td></tr><tr><td>Histidyl-proline diketopiperazine</td></tr><tr><td>Pyroglutamic acid</td></tr><tr><td>Somatostatin</td></tr><tr><td>Stimulatory factors</td></tr><tr><td>B-Endorphin</td></tr><tr><td>17B-Estradiol</td></tr><tr><td>Enkephalins</td></tr><tr><td>Gonadotropin-releasing hormone</td></tr><tr><td>Histamine</td><td></td></tr><tr><td>Serotonin</td><td rowspan="2"></td></tr><tr><td>Substance P</td><td></td></tr><tr><td>Thyrotropin-releasing hormone</td></tr><tr><td>Vasoactive intestinal peptide</td></tr><tr><td>Physiologic conditions</td></tr><tr><td>Anesthesia</td></tr><tr><td>Empty sella syndrome</td></tr><tr><td>Idiopathic</td></tr><tr><td>Intercourse</td></tr><tr><td>Major surgery and disorders of chest wall (burns, herpes, chest percussion)</td></tr><tr><td>Newborns</td></tr><tr><td>Nipple stimulation</td></tr><tr><td>Pregnancy</td></tr><tr><td>Postpartum (nonnursing: days 1-7; nursing: with suckling)</td></tr><tr><td>Sleep</td><td></td></tr><tr><td>Stress</td></tr><tr><td>Postpartum</td></tr><tr><td>Hypothalamic conditions</td></tr><tr><td>Arachnoid cyst</td></tr><tr><td>Craniopharyngioma</td></tr><tr><td>Cystic glioma</td></tr><tr><td>Cysticercosis</td></tr><tr><td>Dermoid cyst</td></tr><tr><td>Epidermoid cyst</td></tr></table>
======================================
<table><tr><td>Pineal tumors</td></tr><tr><td>Pseudotumor cerebri</td></tr><tr><td>Sarcoidosis</td></tr><tr><td>Suprasellar cysts</td></tr><tr><td>Tuberculosis</td></tr><tr><td>Pituitary conditions</td></tr><tr><td>Acromegaly</td></tr><tr><td>Addison disease</td></tr><tr><td>Craniopharyngioma</td></tr><tr><td>Cushing syndrome</td></tr><tr><td>Hypothyroidism</td><td></td></tr><tr><td>Histiocytosis</td><td></td></tr><tr><td>Lymphoid hypophysitis</td></tr><tr><td>Metastatic tumors (especially of the lungs and breasts)</td><td></td></tr><tr><td>Multiple endocrine neoplasia</td></tr><tr><td>elson syndrome</td><td></td></tr><tr><td>Pituitary adenoma (microadenoma or macroadenoma)</td></tr><tr><td>Post-oral contraception</td><td></td></tr><tr><td>Sarcoidosis</td></tr><tr><td>Thyrotropin-releasing hormone administration</td></tr><tr><td>Trauma to stalk</td></tr><tr><td>Tuberculosis</td></tr><tr><td>Metabolic dysfunction</td></tr><tr><td>Ectopic production (hypernephroma, bronchogenic sarcoma)</td></tr><tr><td>Hepatic cirrhosis</td></tr><tr><td>Renal failure</td></tr></table>
======================================
<table><thead><th></th><th>&gt;1000</th><th></th><th></th><th></th><th></th><th></th><th></th><th></th><th></th><th></th></thead><tr><td></td><td>1000</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>500</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>woleee</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td rowspan="8">jw/6u - ujdejoldg</td><td>300</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>200</td><td>ate</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>100</td><td>BIE</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>0</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>50</td><td>040</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>odes</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>siown) Aueyinyd</td><td>SasuaW YM o1yyedo!</td><td>‘uowe UM o1uyedoIp]</td><td>Jawwol4-UeluD</td><td>s6mup 6ulzijinbues</td><td>SeAldadeJUOD [210 }SO</td><td>lusIploJAyjodAH</td><td>eyes A\dw3</td><td>“OSIN</td></tr></table>
======================================
<table><thead><th>Abscess</th><th>Lipoma</th></thead><tr><td>Aneurysm</td><td>Lymphoma</td></tr><tr><td>Arachnoid cyst</td><td>Meningioma</td></tr><tr><td>Cephalocele</td><td>Meningitis (bacterial, fungal, granulomatous)</td></tr><tr><td>Chloroma (granulocytic sarcoma)</td><td>Metastasis</td></tr><tr><td>Colloid cyst</td><td>Mucocele</td></tr><tr><td>Craniopharyngioma</td><td>Nasopharyngeal carcinoma</td></tr><tr><td>Dermoid</td><td>Opticochiasmatic-hypothalamic glioma</td></tr><tr><td>Ectopic neurohypophysis</td><td>Osteocartilaginous tumor</td></tr><tr><td>“Empty” sella</td><td>Paracytic cyst</td></tr><tr><td>Epidermoid tumor</td><td>Pars intermedia cysts</td></tr><tr><td>Germinoma</td><td>Pituitary adenoma</td></tr><tr><td>Hamartoma (tuber cinereum/hypothalamus)</td><td>Rathke’s cleft cyst</td></tr><tr><td>Histiocytosis</td><td>Sarcoidosis</td></tr><tr><td colspan="2">Hyperplasia</td></tr><tr><td>Hypophysitis</td><td></td></tr></table>
======================================
<table><thead><th>Antigen</th><th>Location</th><th>Function</th></thead><tr><td>Thyroglobulin (Tg)</td><td>Thyroid</td><td>Thyroid hormone storage</td></tr><tr><td>Thyroid peroxidase (TPO) (microsomal antigen)</td><td>Thyroid</td><td>Transduction of signal from TSH</td></tr><tr><td>TSH receptor (TSHR)</td><td>Thyroid, lymphocytes, fibroblasts, adipocytes (including retro-orbital)</td><td>Transduction of signal from TSH</td></tr><tr><td>Na*/F symporter (NIS)</td><td>Thyroid, breast, salivary or lacrimal gland, gastric or colonic mucosa, thymus, pancreas</td><td>ATP-driven uptake of I&gt; along with Nat</td></tr></table>
======================================
<table><thead><th rowspan="3">Antibody</th><th rowspan="3">General Population</th><th rowspan="3">Autoimmune Thyroiditis</th><th rowspan="3">Graves Disease</th></thead><thead><th></th><th></th><th></th><th></th></thead><thead><th></th><th></th><th></th><th></th></thead><tr><td>Antithyroglobulin (anti-Tg)</td><td>3%</td><td>35%-60%</td><td>12%-30%</td></tr><tr><td>Antimicrosomal thyroid peroxidase (anti-TPO)</td><td>10%-15%</td><td>80%-99%</td><td>45%-80%</td></tr><tr><td>Anti-TSH receptor (anti-TSHR)</td><td>1%-2%</td><td>6%-60%</td><td>70%-100%</td></tr><tr><td>Anti-Na'/I? symporter (anti-NIS)</td><td>0%</td><td>25%</td><td>20%</td></tr></table>
======================================
<table><thead><th>LATS</th><th>Long-acting thyroid stimulator</th><th>In vivo assay of stimulation of mouse thyroid</th><th>Original description of serum molecule able to stimulate mouse thyroid; no longer used</th></thead><tr><td>TSHR-Ab, TRAb</td><td>ISH receptor antibodies</td><td>Multiple</td><td>All antibodies recognizing the TSH receptor</td></tr><tr><td>TBII</td><td>[SH-binding inhibitory immunoglobulin</td><td>Competitive binding assays with TSH</td><td>Antibodies able to compete with TSH for TSH receptor binding irrespective of biologic activity</td></tr><tr><td>TSAb</td><td>Thyroid-stimulating antibodies</td><td>Bioassays of TSH receptor activation</td><td>TSH receptor- stimulating antibodies</td></tr><tr><td>TSI</td><td>Thyroid-stimulating immunoglobulins</td><td>As TSAb</td><td>Identical to TSAb</td></tr><tr><td>TSBAb, TSHBAb</td><td>[SH stimulation-blocking antibodies</td><td>Competition with TSH in bioassays of TSH receptor activation</td><td>Antibodies able to block activation of the TSH receptor by TSH</td></tr></table>
======================================
<table><tr><td>Hyperthyroidism Gestational Trophoblastic</td><td>activity hCG, high hCG, such as molar pregnancy, may be associated with biochemical and clinical hyperthy-</td></tr><tr><td>Disease and Hyperemesis</td><td>roidism. Symptoms regress with removal of the abnormal trophoblastic tissue and resolution</td></tr><tr><td>Gravidarum</td><td>of elevated levels of hCG. In a similar fashion, when hyperemesis gravidarum is associ- ated with high levels of hCG, mild biochemical and clinical features of hyperthyroidism</td></tr></table>
======================================
<table></table>
======================================
<table><thead><th>Effective</th><th>Regimens ( al Duration: Administration</th><th>6 Months) Dose</th><th>Frequency</th></thead><tr><td>Progestogens</td><td></td><td></td><td></td></tr><tr><td>Medroxyprogesterone acetate</td><td>PO</td><td>30 mg</td><td>Daily</td></tr><tr><td>Megestrol acetate</td><td>PO</td><td>40 mg</td><td>Daily</td></tr><tr><td>Lynoestrenol</td><td>PO</td><td>10 mg</td><td>Daily</td></tr><tr><td>Dydrogesterone</td><td>PO</td><td>20-30 mg</td><td>Daily</td></tr><tr><td colspan="4">Antiprogestins</td></tr><tr><td>Gestrinone</td><td>PO</td><td>1.25 or2.5mg</td><td>Twice weekly</td></tr><tr><td>Danazol</td><td>PO</td><td>400 mg</td><td>Daily</td></tr><tr><td colspan="4">Gonodotropin-Releasing Hormone</td></tr><tr><td>Leuprolide</td><td>SC</td><td>500 mg</td><td>Daily</td></tr><tr><td></td><td>IM</td><td>3.75 mg</td><td>Monthly</td></tr><tr><td>Goserelin</td><td>SC</td><td>3.6 mg</td><td>Monthly</td></tr><tr><td>Buserelin</td><td>IN</td><td>300 ug</td><td>Daily</td></tr><tr><td></td><td>SC</td><td>200 wg</td><td>Daily</td></tr><tr><td>Nafarelin</td><td>IN</td><td>200 wg</td><td>Daily</td></tr></table>
======================================
<table></table>
======================================
<table><thead><th>Anovulation</th><th>Normal or high day 3 FSH and LH</th><th>Ovarian disorders</th><th></th></thead><tr><td>Low FSH, LH, E2</td><td>Abnormal TSH or T4</td><td>High serum prolactin levels</td><td>Low LH, FSH, TSH, GH, ACTH</td></tr><tr><td colspan="4">a Hypothalmic disorders Thyroid disease Hyperprolactinemia Panhypopituitarism</td></tr><tr><td>Anorexia ¢ Medical and psychiatric</td><td>Hypothyroidism e Exclude secondary</td><td>Repeat test to exclude false positive</td><td>Assess and treat condition</td></tr><tr><td colspan="4">assessment Treat condition Aim increase BMI causes Treat condition Supplement with thyroid</td></tr><tr><td>allow spontaneous ovulation</td><td>hormone if indicated ovulation</td><td></td><td></td></tr><tr><td>e If female athlete triad, assess bone density, diet, caloric in take</td><td>e Spontaneous will occur when thyroid function normalizes</td><td>Elevated prolactin</td><td>If a pituatary microadenoma is diagnosed</td></tr><tr><td>Hypogonadotropic hypogonadism ¢ Congenital or acquired</td><td>Hyperthyroidism Evaluate cause Treat condition</td><td>Brain imaging (MRI is the gold standard) to exclude e Pituitary microadenoma e Pituitary macroadenoma</td><td>e Bromocriptine or cabergoline to normalize prolactin level</td></tr><tr><td></td><td></td><td>If no spontaneous ovulation, exclude irreversible damage to pituitary</td><td></td></tr></table>
======================================
<table><thead><th>Male factor</th><th>25-40</th></thead><tr><td>Both male and female factors</td><td>10</td></tr><tr><td>Female factor</td><td>40-55</td></tr><tr><td>Unexplained infertility</td><td>10</td></tr></table>
======================================
<table><tr><td>Tubal or periotoneal factor</td><td>30-40</td></tr><tr><td>Unexplained infertility</td><td>10-15</td></tr><tr><td>Miscellaneous causes</td><td>10-15</td></tr></table>
======================================
<table><thead><th>Semen analysis terminology</th></thead><tr><td>Normozoospermia—all semen parameters normal</td></tr><tr><td>Oligozoospermia—reduced sperm numbers Mild to moderate: 5-20 million/mL of semen Severe: &lt;5 million/mL of semen</td></tr><tr><td>Asthenozoospermia—reduced sperm motility</td></tr><tr><td>Teratozoospermia—increased abnormal forms of sperm</td></tr><tr><td>Oligoasthenoteratozoospermia—sperm variables all subnormal</td></tr><tr><td>Azoospermia—no sperm in semen</td></tr><tr><td>Aspermia (anejaculation)—no ejaculate (ejaculation failure)</td></tr><tr><td>Leucocytospermia—increased white cells in semen</td></tr><tr><td>Necrozoospermia—all sperm are non-viable or non-motile</td></tr><tr><td>Normal seminal fluid analysis (World Health Organization, 2002)</td></tr><tr><td>Volume &gt;2 mL</td></tr><tr><td>Sperm concentration &gt;20 million/mL</td></tr><tr><td>Sperm motility &gt;50% progressive or &gt;25% rapidly progressive</td></tr><tr><td>Morphology (strict criteria) &gt;15% normal forms</td></tr><tr><td>White blood cells &gt;1 million/mL</td></tr><tr><td>Immunobead or mixed antiglobulin reaction test? &lt;10% coated</td></tr></table>
======================================
<table><thead><th>Pretesticular</th><th>Testicular</th></thead><tr><td>Endocrine</td><td>Genetic</td></tr><tr><td>Hypogonadotropic hypogonadism</td><td>Klinefelter’s syndrome</td></tr><tr><td>Coital disorders</td><td>Y chromosome deletions</td></tr><tr><td>Erectile dysfunction</td><td>Immotile cilia syndrome</td></tr><tr><td>Psychosexual</td><td>Congenital</td></tr><tr><td>Endocrine, neural, or vascular</td><td>Cryptorchidism</td></tr><tr><td>Ejaculatory failure</td><td>Infective (orchitis)</td></tr><tr><td>Psychosexual</td><td>Antispermatogenic agents</td></tr><tr><td>After genitourinary surgery</td><td>Heat</td></tr><tr><td>Neural</td><td>Chemotherapy</td></tr><tr><td>Drug related</td><td>Drugs</td></tr><tr><td>Posttesticular</td><td>Irradiation</td></tr><tr><td>Obstructive</td><td>Vascular</td></tr><tr><td>Epididymal</td><td>Torsion</td></tr><tr><td>Congenital</td><td>Varicocele</td></tr><tr><td>Infective</td><td>Immunologic</td></tr><tr><td>Vasal</td><td>Idiopathic</td></tr><tr><td colspan="2">Genetic: cystic fibrosis</td></tr><tr><td colspan="2">Acquired: vasectomy</td></tr><tr><td colspan="2">Epididymal hostility</td></tr><tr><td colspan="2">Epididymal asthenozoospermia</td></tr><tr><td colspan="2">Accessory gland infection</td></tr><tr><td colspan="2">Immunologic</td></tr><tr><td colspan="2">Idiopathic</td></tr><tr><td>Postvasectomy</td><td></td></tr></table>
======================================
<table><thead><th>Cause</th><th>Percentage</th><th>Cause</th><th>Percentag</th></thead><tr><td>No demonstrable cause</td><td>48.5</td><td>Varicocele</td><td>37.4</td></tr><tr><td>Idiopathic abnormal semen</td><td>26.4</td><td>Idiopathic</td><td>25.4</td></tr><tr><td>Varicocele</td><td>12.3</td><td>Testicular failure</td><td>9.4</td></tr><tr><td>Infectious factors</td><td>6.6</td><td>Obstruction</td><td>6.1</td></tr><tr><td>Immunologic factors</td><td>3.1</td><td>Cryptorchidism</td><td>6.1</td></tr><tr><td>Other acquired factors</td><td>2.6</td><td>Low semen volume</td><td>4.7</td></tr><tr><td>Congenital factors</td><td>21</td><td>Semen agglutination</td><td>3.1</td></tr><tr><td>Sexual factors</td><td>1.7</td><td>Semen viscosity</td><td>1.9</td></tr><tr><td>Endocrine disturbances</td><td>0.6</td><td>Other</td><td>5.9</td></tr><tr><td>TOTAL</td><td>103.97</td><td></td><td>100</td></tr></table>
======================================
<table><thead><th>Clinical diagnosis</th><th>Genetic tests</th><th>Most common defects</th><th>Incidence ('</th></thead><tr><td>Congenital bilateral absence of vas deferens (CBAVD)</td><td>Cystic fibrosis (CFTR gene)</td><td>AF508, R117H</td><td>66</td></tr><tr><td>Non-obstructive azoospermia</td><td>Karyotype</td><td>47, XXY AZFa, AZFb?, AZFc</td><td>15-30 10-15</td></tr><tr><td>Severe (&lt;5M/mL) oligozoospermia</td><td>Karyotype</td><td>47, XXY Translocation</td><td>1-2 0.2-0.4</td></tr></table>
======================================
<table><tr><td>Body mass index &gt;27 kg/m?</td></tr><tr><td>Waist-to-hip ratio &gt;0.85</td></tr><tr><td>Waist &gt;100 cm</td></tr><tr><td>Acanthosis nigricans</td></tr></table>
======================================
<table><tr><td>Diagnostic Imaging Uterine Pathology</td><td>implicated infertility polyps, submucous fibroids, intrauterine adhesions, mullerian anomalies, prior expo- sure to diethylstilbestrol (DES), and possibly luteal phase defect. The diagnosis and</td></tr></table>
======================================
<table></table>
======================================
<table><thead><th>Trade Name</th><th>Compound</th><th>Source</th><th>per Ampule</th><th>per Ampule</th><th>Administrati</th></thead><tr><td>Repronex (Ferring Pharmaceuticals, Inc.)</td><td>Menotropin hMG</td><td>Extracted urinary</td><td>75 1U</td><td>75 1U</td><td>IM or SC</td></tr><tr><td>Menopur (Ferring Pharmaceuticals, Inc.)</td><td>Menotropin urinary hMG</td><td>Highly purified</td><td>75 1U</td><td>7510</td><td>SC</td></tr><tr><td>Bravelle (Ferring Pharmaceuticals, Inc.)</td><td>Urofollitropin urinary FSH</td><td>Highly purified</td><td>7510</td><td></td><td>IM or SC</td></tr><tr><td>Follistim (Organon Inc.)</td><td>Follitropin</td><td>Recombinant FSH beta</td><td>75 |U@</td><td></td><td>SC</td></tr><tr><td>Gonal-F (Serono Laboratories, Inc.)</td><td>Follitropin</td><td>Recombinant FSH alpha</td><td>75 |U@</td><td></td><td>SC</td></tr><tr><td>Luveris (Serono Laboratories, Inc.)</td><td>Luteinizing hormone</td><td>Recombinant LH</td><td></td><td>75 1U</td><td>SC</td></tr></table>
======================================
<table><thead><th></th><th>IVF</th><th>GIFT</th><th>ZIFT</th><th>Donor oocyte transfer’</th><th>CPE transfer©</th><th>CPEDO transfer</th><th>Host uterus transfer</th></thead><tr><td>No. of treatments*</td><td>73,406</td><td>549</td><td>763</td><td>7,581</td><td>13,083</td><td>2,721</td><td>1,210</td></tr><tr><td>Cancellations (%)</td><td>14.3%</td><td>10.9%</td><td>10.5%</td><td>8.6%</td><td>9.3%</td><td>9.2%</td><td>7.9%</td></tr><tr><td>No. of retrievals</td><td>62,881</td><td>489</td><td>683</td><td>6,929</td><td></td><td></td><td>1,114</td></tr><tr><td>No. of transfers</td><td>59,004</td><td>477</td><td>604</td><td>6,684</td><td>11,394</td><td>2,395</td><td>1,066</td></tr><tr><td>Transfers per retrieval</td><td>93.8%</td><td>97.5%</td><td>88.4%</td><td>96.5%</td><td>96.1%</td><td>96.9%</td><td>95.7%</td></tr><tr><td>No. of clinical pregnancies</td><td>22,567</td><td>162</td><td>242</td><td>3,413</td><td>2,906</td><td>704</td><td>459</td></tr><tr><td>Rate of pregnancy loss</td><td>16.7%</td><td>25.3%</td><td>15.7%</td><td>14.4%</td><td>20.0%</td><td>20.0%</td><td>16.8%</td></tr><tr><td>No. of deliveries</td><td>18,793</td><td>121</td><td>204</td><td>2,920</td><td>2,324</td><td>563</td><td>382</td></tr><tr><td>Deliveries per retrieval (%)</td><td>29.9%</td><td>24.7%</td><td>29.9%</td><td>42.1%</td><td>19.6%</td><td>22.8%</td><td>34.4%</td></tr><tr><td>Deliveries per transfer (%)</td><td>31.9%</td><td>25.4%</td><td>33.8%</td><td>43.7%</td><td>20.4%</td><td>23.5%</td><td>35.8%</td></tr><tr><td>Singleton delivery (%)</td><td>64.6%</td><td>71.9%</td><td>66.2%</td><td>59.6%</td><td>74.4%</td><td>71.0%</td><td>62.6%</td></tr><tr><td rowspan="2">No. of ectopic pregnancies Rate of ectopic pregnancy (%)</td><td>463</td><td>1</td><td>8</td><td>42</td><td>63</td><td>15</td><td>4</td></tr><tr><td></td><td>2.1%</td><td>0.6%</td><td>3.3%</td><td>1.2%</td><td>2.2%</td><td>2.1%</td><td>0.9%</td></tr></table>
======================================
<table><thead><th>2000 IVF procedures</th><th>retrievals</th><th>Canceled cycles (%)</th><th>retrieval (%)</th><th>pregnancies</th><th>deliveries</th></thead><tr><td colspan="6">Age of women</td></tr><tr><td>Women &lt;35</td><td>17,712</td><td>10.3%</td><td>94.4%</td><td>7,422</td><td>6,495</td></tr><tr><td>Women 35-37</td><td>9,121</td><td>14.9%</td><td>94.2%</td><td>3,473</td><td>2,901</td></tr><tr><td rowspan="2">Women 38-40 Women &gt;40</td><td>7,582</td><td>20.1%</td><td>93.4%</td><td>2,308</td><td>1,761</td></tr><tr><td></td><td>5,022</td><td>25.3%</td><td>90.1%</td><td>896</td><td>528</td></tr></table>
======================================
<table><thead><th></th><th></th><th></th><th></th><th></th><th></th><th></th><th></th><th></th></thead><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr></table>
======================================
<table><thead><th>Age group (yr)</th><th>1980</th><th>1997</th></thead><tr><td>&lt;20</td><td>14.8</td><td>20.7</td></tr><tr><td>20-24</td><td>31.4</td><td>46.8</td></tr><tr><td>25-29</td><td>42.8</td><td>151.0</td></tr><tr><td>30-34</td><td>58.3</td><td>293.6</td></tr><tr><td>35-39</td><td>47.6</td><td>403.2</td></tr><tr><td>40-44</td><td>b</td><td>315.4</td></tr><tr><td>45-49</td><td>b</td><td>2,100.2</td></tr><tr><td>All ages</td><td>37.0</td><td>173.6</td></tr></table>
======================================
<table><tr><td>1989</td><td>4,040,958</td><td>2,798</td><td>0.07</td><td>69.2</td><td></td><td></td><td></td></tr><tr><td>1990</td><td>4,158,212</td><td>3,028</td><td>0.07</td><td>72.8</td><td></td><td>22.0°</td><td></td></tr><tr><td>1991</td><td>4,110,907</td><td>3,346</td><td>0.08</td><td>81.4</td><td></td><td>22.0°</td><td></td></tr><tr><td>1992</td><td>4,065,014</td><td>3,883</td><td>0.09</td><td>95.6</td><td></td><td></td><td></td></tr><tr><td>1993</td><td>4,000,240</td><td>4,168</td><td>0.10</td><td>104.2</td><td></td><td></td><td></td></tr><tr><td>1994</td><td>3,952,767</td><td>4,594</td><td>0.12</td><td>116.2</td><td></td><td></td><td></td></tr><tr><td>1995</td><td>3,899,589</td><td>4,973</td><td>0.13</td><td>127.2</td><td></td><td></td><td></td></tr><tr><td>19964</td><td>3,891,494</td><td>5,939</td><td>0.15</td><td>152.6</td><td>20.9</td><td>38.7</td><td>40.4</td></tr><tr><td>19974</td><td>3,880,894</td><td>6,737</td><td>0.17</td><td>173.6</td><td>18.4</td><td>43.4</td><td>38.2</td></tr></table>
======================================
<table><thead><th>Factors The most common inborn parental chromosomal abnormalities contributing to recurrent abortion are balanced translocations (7—9). In balanced translocations, one</th></thead></table>
======================================
<table><tr><td colspan="2">Cervical incompetence</td></tr><tr><td colspan="2">Acquired</td></tr><tr><td colspan="2">Cervical incompetence</td></tr><tr><td colspan="2">Synechiae</td></tr><tr><td colspan="2">Leiomyomas</td></tr><tr><td colspan="2">Adenomyosis</td></tr><tr><td>Endocrine factors</td><td>17%-20%</td></tr><tr><td colspan="2">Luteal phase insufficiency</td></tr><tr><td>Polycystic ovarian syndrome, including insulin resistance and hyperandrogenism</td><td></td></tr><tr><td>Other androgen disorders</td><td></td></tr><tr><td colspan="2">Diabetes mellitus</td></tr><tr><td colspan="2">Thyroid disorders</td></tr><tr><td colspan="2">Prolactin disorders</td></tr><tr><td>Infectious factors</td><td>0.5%-5%</td></tr><tr><td colspan="2">Bacteria</td></tr><tr><td colspan="2">Viruses</td></tr><tr><td colspan="2">Parasites</td></tr><tr><td colspan="2">Zoonotic</td></tr><tr><td colspan="2">Fungal</td></tr><tr><td>Immunologic factors</td><td>20%-50%</td></tr><tr><td colspan="2">Cellular mechanisms</td></tr><tr><td colspan="2">Suppressor cell or factor deficiency</td></tr><tr><td colspan="2">Alterations in major histocompatibility antigen expression</td></tr><tr><td colspan="2">Alterations in cellular immune regulation</td></tr><tr><td>1. Th1 immune responses to reproductive antigens (embryo or trophoblast)</td><td></td></tr></table>
======================================
<table><tr><td colspan="2">1. Resident endometrial/decidual cells</td></tr><tr><td colspan="2">Few B cells a.</td></tr><tr><td colspan="2">b. TCRaB+ and TCRy6+ cells are present, TCRy5+ cells increase in early pregnancy</td></tr><tr><td colspan="2">c. NK-like, large granular lymphocytes (decidual NK cells) accumulate at sites of implantation</td></tr><tr><td colspan="2">d. NKT cells and “suppressor” macrophage</td></tr><tr><td colspan="2">e. T reg cells</td></tr><tr><td colspan="2">2. Immune cell education and homing</td></tr><tr><td colspan="2">hymic versus extrathymic education</td></tr><tr><td colspan="2">b. Possible in situ education and maintenance</td></tr><tr><td colspan="2">c. Integrins/vascular ligand pairs and mucosal homing</td></tr><tr><td colspan="2">3. Antigen presentation</td></tr><tr><td colspan="2">a. MHC class II molecules are not expressed in the placenta</td></tr><tr><td colspan="2">b. Classical MHC class | molecules HLA-A and HLA-B are not expressed in the placenta</td></tr><tr><td colspan="2">c. Extravillous cytotrophoblast cells express HLA-C, HLA-E, and HLA-G</td></tr><tr><td colspan="2">4. In situ immunoregulation</td></tr><tr><td colspan="2">a. Th1/Th2 cytokine microenvironments and dysregulation</td></tr><tr><td colspan="2">b. Hormonal immunomodulation</td></tr><tr><td colspan="2">1. Progesterone</td></tr><tr><td colspan="2">2. Estrogen</td></tr><tr><td colspan="2">3. Human chorionic gonadotropin (hCG)</td></tr><tr><td colspan="2">4. Prolactin</td></tr><tr><td colspan="2">5. Androgens</td></tr><tr><td colspan="2">6. Others</td></tr><tr><td colspan="2">c. Tryptophan metabolism and indoleamine 2,3 dioxygenase (IDO)</td></tr><tr><td colspan="2">d. Leukemia inhibiting factor (LIF)</td></tr><tr><td colspan="2">Humoral immunity</td></tr><tr><td colspan="2">1. Fetal antigens are recognized by the maternal immune system and humoral responses are mounted</td></tr><tr><td colspan="2">2. Organ nonspecific autoantibodies</td></tr><tr><td colspan="2">a. Anticardiolipin antibodies</td></tr><tr><td colspan="2">b. Lupus anticoagulant</td></tr><tr><td>c. Anti-82 glycoprotein 1 (anti-82G) antibodies</td><td></td></tr></table>
======================================
<table><thead><th></th><th>History</th></thead><tr><td>1.</td><td>Pattern, trimester, and characteristics of prior pregnancy losses</td></tr><tr><td>2.</td><td>History of subfertility or infertility</td></tr><tr><td>3.</td><td>Menstrual history</td></tr><tr><td>4.</td><td>Prior or current gynecologic or obstetric infections</td></tr><tr><td>5.</td><td>Signs or symptoms of thyroid, prolactin, glucose tolerance and hyperandrogenic disorders (including PCOS)</td></tr><tr><td colspan="2">6. Personal or familial thrombotic history</td></tr><tr><td>7.</td><td>Features associated with the antiphospholipid syndrome (thrombosis, false positive test for syphilis)</td></tr><tr><td>8.</td><td>Other autoimmune disorders</td></tr><tr><td>9.</td><td>Medications</td></tr><tr><td>10.</td><td>Environmental exposures, illicit and common drug use (particularly caffeine, alcohol, cigarettes, and in utero DES exposure)</td></tr><tr><td>11.</td><td>Genetic relationship between reproductive partners</td></tr><tr><td>12.</td><td>Family history of recurrent spontaneous abortion, obstetric complications, or any syndrome associated with embryonic or fetal losses</td></tr><tr><td>13.</td><td>Previous diagnostic tests and treatments</td></tr><tr><td></td><td>Physical Examination</td></tr><tr><td></td><td>General physical examination with particular attention to:</td></tr><tr><td colspan="2">1. Obesity</td></tr><tr><td colspan="2">. Hirsutism/acanthosis</td></tr><tr><td colspan="2">. Thyroid examination</td></tr><tr><td colspan="2">. Breast examination/galactorrhea</td></tr><tr><td colspan="2">. Pelvic examination</td></tr><tr><td></td><td>a. Anatomy</td></tr><tr><td></td><td>b. Infection</td></tr></table>
======================================
<table><tr><td>One spontaneous loss</td><td>76%</td></tr><tr><td>Two spontaneous losses</td><td>70%</td></tr><tr><td>Three spontaneous losses</td><td>65%</td></tr><tr><td>Four spontaneous losses</td><td>60%</td></tr><tr><td colspan="2">With:</td></tr><tr><td>Genetic factors</td><td>20%-80%</td></tr><tr><td>Anatomic factors</td><td>60%-90%</td></tr><tr><td>Endocrine factors</td><td>&gt;90%</td></tr><tr><td>Infectious factors</td><td>70%-90%</td></tr><tr><td>Antiphospholipid antibodies</td><td>70%-90%</td></tr><tr><td>Th1 cellular immunity</td><td>70%-87%</td></tr><tr><td>Unknown factors</td><td>40%-90%</td></tr><tr><td colspan="2">Following detection of fetal cardiac activity:</td></tr><tr><td>Unexplained RPL</td><td>77%-97%</td></tr><tr><td>APAS and RPL</td><td>Much lower</td></tr></table>
======================================
<table><thead><th>Excess Risk</th><th>Additional Cases</th></thead><tr><td>Coronary heart disease</td><td>7</td></tr><tr><td>Stroke</td><td>8</td></tr><tr><td>Pulmonary embolism</td><td>8</td></tr><tr><td>Invasive breast cancer</td><td>8</td></tr><tr><td>Dementia (WHIMS) (subset older than age 65)</td><td>23</td></tr><tr><td>Reduced Risk</td><td>Fewer Cases</td></tr><tr><td>Hip fracture</td><td>5</td></tr><tr><td>Colorectal cancer</td><td>6</td></tr></table>
======================================
<table><thead><th>Excess Risk</th><th>Additional Cases</th></thead><tr><td>Stroke</td><td>12</td></tr><tr><td>Deep venous thrombosis</td><td>6</td></tr><tr><td>Reduced Risk</td><td>Fewer Cases</td></tr><tr><td>Hip fracture</td><td>6</td></tr><tr><td colspan="2">No Difference</td></tr><tr><td colspan="2">Coronary heart disease</td></tr><tr><td colspan="2">Invasive breast cancer</td></tr><tr><td>Colorectal cancer</td><td></td></tr></table>
======================================
<table><tr><td>Conjugated equine estrogens</td><td>Premarin</td><td>0.3, 0.45, 0.625, 0.9, 1.25</td></tr><tr><td>Synthetic conjugated estrogens</td><td>Cenestin</td><td>0.3. 0.45, 0.625, 0.9, 1.25</td></tr><tr><td>Esterified estrogens</td><td>Menest</td><td>0.3, 0.625, 1.25, 2.5</td></tr><tr><td>17B-estradiol</td><td>Estrace, generics</td><td>0.5, 1.0, 2.0</td></tr><tr><td>Estrone (estropipate)</td><td>Ortho-Est, Ogen, generics</td><td>0.625, 1.25</td></tr></table>
======================================
<table><tr><td rowspan="5">17B-estradiol matrix patch</td><td>Alora</td><td>0.025, 0.05, 0.075, 0.1</td><td>Twice weekly</td></tr><tr><td></td><td>Climara</td><td>0.025, 0.0375, 0.05, 0.075, 0.1</td><td>Once weekly</td></tr><tr><td></td><td>Esclim</td><td>0.025, 0.0375, 0.05, 0.075, 0.1</td><td>Twice weekly</td></tr><tr><td></td><td>Menostar</td><td>0.014</td><td>Once weekly</td></tr><tr><td></td><td>Vivelle (Dot)</td><td>0.025, 0.0375, 0.05, 0.075, 0.1</td><td>Twice weekly</td></tr><tr><td>17B-estradiol reservoir patch</td><td>Estraderm</td><td>0.025, 0.05, 0.1</td><td>Twice weekly</td></tr><tr><td>17B-estradiol</td><td>Estrogel</td><td>0.035</td><td>Daily application via metered-dose pump</td></tr><tr><td>17B-estradiol</td><td>Estrasorb</td><td>0.05</td><td>Daily application of</td></tr></table>
======================================
<table><thead><th>Composition</th><th>Product Name</th><th>Recommended Dose</th></thead><tr><td colspan="3">Vaginal Creams</td></tr><tr><td>17B-estradiol</td><td>Estrace vaginal cream</td><td>0.5-1 g, 2-3 times weekly</td></tr><tr><td>Conjugated equine estrogens</td><td>Premarin vaginal cream</td><td>0.5-1 g, 2-3 times weekly</td></tr><tr><td colspan="3">Vaginal Rings</td></tr><tr><td>17B-estradiol</td><td>Estring</td><td>Device releases 7.5 g/day for 90 days</td></tr><tr><td>Estradiol acetate</td><td>Femring</td><td>Device releases 5 or 10 wg/day for 90 days (systemic estradiol levels achieved)</td></tr><tr><td colspan="3">Vaginal Tablet</td></tr><tr><td>Estradiol hemihydrate</td><td>Vagifem</td><td>1 tablet (25 wg) twice weekly</td></tr><tr><td colspan="3">Progestogens</td></tr><tr><td>Composition</td><td>Product Name</td><td>Dose</td></tr><tr><td colspan="3">Progestin: Oral Tablet</td></tr><tr><td>Medroxyprogesterone acetate</td><td>Provera, generics</td><td>2.5, 5, 10 mg</td></tr><tr><td>Norethindrone</td><td>Micronor, Nor-QD, generics</td><td>0.35 mg</td></tr><tr><td>Norethindrone acetate</td><td>Aygestin, generics</td><td>5 mg</td></tr><tr><td>Megestrol acetate</td><td>Megace</td><td>20, 40 mg</td></tr><tr><td>Progestin: Intrauterine System</td><td></td><td></td></tr></table>
======================================
<table><thead><th></th><th>Table 32.5 Continued</th><th></th></thead><thead><th colspan="3">Progesterone: Oral Capsule</th></thead><tr><td>Micronized progesterone USP</td><td></td><td>100, 200 mg</td></tr><tr><td colspan="3">Progesterone: Vaginal Gel</td></tr><tr><td>Progesterone</td><td>Prochieve 4%</td><td>45 mg/applicator</td></tr><tr><td colspan="3">Combination Estrogen-Progestogen Products</td></tr><tr><td>Composition</td><td>Product Name</td><td>Dose (per day)</td></tr><tr><td colspan="3">Oral Continuous-Cyclic Regimen</td></tr><tr><td>Conjugated equine estrogens (E)</td><td>Premphase</td><td>0.625 mg E + 5.0 mg P</td></tr><tr><td>+medroxyprogesterone acetate (P)</td><td></td><td>(E alone days 1-14, E + P days 15-28)</td></tr><tr><td colspan="3">Oral Continuous-Combined Regimen</td></tr><tr><td>Conjugated equine estrogens (E)</td><td>Prempro</td><td>0.625 mg E + 2.5 or 5.0 mg P</td></tr><tr><td>+medroxyprogesterone acetate (P)</td><td></td><td>0.3 or 0.45 mg E + 1.5 mg P</td></tr><tr><td>Ethinyl estradiol (E)</td><td>Femhrt</td><td>5 wg E+ 1mgP</td></tr><tr><td colspan="3">+norethindrone acetate (P)</td></tr><tr><td>17B-estradiol (E)</td><td>Activella</td><td>1 mgE + 0.5 mg P</td></tr><tr><td colspan="3">+norethindrone acetate (P)</td></tr><tr><td colspan="3">Oral Intermittent-Combined Regimen</td></tr><tr><td>17B-estradiol (E)</td><td>Ortho-Prefest</td><td>1 mg E + 0.09 mg P</td></tr><tr><td>+norgestimate (P)</td><td></td><td>(E alone for 3 days, followed by E + P for 3 days)</td></tr><tr><td colspan="3">Transdermal Continuous-Combined Regimen</td></tr><tr><td>17B-estradiol (E)</td><td>CombiPatch</td><td>0.05 mg E + 0.14 or 0.25 mg P</td></tr><tr><td>+norethindrone acetate (P)</td><td></td><td>Twice weekly</td></tr><tr><td>17B-estradiol (E)</td><td>Climara Pro</td><td>0.045 mg E + 0.0015 mg P</td></tr><tr><td>+ levonorgestrel (P)</td><td></td><td>Once weekly</td></tr></table>
======================================
<table><thead><th>Characteristic</th><th>Relative Risk</th></thead><tr><td>Nulliparity</td><td>2-3</td></tr><tr><td>Late menopause</td><td>2.4</td></tr><tr><td colspan="2">Obesity</td></tr><tr><td>21-50 lb overweight</td><td>3</td></tr><tr><td>&gt;50 Ib overweight</td><td>10</td></tr><tr><td>Diabetes mellitus</td><td>2.8</td></tr><tr><td>Unopposed estrogen therapy</td><td>4-8</td></tr><tr><td>Tamoxifen therapy</td><td>2-3</td></tr><tr><td>Atypical endometrial hyperplasia</td><td>8-29</td></tr><tr><td>HNPCC syndrome</td><td>20</td></tr></table>
======================================
<table><thead><th>[ype of Hyperplasia</th><th>Progression to Cancer (%)</th></thead><tr><td>simple (cystic without atypia)</td><td>1</td></tr><tr><td>Complex (adenomatous without atypia)</td><td>3</td></tr><tr><td colspan="2">Atypical</td></tr><tr><td>Simple (cystic with atypia)</td><td>8</td></tr><tr><td>Complex (adenomatous with atypia)</td><td>29</td></tr></table>
======================================
<table><thead><th>Cause of Bleeding</th><th>Percentage</th></thead><tr><td>Endometrial atrophy</td><td>60-80</td></tr><tr><td>Estrogen replacement therapy</td><td>15-25</td></tr><tr><td>Endometrial polyps</td><td>2-12</td></tr><tr><td>Endometrial hyperplasia</td><td>5-10</td></tr><tr><td>Endometrial cancer</td><td>10</td></tr></table>
======================================
<table><thead><th>Stage</th><th>Characteristic</th></thead><tr><td>1</td><td>Confined to the corpus</td></tr><tr><td>la G123</td><td>Uterine cavity &lt;8 cm</td></tr><tr><td>Ib G123</td><td>Uterine cavity &gt;8 cm</td></tr><tr><td>I</td><td>Involves the corpus and cervix, but has not extended outside the uterus</td></tr><tr><td>Ill</td><td>Extends outside the uterus, but not outside the true pelvis</td></tr><tr><td>IV</td><td>Extends outside the true pelvis or obviously involves the mucosa of the bladder or rectum</td></tr><tr><td>IVa</td><td>Spread to adjacent organs</td></tr><tr><td>IVb</td><td>Spread to distant organs</td></tr></table>
======================================
<table><thead><th>Stage</th><th>Finding</th></thead><tr><td>la G123</td><td>No myometrial invasion</td></tr><tr><td>Ib G123</td><td>&lt;'b Myometrial invasion</td></tr><tr><td>Ic G123</td><td>&gt;" Myometrial invasion</td></tr><tr><td>Ha G123</td><td>Extension to endocervical glands</td></tr><tr><td>IIb G123</td><td>Cervical stromal invasion</td></tr><tr><td>Ia G123</td><td>Positive uterine serosa, adnexa, and/or peritoneal cytology</td></tr><tr><td>IIb G123</td><td>Vaginal metastasis</td></tr><tr><td>Ile G123</td><td>Metastasis to pelvic and/or para-aortic lymph nodes</td></tr><tr><td>IVa G123</td><td>Tumor invasion of bladder and/or bowel mucosa</td></tr><tr><td>IVb</td><td>Distant metastasis including intra-abdominal and/or inguinal lymph nodes</td></tr></table>
======================================
<table><thead><th rowspan="3">Grade</th><th>Clinical</th><th>Stage |</th><th>Endometrial Carcinoma</th><th></th><th></th></thead><thead><th></th><th rowspan="2">No</th><th colspan="2">Pelvic Nodes</th><th colspan="2">Aortic Nodes</th></thead><thead><th></th><th></th><th>No.</th><th>%</th><th>No.</th><th>%</th></thead><tr><td>1</td><td>180</td><td>5</td><td>3</td><td>3</td><td>2</td></tr><tr><td rowspan="2">2 3</td><td>288</td><td>25</td><td>9</td><td>14</td><td>5</td></tr><tr><td></td><td>153</td><td>28</td><td>18</td><td>17</td><td>11</td></tr></table>
======================================
<table><thead><th rowspan="2">Myometrial Invasion</th><th rowspan="2">No.</th><th colspan="2">Pelvic Nodes</th><th colspan="2">Aortic Nodes</th></thead><thead><th></th><th></th><th>No.</th><th>%o</th><th>No.</th><th>%</th></thead><tr><td></td><td>87</td><td>1</td><td>1</td><td>1</td><td>1</td></tr><tr><td>Inner third</td><td>279</td><td>15</td><td>5</td><td>8</td><td>3</td></tr><tr><td>Middle third</td><td>116</td><td>7</td><td>6</td><td>1</td><td>1</td></tr><tr><td>Outer third</td><td>139</td><td>35</td><td>25</td><td>24</td><td>17</td></tr></table>
======================================
<table><thead><th>Surgical-Pathologic Finding</th><th>Percentage of Patients</th></thead><tr><td colspan="2">Histology</td></tr><tr><td>Adenocarcinoma</td><td>80</td></tr><tr><td>Adenosquamous</td><td>16</td></tr><tr><td>Other (papillary serous, clear cell)</td><td>4</td></tr><tr><td colspan="2">Grade</td></tr><tr><td>1</td><td>29</td></tr><tr><td>2</td><td>46</td></tr><tr><td>3</td><td>25</td></tr><tr><td colspan="2">Myometrial invasion</td></tr><tr><td></td><td>14</td></tr><tr><td>Inner third</td><td>45</td></tr><tr><td>Middle third</td><td>19</td></tr><tr><td>Outer third</td><td>22</td></tr><tr><td>Lymph-vascular space invasion</td><td>15</td></tr><tr><td>Isthmic tumor</td><td>16</td></tr><tr><td>Adnexal involvement</td><td>5</td></tr><tr><td>Positive peritoneal cytology</td><td>12</td></tr><tr><td>Pelvic lymph node metastasis</td><td>9</td></tr><tr><td>Aortic lymph node metastasis</td><td>6</td></tr><tr><td>Other extrauterine metastasis</td><td>6</td></tr></table>
======================================
<table><thead><th>Age</th></thead><tr><td>Histologic type</td></tr><tr><td>Histologic grade</td></tr><tr><td>Myometrial invasion</td></tr><tr><td>Lymph-vascular space invasion</td></tr><tr><td>sthmus-—cervix extension</td></tr><tr><td>Adnexal involvement</td></tr><tr><td>Lymph node metastasis</td></tr><tr><td>ntraperitoneal tumor</td></tr><tr><td>Tumor size</td></tr><tr><td>Peritoneal cytology</td></tr><tr><td>Hormone receptor status</td></tr><tr><td>DNA ploidy/proliferative index</td></tr><tr><td>Genetic/molecular tumor markers</td></tr></table>
======================================
<table></table>
======================================
<table><tr><td rowspan="2">Landgren et al. (178)</td><td>1976</td><td>=</td><td>124</td><td>22</td><td>68</td><td>7</td></tr><tr><td></td><td></td><td>I-IV</td><td>26</td><td>42</td><td>22</td><td></td></tr><tr><td rowspan="2">Abayomi et al. (179)</td><td>1982</td><td>|</td><td>50</td><td>26</td><td>78</td><td>15</td></tr><tr><td></td><td></td><td>I-IV</td><td>6</td><td></td><td>10</td><td></td></tr><tr><td rowspan="2">Patanaphan et al. (180)</td><td>1985</td><td>=</td><td>42</td><td>14</td><td>64</td><td>2</td></tr><tr><td></td><td></td><td>I-IV</td><td>0</td><td>60</td><td>20</td><td></td></tr><tr><td rowspan="2">Jones and Stout (181)</td><td>1986</td><td>|</td><td>146</td><td>22</td><td>61</td><td>4</td></tr><tr><td></td><td></td><td>I-IV</td><td>4</td><td>79</td><td>14</td><td></td></tr><tr><td>Varia et al. (182)</td><td>1987</td><td>|</td><td>73</td><td>21</td><td>43</td><td>10</td></tr><tr><td>Wang et al. (183)</td><td>1987</td><td>|</td><td>41</td><td>22</td><td>76</td><td>5</td></tr><tr><td>Grigsby et al. (184)</td><td>1987</td><td></td><td>69</td><td>9</td><td>88</td><td>16</td></tr><tr><td rowspan="2">Taghian et al. (185)</td><td>1988</td><td>|</td><td>94</td><td>6</td><td>70</td><td>17</td></tr><tr><td></td><td></td><td>I-IV</td><td>0</td><td>10</td><td>27</td><td></td></tr><tr><td>Lehoczky et al. (186)</td><td>1991</td><td></td><td>171</td><td>20</td><td>75</td><td>0</td></tr><tr><td rowspan="2">Kupelian et al. (187)</td><td>1993</td><td>=</td><td>137</td><td>14</td><td>85</td><td></td></tr><tr><td></td><td></td><td>I-IV</td><td>5</td><td>32</td><td>49</td><td></td></tr></table>
======================================
<table><tr><td rowspan="5">Postoperative Adjuvant Therapy</td><td>Postoperative therapy should be based on prognostic factors determined by surgical and pathologic staging. Patients can generally be classified into three treatment cate- gories (Table 33.14).:</td></tr><tr><td></td><td>1. Low Risk Patients who show a low incidence of recurrence and a high rate of cure without any postoperative therapy</td></tr><tr><td></td><td>2. Intermediate Risk Patients who have a reduced rate of surgical cure but may or may not benefit from additional therapy</td></tr><tr><td></td><td>3. High Risk Patients who have a high rate of recurrence and a low survival rate without postoperative therapy</td></tr><tr><td></td><td>Options for postoperative management in these patients include observation, vaginal vault irradiation, external pelvic irradiation, extended-field (pelvic and para-aortic) irradiation, whole-abdomen irradiation, progestins, or systemic chemotherapy (see Fig. 33.7).</td></tr><tr><td>Observation</td><td>Patients with grade 1 and 2 lesions without myometrial invasion (stage Ia, grades 1 and 2) have an excellent prognosis and require no postoperative therapy. In a GOG</td></tr><tr><td>1370</td><td></td></tr></table>
======================================
<table><thead><th>Surgical-Pathologic Findings</th><th>Stage</th><th>Postoperative Treatment</th></thead><tr><td colspan="3">Low risk</td></tr><tr><td>G1, G2, no myoinvasion No cervix/isthmus invasion Negative peritoneal cytology No LVSI No evidence of metastasis</td><td>la G1, 2</td><td></td></tr><tr><td colspan="3">Intermediate risk &lt;50% Ib 2 cuff irradiation</td></tr><tr><td>G1, G2, myoinvasion G3, no myoinvasion</td><td>G1, la G3</td><td>Vaginal</td></tr><tr><td>G3, &lt;50% myoinvasion G1, G2 isthmus/cervix extension</td><td>Ib G3 lla G1, G2</td><td>Pelvic versus vaginal cuff irradiation</td></tr><tr><td>G1, G2, G3 &gt;50% myoinvasion G3, isthmus/cervix extension G1, G2, G3 cervix invasion</td><td>Ic G1, G2, G3 Ila G3 Ib G1, G2, G3</td><td>Pelvic irradiation plus vaginal cuff boost</td></tr><tr><td>LVSI Positive</td><td>Illa (+</td><td></td></tr><tr><td colspan="3">peritoneal cytology cytology) Progestin</td></tr><tr><td>High risk Adnexal/serosal/parametrial spread Vaginal metastasis Lymph node metastasis</td><td>Ila G1, G2, G3 IIb G1, G2, G3 Ic G1, G2, G3</td><td>Pelvic and vaginal irradiation (Extended-field radiation therapy if positive aortic/common iliac lymph nodes)</td></tr><tr><td>Bladder/rectal invasion Intraperitoneal spread</td><td>IVa IVb</td><td>Pelvic and vaginal irradiation Whole-abdomen irradiation; systemic</td></tr></table>
======================================
<table><tr><td>Therapy regional surgical endometrial cancer should be treated with radiotherapy (191,264—271). The best local</td></tr></table>
======================================
<table><thead><th>Study</th><th></th><th>Progestin</th><th>No. of Patients</th><th>Response Rate (%)</th></thead><thead><th>Piver et al. (274)</th><th>HPC</th><th>1,000 mg/wk IM</th><th>51</th><th>14</th></thead><tr><td></td><td>MPA</td><td>1,000 mg/wk IM</td><td>37</td><td>19</td></tr><tr><td rowspan="2">Podratz et al. (275)</td><td>HPC</td><td>1-3 g/wk IM</td><td>33</td><td>9</td></tr><tr><td></td><td>MA</td><td>320 mg/d PO</td><td>81</td><td>11</td></tr><tr><td rowspan="3">Thigpen et al. (276,277)</td><td>MPA</td><td>150 mg/d PO</td><td>219</td><td>14</td></tr><tr><td></td><td></td><td>200 mg/d PO</td><td>138</td><td>26</td></tr><tr><td></td><td></td><td>1,000 mg/d PO</td><td>140</td><td>18</td></tr></table>
======================================
<table><thead><th rowspan="2">Stage</th><th colspan="2">Patients Treated</th><th colspan="2"></th></thead><thead><th></th><th>No.</th><th>%</th><th>3-Year</th><th>5-Year</th></thead><tr><td colspan="5">Surgical</td></tr><tr><td>|</td><td>3,996</td><td>70</td><td>92</td><td>87</td></tr><tr><td>I</td><td>709</td><td>12</td><td>82</td><td>76</td></tr><tr><td>Ul</td><td>758</td><td>13</td><td>66</td><td>59</td></tr><tr><td>IV</td><td>231</td><td>4</td><td>23</td><td>18</td></tr><tr><td colspan="5">Clinical</td></tr><tr><td>I</td><td>232</td><td>61</td><td>63</td><td>54</td></tr><tr><td>I</td><td>64</td><td>16</td><td>53</td><td>Al</td></tr><tr><td>Ill</td><td>54</td><td>14</td><td>30</td><td>23</td></tr><tr><td>IV</td><td>33</td><td>8</td><td>12</td><td>12</td></tr><tr><td>TOTAL</td><td>6,260</td><td>100</td><td>82</td><td>76</td></tr></table>
======================================
<table><thead><th rowspan="2"></th><th></th><th rowspan="2"></th><th rowspan="2"></th></thead><thead><th></th><th></th><th></th><th></th></thead><tr><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td></tr></table>
======================================
<table><thead><th>1. Pure nonepithelial tumors</th></thead><tr><td>A. Homologous</td></tr><tr><td>1. Endometrial stromal tumors</td></tr><tr><td>a. Low-grade stromal sarcoma</td></tr><tr><td>b. High-grade or undifferentiated stromal sarcoma</td></tr><tr><td>2. Smooth muscle tumors</td></tr><tr><td>a. Leiomyosarcoma</td></tr><tr><td>b. Leiomyoma variants</td></tr><tr><td>. Cellular leiomyoma</td></tr><tr><td>2. Leiomyoblastoma (epithelioid leiomyoma)</td></tr><tr><td rowspan="2">c. Benign metastasizing tumors . Intravenous leiomyomatosis</td></tr><tr><td></td><td></td><td></td></tr><tr><td>2. Benign metastasizing leiomyoma</td></tr><tr><td>3. Disseminated peritoneal leiomyomatosis</td><td></td></tr><tr><td>B. Heterologous</td><td></td></tr><tr><td>1. Rhabdomyosarcoma</td></tr><tr><td>2. Chondrosarcoma</td><td></td></tr><tr><td>3. Osteosarcoma</td></tr><tr><td>4 Liposarcoma</td></tr><tr><td>Il. Mixed epithelial-nonepithelial tumors</td></tr><tr><td>A. Malignant mixed miillerian tumor</td></tr><tr><td>1. Homologous (carcinosarcoma)</td></tr><tr><td>2 Heterologous</td></tr><tr><td>B. Adenosarcoma</td></tr></table>
======================================
<table><tr><td>Histologic Appearance of Invasion</td><td>required correctly depth involvement when microinvasion is suspected. Early invasion is characterized by a</td></tr></table>
======================================
<table><thead><th>Stage 0</th><th colspan="3">Carcinoma in situ, intraepithelial carcinoma (cases of stage 0 should not be included in any therapeutic statistics).</th></thead><tr><td colspan="4">Invasive Carcinoma</td></tr><tr><td rowspan="7">Stage I?</td><td colspan="3">Carcinoma strictly confined to the cervix (extension to the corpus should be disregarded).</td></tr><tr><td></td><td>Stage la</td><td>Preclinical</td><td>carcinomas of the cervix, that is, those diagnosed only by microscopy.</td></tr><tr><td></td><td></td><td>Stage lal</td><td>Lesion with $3 mm invasion.</td></tr><tr><td></td><td></td><td>la2</td><td>Lesions detected microscopically that can be measured. The upper limit of the measurement should show a depth of invasion of &gt;3-5 mm taken from the base of the epithelium, either surface or glandular, from which it originates, and a second dimension, the horizontal spread, must not exceed 7 mm. Larger lesions should be staged as Ib.</td></tr><tr><td></td><td>Ib</td><td>Lesions</td><td>invasive &gt;5 mm.</td></tr><tr><td></td><td></td><td>Stage Ib1</td><td>Lesion =4 cm.</td></tr><tr><td></td><td></td><td>Ib2</td><td>Lesions &gt;4 cm.</td></tr><tr><td rowspan="4">Stage II’</td><td>_ The carcinoma</td><td>extends</td><td>beyond the cervix but has not extended onto the wall.</td></tr><tr><td></td><td>The carcinoma</td><td>involves</td><td>the vagina, but not the lower one third.</td></tr><tr><td></td><td>Stage lla</td><td>No obvious</td><td>parametrial involvement.</td></tr><tr><td></td><td>IIb</td><td>Obvious</td><td>parametrial involvement.</td></tr><tr><td rowspan="3">Stage IIIS</td><td>The carcinoma the tumor hydronephrosis</td><td>has and the pelvic or</td><td>extended onto the pelvic wall. On rectal examination, there is no cancer-free space between wall. The tumor involves the lower one third of the vagina. All cases with nonfunctioning kidney.</td></tr><tr><td></td><td>Stage Illa</td><td>No extension</td><td>to the pelvic wall.</td></tr><tr><td></td><td>IIIb</td><td>Extension</td><td>onto the pelvic wall and/or hydronephrosis or nonfunctioning kidney.</td></tr><tr><td colspan="4">Stage IV The carcinoma has extended beyond the true pelvis or has clinically involved the mucosa of the bladder or rectum. A bullous edema, as such, does not permit a case to be allotted to stage IV.</td><td rowspan="3"></td></tr><tr><td></td><td>Stage IVa</td><td>Spread to</td><td>the growth to adjacent organs.</td></tr><tr><td></td><td>IVb</td><td>Spread to</td><td>distant organs.</td></tr><tr><td colspan="4">2 The diagnosis of both stages la1 and la2 should be based on microscopic examination of removed tissue, preferably a cone, which must include the entire lesion. The depth of invasion should not be more than 5 mm taken from the base of the epithelium, either surface or glan- dular, from which it originates. The second dimension, the horizontal spread, must not exceed 7 mm. Vascular space involvement, either lymphatic, should not alter the staging but should be specifically recorded because it affect treatment decisions in the future.</td></tr></table>
======================================
<table><tr><td rowspan="3">Physical examination?</td><td>Palpate lymph nodes</td></tr><tr><td></td><td>Examine vagina</td></tr><tr><td></td><td>Bimanual rectovaginal examination (under anesthesia recommended)</td></tr><tr><td rowspan="4">Radiologic studies*</td><td>ntravenous pyelogram</td></tr><tr><td></td><td>Barium enema</td></tr><tr><td></td><td>Chest x-ray</td></tr><tr><td></td><td>Skeletal x-ray</td></tr><tr><td rowspan="7">Procedures?</td><td>Biopsy</td></tr><tr><td></td><td>Conization</td></tr><tr><td></td><td>Hysteroscopy</td></tr><tr><td></td><td>Colposcopy</td></tr><tr><td></td><td>Endocervical curettage</td></tr><tr><td></td><td>Cystoscopy</td></tr><tr><td></td><td>Proctoscopy</td></tr><tr><td rowspan="7">Optional studies’</td><td></td><td>Computerized axial tomography</td></tr><tr><td></td><td>Lymphangiography</td></tr><tr><td>Ultrasonography</td></tr><tr><td></td><td>Magnetic resonance imaging</td></tr><tr><td></td><td>Positron emission tomography</td></tr><tr><td></td><td>Radionucleotide scanning</td></tr><tr><td></td><td>Laparoscopy</td></tr></table>
======================================
<table><thead><th>Stage</th><th>No. of Patients</th><th>Positive Pelvic Nodes (%)</th><th>Positive Para-aortic Nodes (%)</th></thead><tr><td>la1 (&lt;3 mm)</td><td>179?</td><td>0.5</td><td>0</td></tr><tr><td>la2 (&gt;3-5 mm)</td><td>842</td><td>4.8</td><td>&lt;1</td></tr><tr><td>Ib</td><td>1,926°</td><td>15.9</td><td>2.2</td></tr><tr><td>Ila</td><td>110°</td><td>24.5</td><td>11</td></tr><tr><td>IIb</td><td>324°</td><td>31.4</td><td>19</td></tr><tr><td>Tl</td><td>125¢</td><td>44.8</td><td>30</td></tr><tr><td>IVa</td><td>23°</td><td>55</td><td>40</td></tr></table>
======================================
<table><thead><th>Stage la1</th><th>=3 mm invasion, no LVS!</th><th>Conization or type | hysterectomy</th></thead><tr><td></td><td>=3 mm invasion, w/LVSI</td><td>Radical trachelectomy or type | pelvic lymph node dissection radical hysterectomy with</td></tr><tr><td>a2</td><td>&gt;3-5 mm invasion</td><td>Radical trachelectomy or type | pelvic lymphadenectomy radical hysterectomy with</td></tr><tr><td>Ib1</td><td>&gt;5 mm invasion, &lt;2 cm</td><td>Radical trachelectomy or type | pelvic lymphadenectomy | radical hysterectomy with</td></tr><tr><td rowspan="2">Ib2</td><td>&gt;5 mm invasion, &gt;2 cm</td><td>Type Ill radical hysterectomy with pelvic lymphadenectomy</td></tr><tr><td></td><td>&gt;5 mm invasion</td><td>lymphadenectomy or primary c| Type Ill radical hysterectomy wi ith pelvic and para-aortic emoradiation</td></tr><tr><td>Stage Ila</td><td></td><td>lymphadenectomy or primary c| Type Ill radical hysterectomy wi ith pelvic and para-aortic emoradiation</td></tr><tr><td>lib, Ila, IIb</td><td></td><td>Primary chemoradiation</td></tr><tr><td>Stage IVa</td><td></td><td>Primary chemoradiation or primary exenteration</td></tr><tr><td>IVb</td><td></td><td>Primary chemotherapy + radiat ion</td></tr></table>
======================================
<table><thead><th></th><th>Surgery</th><th>Radiation</th></thead><tr><td>Survival</td><td>85%</td><td>85%</td></tr><tr><td>Serious complications</td><td>Urologic fistulas 1%-2%</td><td>Intestinal and urinary strictures and fistulas 1.4%-5.3%</td></tr><tr><td>Vagina</td><td>Initially shortened, but may lengthen with regular intercourse</td><td>Fibrosis and possible stenosis, particularly in postmenopausal patients</td></tr><tr><td>Ovaries</td><td>Can be conserved</td><td>Destroyed</td></tr><tr><td>Chronic effects</td><td>Bladder atony in 3%</td><td>Radiation fibrosis of bowel and bladder in 6%-8%</td></tr><tr><td>Applicability</td><td>Best candidates are younger than 65 years of age, &lt;200 lb, and in good health</td><td>All patients are potential candidates</td></tr><tr><td>Surgical mortality</td><td>1%</td><td>1% (from pulmonary embolism during intracavitary therapy)</td></tr></table>
======================================
<table><thead><th></th><th>Table 34.6 FIGO Staging of Vaginal Canc</th></thead><tr><td>Stage 0</td><td>Carcinoma in situ, intraepithelial carcinoma.</td></tr><tr><td>Stage |</td><td>The carcinoma is limited to the vaginal wall.</td></tr><tr><td>Stage Il</td><td>The carcinoma has involved the subvaginal tissue but has not extended to the pelvic wall.</td></tr><tr><td>Stage III</td><td>The carcinoma has extended to the pelvic wall.</td></tr><tr><td>Stage IV</td><td>The carcinoma has extended beyond the true pelvis or has involved the mucosa of the bladder or rectum.</td></tr><tr><td>IVa</td><td>Spread of the growth to adjacent organs.</td></tr><tr><td>IVb</td><td>Spread to distant organs.</td></tr></table>
======================================
<table><thead><th rowspan="2">Stage</th><th>Table 34.7 Primary</th><th>Vaginal Carcinoma: 5-year Survival</th><th></th></thead><thead><th></th><th>No. of Patients</th><th>No. Surviving 5 Years</th><th>Percentage</th></thead><tr><td>1</td><td>172</td><td>118</td><td>68.6</td></tr><tr><td>I</td><td>236</td><td>108</td><td>45.8</td></tr><tr><td>Il</td><td>203</td><td>62</td><td>30.5</td></tr><tr><td rowspan="2">IV TOTAL</td><td>114</td><td>20</td><td>17.5</td></tr><tr><td></td><td>725</td><td>308</td><td>42.5</td></tr></table>
======================================
<table><thead><th colspan="2">Table 35.1 Epithelial Ovarian Tumors</th></thead><thead><th>Histologic Type</th><th>Cellular Type</th></thead><tr><td>I Serous</td><td>Endosalpingeal</td></tr><tr><td colspan="2">A. Benign</td></tr><tr><td colspan="2">B. Borderline</td></tr><tr><td colspan="2">C. Malignant</td></tr><tr><td>HW. Mucinous</td><td>Endocervical</td></tr><tr><td colspan="2">A. Benign</td></tr><tr><td colspan="2">B. Borderline</td></tr><tr><td>C. Malignant</td><td></td></tr><tr><td>HI. Endometrioid</td><td>Endometrial</td></tr><tr><td colspan="2">A. Benign</td></tr><tr><td colspan="2">B. Borderline</td></tr><tr><td colspan="2">C. Malignant</td></tr><tr><td>IV. Clear-cell “mesonephroid”</td><td>Miillerian</td></tr><tr><td colspan="2">A. Benign</td></tr><tr><td colspan="2">B. Borderline</td></tr><tr><td colspan="2">C. Malignant</td></tr><tr><td>Brenner</td><td>Transitional</td></tr><tr><td colspan="2">A. Benign</td></tr><tr><td colspan="2">B. Borderline (proliferating)</td></tr><tr><td colspan="2">C. Malignant</td></tr><tr><td>Vi. Mixed epithelial</td><td>Mixed</td></tr><tr><td colspan="2">A. Benign</td></tr><tr><td colspan="2">B. Borderline</td></tr><tr><td colspan="2">C. Malignant</td></tr><tr><td>Vil. Undifferentiated</td><td>Anaplastic</td></tr><tr><td>Vil. Unclassified</td><td>Mesothelioma, etc</td></tr></table>
======================================
<table><thead><th>Stage I</th><th>Growth limited to the ovaries.</th></thead><tr><td rowspan="2">la</td><td>Growth limited to one ovary; no ascites containing malignant cells.</td></tr><tr><td></td><td>No tumor on the external surface; capsule intact.</td></tr><tr><td rowspan="2">Ib</td><td>Growth limited to both ovaries; no ascites containing malignant cells.</td></tr><tr><td></td><td>No tumor on the external surfaces; capsules intact.</td></tr><tr><td>Ic?</td><td>Tumor either stage la or Ib but with tumor on the surface of one or both ovaries; or with capsule ruptured; or with ascites present containing malignant cells or with positive peritoneal washings.</td></tr><tr><td>Stage Il</td><td>Growth involving one or both ovaries with pelvic extension.</td></tr><tr><td>Ila</td><td>Extension and/or metastases to the uterus and/or fallopian tubes.</td></tr><tr><td>IIb</td><td>Extension to other pelvic tissues.</td></tr><tr><td>IIc?</td><td>Tumor either stage Ila or IIb but with tumor on the surface of one or both ovaries; or with capsule(s) ruptured; or with ascites present containing malignant cells or with positive peritoneal washings.</td></tr><tr><td>Stage III</td><td>Tumor involving one or both ovaries with peritoneal implants outside the pelvis and/or positive retroperitoneal or inguinal nodes. Superficial liver metastasis equals stage III. Tumor is limited to the true pelvis, but with histologically proven malignant extension to small bowel or omentum.</td></tr><tr><td>Ila</td><td>Tumor grossly limited to the true pelvis with negative nodes but with histologically confirmed microscopic seeding of abdominal peritoneal surfaces.</td></tr><tr><td>IIb</td><td>Tumor of one or both ovaries with histologically confirmed implants of abdominal peritoneal surfaces, none exceeding 2 cm in diameter. Nodes negative.</td></tr><tr><td>IIIc</td><td>Abdominal implants &gt;2 cm in diameter or positive retroperitoneal or inguinal nodes or both.</td></tr><tr><td>Stage IV</td><td>Growth involving one or both ovaries with distant metastasis. If pleural effusion is present, there must be positive cytologic test results to allot a case to stage IV. Parenchymal liver metastasis equals stage IV.</td></tr></table>
======================================
<table><thead><th>Low Risk</th><th>High Risk</th></thead><tr><td>Low grade</td><td>High grade</td></tr><tr><td>on-clear cell histologic type</td><td>Clear cell histologic type</td></tr><tr><td>ntact capsule</td><td>Tumor growth through capsule</td></tr><tr><td>o surface excrescences</td><td>Surface excrescences</td></tr><tr><td>0 ascites</td><td>Ascites</td></tr><tr><td>egative peritoneal cytologic findings</td><td>Malignant cells in fluid</td></tr><tr><td>Unruptured or intraoperative rupture</td><td>Preoperative rupture</td></tr><tr><td>o dense adherence</td><td>Dense adherence</td></tr><tr><td>Diploid tumor</td><td>Aneuploid tumor</td></tr></table>
======================================
<table><thead><th colspan="5">Ovarian Cancer: Recommended Regimens</th></thead><thead><th>Drugs</th><th>Dose (mg/m?)*</th><th>Route</th><th>Interval (weeks)</th><th>Treatments (cycles)</th></thead><tr><td colspan="5">Standard regimens</td></tr><tr><td colspan="5">Intraperitoneal chemotherapy</td></tr><tr><td>Paclitaxel</td><td>135</td><td>IV</td><td>3, day 1</td><td>6</td></tr><tr><td>Cisplatin</td><td>50-100</td><td>IP</td><td>day 2</td><td></td></tr><tr><td>Paclitaxel</td><td>60</td><td>IP</td><td>day 8</td><td></td></tr><tr><td colspan="5">Intravenous chemotherapy</td></tr><tr><td>Paclitaxel</td><td>175</td><td>IV</td><td>3</td><td>6-8</td></tr><tr><td>Carboplatin</td><td>*AUC = 5-6</td><td>IV</td><td></td><td></td></tr><tr><td>Paclitaxel</td><td>135</td><td>IV</td><td>3</td><td>6-8</td></tr><tr><td>Cisplatin</td><td>75</td><td>Iv</td><td></td><td></td></tr><tr><td colspan="5">Alternative drugs”</td></tr><tr><td>Docetaxel</td><td>75</td><td>IV</td><td>3</td><td></td></tr><tr><td>Doxorubicin, liposomal</td><td>35-50</td><td>Iv</td><td>3-4</td><td></td></tr><tr><td rowspan="2">Topotecan</td><td></td><td>1.0-1.25</td><td>IV</td><td>1</td><td></td></tr><tr><td>4.0</td><td>IV</td><td>3 (daily x 3-5 days)</td><td></td></tr><tr><td>Etoposide</td><td>50</td><td>PO</td><td>3, days 14-21</td><td></td></tr></table>
======================================
<table><thead><th>1. Primitive germ cell tumors</th><th>3. Monodermal teratoma and somatic-type</th></thead><tr><td>A. Dysgerminoma</td><td>tumors associated with dermoid cysts</td></tr><tr><td>B. Yolk sac tumor</td><td>A. Thyroid tumor</td></tr><tr><td>C. Embryonal carcinoma</td><td>1. Struma ovarii</td></tr><tr><td>D. Polyembryoma</td><td>a. Benign</td></tr><tr><td>E. Non-gestational choriocarcinoma</td><td>b. Malignant</td></tr><tr><td>F. Mixed germ cell tumor</td><td>B. Carcinoid</td></tr><tr><td>2. Biphasic or triphasic teratoma</td><td>C. Neuroectodermal tumor</td></tr><tr><td>A. Immature teratoma</td><td>D. Carcinoma</td></tr><tr><td>B. Mature teratoma</td><td>E. Melanocytic</td></tr><tr><td>1. Solid</td><td>F. Sarcoma</td></tr><tr><td>2. Cystic</td><td>G. Sebaceous tumor</td></tr><tr><td>a. Dermoid cyst</td><td>H. Pituitary-type tumor</td></tr><tr><td>b. Fetiform teratoma (homunculus)</td><td>I. Others</td></tr></table>
======================================
<table><thead><th>Dysgerminoma malignant germ tumor, accounting 30% to 40% of all ovarian cancers of germ cell origin (2,3,399). The tumors represent</th></thead><tr><td>only 1% to 3% of all ovarian cancers, but they represent as many as 5% to 10% of ovarian</td></tr><tr><td>cancers in patients younger than 20 years. Seventy-five percent of dysgerminomas occur</td></tr><tr><td>between the ages of 10 and 30 years, 5% occur before the age of 10 years, and they rarely</td></tr><tr><td>occur after 50 years of age (2,3,397). Because these malignancies occur in young women, 20% to 30% of ovarian malignancies associated with pregnancy are dysgerminomas.</td></tr></table>
======================================
<table><thead><th>Regimen and Drugs</th><th>Dose and Schedule*</th></thead><tr><td colspan="2">BEP</td></tr><tr><td>Bleomycin</td><td>15 units/m?/week x 5; then on day 1 of course 4</td></tr><tr><td>Etoposide</td><td>100 mg/m*/day x 5 days every 3 weeks</td></tr><tr><td>Cisplatin</td><td>20 mg/m?/day x 5 days, or 100 mg/m?/day x 1 day every 3 weeks</td></tr><tr><td colspan="2">VBP</td></tr><tr><td>Vinblastine</td><td>0.15 mg/kg days 1 and 2 every 3 weeks</td></tr><tr><td>Bleomycin</td><td>15 units/m?/week x 5; then on day 1 of course 4</td></tr><tr><td>Cisplatin</td><td>100 mg/m? on day 1 every 3 weeks</td></tr><tr><td colspan="2">VAC</td></tr><tr><td>Vincristine</td><td>1-1.5 mg/m? on day 1 every 4 weeks</td></tr><tr><td>Actinomycin D</td><td>0.5 mg/day x 5 days every 4 weeks</td></tr><tr><td>Cyclophosphamide</td><td>150 meg/m2/day X 5 days every 4 weeks</td></tr></table>
======================================
<table><tr><td>Day 1</td><td>Vincristine 1 mg/m? IV; methotrexate 300 mg/m? as a 12-hr infusion</td></tr><tr><td>Day 2</td><td>Bleomycin 15 mg as a 24-hr infusion: folinic acid rescue started at 24 hrs after the start of methotrexate in a dose of 15 mg every 12 hrs for 4 doses</td></tr><tr><td>Day 3</td><td>Bleomycin infusion 15 mg by 24-hr infusion</td></tr><tr><td>Day 4</td><td>Cisplatin 120 mg/m? as a 12-hr infusion, given with hydration and 3 g magnesium sulfate supplementation</td></tr><tr><td colspan="2">ACE</td></tr><tr><td>Days 1-5</td><td>Etoposide (VP16-213) 100 mg/m?, days 1-5</td></tr><tr><td>Days 3, 4,5</td><td>Actinomycin D 0.5 mg IV, days 3, 4, and 5</td></tr><tr><td>Day 5</td><td>Cyclophosphamide 500 mg/m? IV, day 5</td></tr><tr><td colspan="2">OMB</td></tr><tr><td>Day 1</td><td>Vincristine 1 mg/m? IV; methotrexate 300 mg/m? as a 12-hr infusion</td></tr><tr><td>Day 2</td><td>Bleomycin 15 mg by 24-hr infusion; folinic acid rescue started at 24 hrs after start of methotrexate in a dose of 15 mg every 12 hrs for 4 doses</td></tr><tr><td></td><td>Bleomycin 15 mg by 24-hr infusion</td></tr></table>
======================================
<table><tr><td>1. Granulosa-stromal cell tumors</td></tr><tr><td>A. Granulosa cell tumor</td></tr><tr><td>B. Tumors in thecoma-fibroma group</td></tr><tr><td>1. Thecoma</td></tr><tr><td>2. Fibroma</td></tr><tr><td>3. Unclassified</td></tr><tr><td>2. Androblastomas; Sertoli-Leydig cell tumors</td></tr><tr><td>A. Well-differentiated</td></tr><tr><td>1. Sertoli cell tumor</td></tr><tr><td>2. Sertoli-Leydig cell tumor</td></tr><tr><td>3. Leydig cell tumor; hilus cell tumor</td></tr><tr><td>B. Moderately differentiated</td></tr><tr><td>C. Poorly differentiated (sarcomatoid)</td></tr><tr><td>D. With heterologous elements</td></tr><tr><td>3. Gynandroblastoma</td></tr><tr><td>4. Unclassified</td></tr></table>
======================================
<table><thead><th></th><th>The 5-year survival rate is 70% to 90%, and recurrences thereafter are uncommon (3,492). Most fatalities occur in the presence of poorly differentiated lesions.</th></thead><tr><td>Uncommon Ovarian Cancers</td><td>There are several varieties of malignant ovarian tumors that together constitute only 0.1% of ovarian malignancies (2). Two of these lesions are the lipoid (or lipid) cell tumors and the primary ovarian sarcomas.</td></tr><tr><td rowspan="2">Lipoid Cell Tumors</td><td>Lipoid cell tumors are believed to arise in adrenal cortical rests that reside in the vicinity of the ovary. More than 100 cases have been reported, and bilateral disease has been noted in only a few (2). Most are associated with virilization and, occasionally, with obesity, hypertension, and glucose intolerance reflecting corticosteroid secretion. Rare cases of estrogen secretion and isosexual precocity have been reported.</td></tr><tr><td></td><td>Most of these tumors have benign or low-grade behavior, but about 20%, most of which are initially larger than 8 cm in diameter, are associated with metastatic lesions. Metastases are usually in the peritoneal cavity but rarely occur at distant sites. The primary treatment is surgical extirpation of the primary lesion. There are no data regard- ing the effectiveness of radiation or chemotherapy for this disease.</td></tr><tr><td rowspan="2">Sarcomas 1524</td><td>Malignant mixed mesodermal sarcomas of the ovary are extremely rare; only about 100 cases have been reported. Most lesions are heterologous, and 80% occur in post- menopausal women. The signs and symptoms are similar to those of most ovarian malig- nancies. These lesions are biologically aggressive, and most patients have evidence of metastases. There is no effective treatment for ovarian sarcomas, and most die within 2</td></tr><tr><td></td><td>patients years. Doxorubicin, with or without cyclophosphamide, has produced an occasional partial response, and cisplatin is currently undergoing clinical trials (493-497). For patients in whom all macroscopic disease can be resected, we have observed disease-free survival of more than 3 years in two patients treated with six cycles of cisplatin and epirubicin.</td></tr></table>
======================================
<table></table>
======================================
<table><thead><th>Stage 0</th><th>Carcinoma in situ* (limited to tubal mucosa).</th></thead><tr><td>Stage |</td><td>Growth is limited to the fallopian tubes.</td></tr><tr><td>la</td><td>Growth is limited to one tube with extension into the submucosa‘ and/or muscularis but not penetrating the serosal surface; no ascites.</td></tr><tr><td>Ib</td><td>Growth is limited to both tubes with extension into the submucosa‘ and/or muscularis but not penetrating the serosal surface; no ascites.</td></tr><tr><td>Ic</td><td>Tumor either stage la or Ib but with tumor extension through or onto the tubal serosa; or with ascites present containing malignant cells or with positive peritoneal washings.</td></tr><tr><td>Stage II</td><td>Growth involving one or both fallopian tubes with pelvic extension.</td></tr><tr><td>Ha</td><td>Extension and/or metastasis to the uterus and/or ovaries.</td></tr><tr><td>IIb</td><td>Extension to other pelvic tissues.</td></tr><tr><td>Ic</td><td>Tumor either stage Ila or Ilb but with tumor extension through or onto the tubal serosa; or with ascites present containing malignant cells or with positive peritoneal washings.</td></tr><tr><td>Stage III</td><td>Tumor involves one or both fallopian tubes with peritoneal implants outside of the pelvis and/or positive retroperitoneal or inguinal nodes. Superficial liver metastases equals stage III. Tumor appears limited to the true pelvis but with histologically proven malignant extension to the small bowel or omentum.</td></tr><tr><td>Ila</td><td>Tumor is grossly limited to the true pelvis with negative nodes but with histologically confirmed microscopic seeding of abdominal peritoneal surfaces.</td></tr><tr><td>IIb</td><td>Tumor involving one or both tubes with histologically confirmed implants of abdominal peritoneal surfaces, none exceeding 2 cm in diameter. Lymph nodes are negative.</td></tr><tr><td>IIc</td><td>Abdominal implants greater than 2 cm in diameter and/or positive retroperitoneal or inguinal nodes.</td></tr><tr><td>Stage IV</td><td>Growth involving one or both fallopian tubes with distant metastases. If pleural effusion is present, there must be positive cytology to be stage IV. Parenchymal liver metastases equals stage IV.</td></tr></table>
======================================
<table><thead><th>Type</th><th>Percent</th></thead><tr><td>Squamous</td><td>92</td></tr><tr><td>Melanoma</td><td>2-4</td></tr><tr><td>Basal cell</td><td>2-3</td></tr><tr><td>Bartholin gland (adenocarcinoma, squamous cell, transitional cell, adenoid cystic)</td><td>1</td></tr><tr><td>Metastatic</td><td>1</td></tr><tr><td>Verrucous</td><td>&lt;1</td></tr><tr><td>Sarcoma</td><td>&lt;l</td></tr><tr><td>Appendage (e.g., hidradenocarcinoma)</td><td>Rare</td></tr></table>
======================================
<table><thead><th>Author</th><th>Positive Inguinal- femoral LN</th><th>Positive Pelvic LN/Patients with Pelvic LND</th><th>LN/Patients with Negative Inguinal- femoral NL</th><th>LN/Patients with Positive Inguinal- femoral NL</th></thead><tr><td>Rutledge et al., 1970 (39)</td><td>33/86 (38%)</td><td>12/72 (17%)</td><td>0/53 (0%)</td><td>12/33 (36%)</td></tr><tr><td>Collins et al., 1971 (52)</td><td>27/98 (28%)</td><td>11/98 (11%)</td><td>4/71 (6%)</td><td>7/27 (26%)</td></tr><tr><td>Morley, 1976 (53)</td><td>67/180 (37%)</td><td>6/23 (26%)</td><td>0/113 (0%)</td><td>6/67 (9%)</td></tr><tr><td>Krupp and Bohm, 1978 (54)</td><td>40/195 (21%)</td><td>10/195 (5%)</td><td>1/155 (0.6%)</td><td>9/40 (23%)</td></tr><tr><td>Benedet et al., 1979 (55)</td><td>34/120 (28%)</td><td>4/51 (8%)</td><td></td><td></td></tr><tr><td>Curry et al., 1980 (12)</td><td>57/191 (30%)</td><td>9/52 (17%)</td><td>0/134 (0%)</td><td>9/57 (16%)</td></tr><tr><td>Iversen et al., 1980 (56)</td><td>90/262 (34%)</td><td>7/100 (7%)</td><td>1/172 (0.6%)</td><td>6/90 (7%)</td></tr><tr><td>Hacker et al., 1983 (13)</td><td>31/113 (27%)</td><td>6/18 (33%)</td><td>0/82 (0%)</td><td>6/31 (19%)</td></tr><tr><td>Podratz et al., 1983 (40)</td><td>59/175 (34%)</td><td>7/114 (6%)</td><td>0/116 (0%)</td><td>7/59 (12%)</td></tr><tr><td>Monaghan and Hammond, 1984 (14)</td><td>37/134 (28%)</td><td>3/80 (4%)</td><td></td><td></td></tr><tr><td>Hopkins et al., 1991 (57)</td><td>61/145 (42%)</td><td>13/38 (34%)</td><td>0/84 (0%)</td><td>13/61 (21%)</td></tr><tr><td>Keys, 1993 (58)</td><td>203/588 (35%)</td><td>15/53 (28%)</td><td></td><td></td></tr><tr><td>TOTAL</td><td>739/2,287 (32%)</td><td>103/894 (12%)</td><td>6/980 (0.6%)</td><td>75/465 (16%)</td></tr></table>
======================================
<table><thead><th colspan="4">Vulva Versus Depth of Stromal Invasion</th></thead><thead><th>Depth of Invasion</th><th>No.</th><th>Positive Nodes</th><th>Nodes</th></thead><tr><td>&lt;1 mm</td><td>163</td><td>0</td><td>0</td></tr><tr><td>1.1-2 mm</td><td>145</td><td>11</td><td>7.7</td></tr><tr><td>2.1-3 mm</td><td>131</td><td>11</td><td>8.3</td></tr><tr><td>3.1-5 mm</td><td>101</td><td>27</td><td>26.7</td></tr><tr><td>&gt;5</td><td>38</td><td>13</td><td>34.2</td></tr><tr><td>TOTAL</td><td>578</td><td>62</td><td>10.7</td></tr></table>
======================================
<table><thead><th>FIGO Stage</th><th>TNM Classification</th><th>Clinical/Pathologic Findings</th></thead><tr><td>Stage 0</td><td>Tis*</td><td>Carcinoma in situ, intraepithelial carcinoma</td></tr><tr><td>Stage |</td><td>T,NoMo</td><td>Tumor confined to vulva and/or perineum, =2 cm in greatest dimension, nodes are negative</td></tr><tr><td>la’</td><td></td><td>Stromal invasion =1 mm</td></tr><tr><td>Ib</td><td></td><td>Stromal invasion &gt;1 mm II</td></tr><tr><td>Stage Il</td><td>T,NoMo</td><td>Tumor confined to vulva and/or perineum, &gt;2 cm in greatest dimension, nodes are negative</td></tr><tr><td>Stage III</td><td>T,NoMo</td><td>Tumor of any size with 1. Adjacent spread to lower urethra, vagina, or anus or</td></tr><tr><td>Stage IVa</td><td>T,_;N,Mo</td><td>2. Unilateral regional lymph node metastases Tumor of any size with</td></tr><tr><td></td><td>TyNonyMo TanyNoMo</td><td>1. Adjacent spread to upper urethra, bladder mucosa, rectal mucosa, pelvic bone or 2. Bilateral regional lymph node metastases</td></tr></table>
======================================
<table><tr><td>Primary : Primary tumor cannot be assessed</td><td></td><td>Regional lymph Regional lymph nodes are the femoral and inguinal nodes</td></tr><tr><td>primary Carcinoma in situ (preinvasive carcinoma)</td><td>Na:</td><td>Regional lymph No lymph node metastases</td></tr><tr><td>Tumor confined to the vulva and/or perineum,</td><td>N,:</td><td>Unilateral regional lymph node metastases</td></tr><tr><td>=2 cm in greatest dimension</td><td>N,</td><td>Bilateral regional lymph node metastases</td></tr><tr><td>Tumor confined to the vulva and/or perineum,</td><td>M __</td><td>Distant metastases</td></tr><tr><td>&gt;2 cm in greatest dimension</td><td>Mx</td><td>Presence of distant metastases cannot be assessed</td></tr><tr><td>Tumor invades any of the following: lower urethra, vagina, anus</td><td>M,</td><td>No distant metastases</td></tr><tr><td>Tumor invades any of the following: bladder mucosa, rectal</td><td>M,</td><td>_ Distant metastases (including pelvic lymph node metastases</td></tr></table>
======================================
<table></table>
======================================
<table><thead><th>FIGO Stage</th><th>No. of Patients</th><th>Corrected 5-Year Survival (%;</th></thead><tr><td>1</td><td>148 (26%)</td><td>98%</td></tr><tr><td>Il</td><td>191 (33%)</td><td>85%</td></tr><tr><td>Ml</td><td>176 (31%)</td><td>74%,</td></tr><tr><td>IV</td><td>62 (11%)</td><td>31%</td></tr><tr><td>All stages</td><td>577</td><td>79%</td></tr></table>
======================================
<table><thead><th></th><th>Clark Level (125)</th><th>Chung Depth of Invasion (124)</th><th>Breslow Tumor Thickness (126)</th></thead><tr><td>1</td><td>Intraepithelial</td><td>Intraepithelial</td><td>&lt;0.76 mm</td></tr><tr><td>I</td><td>Into papillary dermis</td><td>&lt;1 mm from granular layer</td><td>0.76-1.5 mm Superficial invasion</td></tr><tr><td>Ml</td><td>Filling dermal papillae</td><td>1.1-2.0 mm from granular layer</td><td>1.51-2.25 mm Intermediate invasion</td></tr><tr><td>IV</td><td>Into reticular dermis</td><td>&gt;2 mm from granular layer</td><td>2.26-3.0 Intermediate invasion</td></tr><tr><td>Vv</td><td>Into subcutaneous fat</td><td>Into subcutaneous fat</td><td>&gt;3 mm Deep invasion</td></tr></table>
======================================
<table><thead><th colspan="3">Stratified by Breslow Microstaging</th></thead><thead><th>Breslow Tumor Thickness</th><th>No. of Patients</th><th>% DOD</th></thead><tr><td>&lt;0.76 mm</td><td>31 [19]</td><td>7 (23%) [1 (5%) I?</td></tr><tr><td>0.76-1.5 mm</td><td>35</td><td>6 (17%)</td></tr><tr><td>1.51-3.0 mm</td><td>42</td><td>23 (55%)</td></tr><tr><td>&gt;3.0 mm</td><td>195</td><td>131 (67%)</td></tr></table>
======================================
<table><thead><th>FIGO Stage</th><th>No. of Patients</th><th>No. of Patients with Recurrent Disease</th><th>No. of Patients NED at last F/U"</th></thead><tr><td>1</td><td>15 (21%)</td><td>3 (20%)</td><td>14 (93%)</td></tr><tr><td>I</td><td>16 (23%)</td><td>2 (13%)</td><td>15 (94%)</td></tr><tr><td>Il</td><td>30 (42%)</td><td>11 (37%)</td><td>22 (73%)</td></tr><tr><td>IV</td><td>10 (14%)</td><td>5 (50%)</td><td>5 (50%)</td></tr><tr><td>TOTAL</td><td>71 (14%)</td><td>21</td><td>56 (79%)</td></tr></table>
======================================
<table><thead><th>Features</th><th>Complete Mole</th><th>Partial Mole</th></thead><tr><td>Fetal or embryonic tissue</td><td>Absent</td><td>Present</td></tr><tr><td>Hydatidiform swelling of chorionic villi</td><td>Diffuse</td><td>Focal</td></tr><tr><td>Trophoblastic hyperplasia</td><td>Diffuse</td><td>Focal</td></tr><tr><td>Scalloping of chorionic villi</td><td>Absent</td><td>Present</td></tr><tr><td>Trophoblastic stromal inclusions</td><td>Absent</td><td>Present</td></tr><tr><td>Karyotype</td><td>46,XX (90%); 46,XY</td><td>Triploid</td></tr></table>
======================================
<table><thead><th>Stage |</th><th>Disease confined to uterus</th></thead><tr><td>la</td><td>Disease confined to uterus with no risk factors</td></tr><tr><td>Ib</td><td>Disease confined to uterus with one risk factor</td></tr><tr><td>Ic</td><td>Disease confined to uterus with two risk factors</td></tr><tr><td>Stage II</td><td>Gestational trophoblastic tumor extending outside uterus but limited to genital structures (adnexa, vagina, broad ligament)</td></tr><tr><td>LE</td><td>Gestational trophoblastic tumor involving genital structures without risk factors</td></tr><tr><td>Ib</td><td>Gestational trophoblastic tumor extending outside uterus but limited to genital structures with one risk factor</td></tr><tr><td>IIc</td><td>Gestational trophoblastic tumor extending outside uterus but limited to genital structures with two risk factors</td></tr><tr><td>Stage III</td><td>Gestational trophoblastic disease extending to lungs with or without known genital tract involvement</td></tr><tr><td>Ila</td><td>Gestational trophoblastic tumor extending to lungs with or without genital tract involvement and with no risk factors</td></tr><tr><td>IIb</td><td>Gestational trophoblastic tumor extending to lungs with or without genital tract involvement and with one risk factor</td></tr><tr><td>IIc</td><td>Gestational trophoblastic tumor extending to lungs with or without genital tract involvement and with two risk factors</td></tr><tr><td>Stage IV</td><td>All other metastatic sites</td></tr><tr><td>IVa</td><td>All other metastatic sites without risk factors</td></tr><tr><td>IVb</td><td>All other metastatic sites with one risk factor</td></tr><tr><td>IVc</td><td>All other metastatic sites with two risk factors</td></tr></table>
======================================
<table><thead><th></th><th>0</th><th>1</th><th>2</th><th>4</th></thead><tr><td>Age (years)</td><td>339</td><td>&gt;39</td><td></td><td></td></tr><tr><td>Antecedent pregnancy</td><td>Hydatidiform mole</td><td>Abortion</td><td>— Term</td><td></td></tr><tr><td>Interval between end of antecedent pregnancy and start of chemotherapy (months)</td><td>&lt;4</td><td>4-6</td><td>7-12</td><td>&gt;12</td></tr><tr><td>Human chorionic gonadotropin (IU/L)</td><td>&lt;108</td><td>10°-104</td><td>104-10°</td><td>&gt;10°</td></tr><tr><td>ABO groups</td><td></td><td>OorA</td><td>B or AB</td><td></td></tr><tr><td>Largest tumor, including uterine (cm)</td><td>&lt;3</td><td>3-5</td><td>&gt;5</td><td></td></tr><tr><td>Site of metastases</td><td></td><td>Spleen, kidney</td><td>Gastrointestinal tract, liver</td><td>— Brain</td></tr><tr><td>Number of metastases</td><td></td><td>1-3</td><td>4-8</td><td>8</td></tr></table>
======================================
<table><tr><td colspan="2">Stage |</td></tr><tr><td>Initial</td><td>Single-agent chemotherapy or hysterectomy with adjunctive chemotherapy</td></tr><tr><td rowspan="4">Resistant</td><td>Combination chemotherapy</td></tr><tr><td></td><td>Hysterectomy with adjunctive chemotherapy</td></tr><tr><td></td><td>Local resection</td></tr><tr><td></td><td>Pelvic infusion</td></tr><tr><td colspan="2">Stage II and III</td></tr><tr><td colspan="2">Low risk*</td></tr><tr><td>Initial</td><td>Single-agent chemotherapy</td></tr><tr><td>Resistant</td><td>Combination chemotherapy</td></tr><tr><td colspan="2">High risk?</td></tr><tr><td>Initial</td><td>Combination chemotherapy</td></tr><tr><td>Resistant</td><td>Second-line combination chemotherapy</td></tr><tr><td colspan="2">Stage IV</td></tr><tr><td>Initial</td><td>Combination chemotherapy</td></tr><tr><td>Brain</td><td>Whole-heat irradiation (3,000 cGy)</td></tr><tr><td></td><td>Craniotomy to manage complications</td></tr><tr><td>Liver</td><td>Resection to manage complications</td></tr><tr><td>Resistant?</td><td>Second-line combination chemotherapy</td></tr></table>
======================================
<table><tr><td>Primary tumor (T)</td><td></td></tr><tr><td>1X</td><td>Primary tumor cannot be assessed</td></tr><tr><td>T,</td><td>No evidence of primary tumor</td></tr><tr><td>Tis</td><td>Carcinoma in situ</td></tr><tr><td>Tis (DCIS)</td><td>Ductal carcinoma in situ</td></tr><tr><td>Tis (LCIS)</td><td>Lobular carcinoma in situ</td></tr><tr><td>Tis (Paget)</td><td>Paget disease of the nipple with no tumor</td></tr><tr><td>T,</td><td>Tumor 2 cm or less in greatest dimension</td></tr><tr><td>Tinie</td><td>Microinvasion 0.1 cm or less in greatest dimension</td></tr><tr><td>T,,</td><td>Tumor more than 0.1 cm but not more than 0.5 cm in greatest dimension</td></tr><tr><td>Ty,</td><td>More than 0.5 cm but not more than 1 cm in greatest dimension</td></tr><tr><td>The</td><td>More than 1 cm but not more than 2 cm in greatest dimension</td></tr><tr><td>&gt;</td><td>Tumor more than 2 cm but not more than 5 cm in greatest dimension</td></tr><tr><td>3</td><td>Tumor more than 5 cm in greatest dimension</td></tr><tr><td>4</td><td>Tumor of any size with direct extension to chest wall or skin</td></tr><tr><td>4A</td><td>Extension to chest wall, not including pectoralis muscle</td></tr><tr><td>ap</td><td>Edema (including peau d’orange) or ulceration of the skin of breast or satellite skin nodules confined to same breast</td></tr><tr><td>Ty</td><td>Both T,, and T,,</td></tr><tr><td>Ty</td><td>nflammatory carcinoma</td></tr><tr><td>Lymph node (N)</td><td></td></tr><tr><td colspan="2">Clinical</td></tr><tr><td>NX</td><td>Regional lymph nodes cannot be assessed (e.g., previously removed)</td></tr><tr><td>No</td><td>o regional lymph node metastasis</td></tr><tr><td>N,</td><td>Metastasis to movable ipsilateral axillary lymph node(s)</td></tr><tr><td>N,</td><td>Metastases to ipsilateral axillary lymph node(s) fixed or matted, or in clinically apparent ipsilateral mammary nodes in the absence of clinically evident axillary node metastasis</td></tr><tr><td>N,,</td><td>Metastasis in ipsilateral axillary lymph nodes fixed to one another (matted) or to other structures</td></tr><tr><td>No,</td><td>Metastasis only in clinically apparent ipsilateral internal mammary nodes and in the absence of clinically evident axillary lymph node metastasis</td></tr><tr><td>N,</td><td>Metastasis in ipsilateral infraclavicular lymph node(s) with or without axillary lymph node involvement, or in clinically apparent ipsilateral internal mammary lymph nodes and in the presence of clinically evident axillary lymph node metastasis; or metastasis in ipsilateral supraclavicular lymph nodes with or without axillary or internal mammary lymph node involvement</td></tr><tr><td>N,,</td><td>Metastasis in ipsilateral infraclavicular lymph nodes</td></tr><tr><td>Ns,</td><td>Metastasis in ipsilateral internal mammary lymph nodes and axillary lymph nodes</td></tr><tr><td>N3.</td><td>Metastasis in ipsilateral supraclavicular lymph node(s)</td></tr></table>
======================================
<table><thead><th></th><th>No regional lymph nod IHC cluster greater than 0.2 mm le metastasis histologically, positive IHC, no</th></thead><tr><td></td><td>No regional lymph nod le metastasis histologically, negative molecular findings (RT-PCR)</td></tr><tr><td></td><td>No regional lymph nod le metastasis histologically, positive molecular findings (RT-PCR)</td></tr><tr><td></td><td>Metastasis in disease detected by sentinel to 3 axillary lym e(s), and/or in internal mammary nodes with microscopic lymph node dissection but not clinically apparent</td></tr><tr><td></td><td>Micrometastasis (&gt;0.2 mm, noni e &gt;2.0 mm)</td></tr><tr><td></td><td>Metastasis in to 3 axillary lym je(s)</td></tr><tr><td></td><td>Metastasis in i dissection but nternal mammary not clinically app. arent with microscopic disease detected by sentinel lymph node</td></tr><tr><td></td><td>Metastasis in to 3 axillary lym e(s), and in internal mammary nodes with microscopic disease detected by sentinel lymph node dissection but not clinically apparent</td></tr><tr><td></td><td>axillary lymph Metastasis in 4 to 9 axillary lym les (at least 1 tumor deposit &gt;2.0 mm)</td></tr><tr><td></td><td>Metastasis in clinically apparent internal mammary lymph nodes in the absence of axillary lymph node metastasis</td></tr><tr><td></td><td>Metastasis in 10 or more axi lary lymph nodes, or in infraclavicular lymph nodes, or in clinically apparent ipsilateral internal mammary nodes in the presence of 1 or more positive axillary nodes; or in more than 3 axillary nodes with clinically negative microscopic metastasis in internal mammary lymph nodes; or in ipsilateral supraclavicular lymph nodes</td></tr><tr><td></td><td>Metastasis in 10 or more axi metastasis in infraclavicular lary lymph nodes (at least one tumor deposit greater than 2.0 mm), or ymph nodes</td></tr><tr><td></td><td>Metastasis in clinically apparent ipsilateral internal mammary nodes in the presence of 1 or more positive axillary nodes; or in more than 3 axillary nodes and in internal mammary nodes with microscopic disease detected by sentinel lymph node dissection but not clinically apparent</td></tr><tr><td></td><td>Metastasis in ipsilateral supraclavicular nodes</td></tr><tr><td colspan="2">Distant metastasis (M)</td></tr><tr><td></td><td>Presence of distant metastasis cannot be assessed</td></tr></table>
======================================
<table><thead><th></th><th></th><th></th><th>Metastasis</th></thead><tr><td>Stage 0</td><td></td><td></td><td>M 0</td></tr><tr><td>Stage |</td><td>=</td><td>o</td><td>o</td></tr><tr><td rowspan="4">Stage Ila IIb</td><td>Oo</td><td>Zz =</td><td>o</td></tr><tr><td></td><td>=</td><td>Zz =</td><td>oO</td></tr><tr><td></td><td>NR</td><td>Zz o</td><td>oO EGEGEGEGEGEGEGEGEGE&lt;</td></tr><tr><td></td><td>nN</td><td>Zz =</td><td>o</td></tr><tr><td></td><td>w</td><td>Zz o</td><td>=)</td></tr><tr><td rowspan="5">Stage Illa</td><td>o</td><td>Zz NR</td><td>o</td></tr><tr><td></td><td>—_</td><td>Zz NR</td><td>fo}</td></tr><tr><td></td><td>NR</td><td>Zz NR</td><td>o</td></tr><tr><td></td><td>w</td><td>Zz =</td><td>o</td></tr><tr><td></td><td>w</td><td>Zz NR</td><td>o</td></tr><tr><td rowspan="3">IIIb</td><td>&gt; Slalalalalalalalalalala/a</td><td>Zz o</td><td>oO ESE</td></tr><tr><td></td><td></td><td>Zz =</td><td>oO</td></tr><tr><td></td><td></td><td>Zz NR</td><td>o</td></tr><tr><td rowspan="2">IIc Stage IV</td><td></td><td>Z w</td><td>=) SES</td></tr><tr><td></td><td></td><td>&gt; 5 ~&lt; Zz</td><td></td></tr></table>
======================================
<table><thead><th>Factor</th><th>Increased Risk of Recurrence</th></thead><tr><td>Size</td><td>Larger tumors</td></tr><tr><td>Histologic grade</td><td>High-grade tumors</td></tr><tr><td>DNA ploidy</td><td>Aneuploid tumors</td></tr><tr><td>Labeling index</td><td>High index (&gt;3%)</td></tr><tr><td>S phase fraction</td><td>High fraction (&gt;5%)</td></tr><tr><td>Lymphatic-vascular invasion</td><td>Present</td></tr><tr><td>Cathepsin D</td><td>High levels</td></tr><tr><td>HER-2/neu oncogene expression</td><td>High expression</td></tr><tr><td>Epidermal growth factor</td><td>High levels</td></tr></table>
======================================
<table><thead><th>AJCC Stage</th><th>5-Year Survival (%)</th><th>10-Year Survival (%)</th></thead><tr><td>Stage 0</td><td>95</td><td>90</td></tr><tr><td>Stage |</td><td>85</td><td>70</td></tr><tr><td>Stage Ila</td><td>70</td><td>50</td></tr><tr><td>IIb</td><td>60</td><td>40</td></tr><tr><td>Stage Illa</td><td>55</td><td>30</td></tr><tr><td>IIb</td><td>30</td><td>20</td></tr><tr><td>Stage IV</td><td>5-10</td><td>2</td></tr><tr><td>All</td><td>65</td><td>30</td></tr></table>
======================================
<table><thead><th>Age</th><th>Therapy</th><th>Reduction in Annual Odds of Recurrence</th><th>Reduction in Annual Odds of Death</th></thead><tr><td>&lt;50</td><td>Tamoxifen X 5 yrs</td><td>45+8</td><td>32+10</td></tr><tr><td>50-59</td><td>Tamoxifen X 5 yrs</td><td>37 +6</td><td>1148</td></tr><tr><td>60-69</td><td>Tamoxifen X 5 yrs</td><td>5445</td><td>3346</td></tr><tr><td>&lt;40</td><td>Polychemotherapy</td><td>37 +7</td><td>27 +8</td></tr><tr><td>40-49</td><td>Polychemotherapy</td><td>3545</td><td>2745</td></tr><tr><td>50-59</td><td>Polychemotherapy</td><td>2244</td><td>444</td></tr><tr><td>60-69</td><td>Polychemotherapy</td><td>18 +4</td><td>8 +4</td></tr></table>